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ABSTRACT 
Prostate cancer (PCa) accounts for 9.6% of all new cancers in men worldwide and is 
the second leading cause of cancer death in men. Localized PCa is treated with 
androgen deprivation therapy (ADT), as the prostate and prostate tumours are 
dependent on androgens for survival. Unfortunately, on average within two years, in 
half the patients PCa recurs, and is often more aggressive, presenting with overt 
metastases and chemotherapy and ADT resistant neuroendocrine tumours in 10-30% 
of patients. However, reactivation of AR signalling through various mechanisms 
underlies resistance to ADT in the majority of cases. This has led to continued 
development of antagonists to the androgen receptor (AR) and inhibitors of androgen 
synthesis to combat PCa which result in extended time to progression and cancer 
specific survival in advanced PCa patients. However, even the latest AR targeting 
drugs offer only temporary remission of 3 to 4 months, with the cancer becoming 
quickly resistant, indicating a lack of comprehensive understanding of the processes 
involved in PCa progression. Other cellular pathways may need to be targeted in 
conjunction with AR to prevent progression.  
A major side effect of ADT is the induction of features of the metabolic syndrome, 
including persistent hyperinsulinaemia, which is specifically associated with poor 
outcomes, including rapid progression and increased cancer mortality. It was 
hypothesized that following androgen withdrawal, high insulin levels promote an 
adaptive response that drives castrate resistance PCa progression. The overall aim of 
this thesis was to determine the direct effects of insulin in prostate cancer cells. In 
particular, to characterise the unique pathways regulated in PCa cells by insulin in 
the absence of androgens.  
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Aim one interrogated publically available patient databases, observing that insulin 
receptor (INSR) was more commonly upregulated than IGF1R from primary versus 
metastatic prostate tumours across several clinical datasets. These results were 
supported by our observations from PCa cell models whereby insulin receptor 
expression was inversely expressed compared to AR, but IGF1R was positively 
correlated to AR. It was observed that IGF1R expression was decreased with 
androgen deprivation therapy and this could result, in some cell lines in a significant 
increase in the ratio of insulin to IGF1 receptors. Together this suggests that INSR / 
IR expression is highest when AR is low or cells are androgen insensitive.   
An unexpected finding was that cells treated with DHT increased insulin receptor 
levels.  This led to studies examining the subcellular localisation of IR and the 
finding of IR in the nucleus. IR was largely cytoplasmic, with increased 
immunostaining appearing in the nucleus following treatment.  These results were 
confirmed by subcellular fractionation, where DHT treatment increased nuclear IR.   
Several studies have established altered insulin receptor expression in prostate 
cancer, without identifying downstream functions. To address this, transcriptional 
profiling of the AR-responsive LNCaP cell line was undertaken following 10hr 
insulin treatment (10nM) in the presence and absence of androgen (1nM R1881). 
This identified a number of pathways uniquely upregulated by insulin including 
genes associated with increased potential for migration and invasion. It was observed 
that in the absence of androgens, 10nM insulin promotes up to 70% increased 
transwell migration and 50% increased Matrigel invasion of LNCaP and 22RV1 cell 
lines, which does not occur in the presence of DHT. Importantly, insulin-induced 
migration and invasion was blocked by inhibitors of insulin receptor, BMS-745807-
04 and CP-751871, as well as genetic knockdown of IR, indicating these are direct 
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effects of insulin. Anti-androgens, alone and in combination with insulin also 
induced migration and invasion. These results are highly relevant clinically as 
advanced prostate cancer patients are prescribed anti-androgens and are often 
concurrently hyperinsulinaemic. 
Microarray analysis showed that insulin induced transcriptional changes associated 
with epithelial-to-mesenchymal transition (EMT) and neuroendocrine trans-
differentiation (NEtD) processes. EMT is a well characterized pathway in various 
cancers that is involved in gain of migration and invasion, and transforms stationary 
‘epithelial’ cells into motile and invasive ‘mesenchymal’ cells. Further validation 
showed consistent upregulation of EMT transcription factors FOXC2 and Zeb1 by 
insulin and anti-androgens across three PCa cell lines, however, epithelial markers E-
cadherin and Epcam remained unchanged, suggesting a partial EMT. Knockdown of 
FOXC2 prevented insulin induced migration and EMT-like changes, indicating 
FOXC2 may drive these direct effects of insulin in PCa. Zeb1 appeared to be more 
influenced by the androgen axis. Clinical samples from two publicly available 
databases also showed significant positive correlations between IR and FOXC2 in 
both localized and metastatic PCa, which was not observed for Zeb1. NEtD is 
proposed in PCa as a mechanism for rise of invasive neuroendocrine tumours. 
Certain neuroendocrine markers were also upregulated by insulin as early as 20 
hours post treatment, indicating insulin may also accelerate NEtD processes in PCa.  
Recent studies report ‘obesity factors’ promoting EMT in prostate cancer cells. The 
data indicates insulin can promote this plasticity and make a strong case for 
investigating the clinical efficacy of using insulin-sensitizing drugs such as 
metformin as an adjuvant therapy for PCa treatment. Metformin is a commonly 
prescribed diabetic medicine that promotes insulin sensitization and treats 
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hyperinsulinaemia. Additionally, at the cellular level, it activates AMP kinase 
(AMPK) and inhibits key signalling molecules downstream of both insulin and 
androgen. Functional studies with metformin show inhibition of LNCaP cell 
invasion. Thus, metformin or other insulin-lowering therapies, potentially hold great 
promise as adjuvant therapy for advanced prostate cancer. 
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1.1  Anatomy and development of the Prostate  
The human prostate is a tubular-alveolar gland composed of a stromal compartment 
surrounding epithelium glandular acini (Kumar & Majumder, 1995). The stromal 
compartment is composed of an assortment of non-prostate specific cells, such as 
nerves, fibroblasts, endothelial cells and smooth muscle cells, while the epithelial 
compartment is composed of luminal secretory cells, basal cells and neuroendocrine 
(NE) cells (Sun, Niu, & Huang, 2009) (Figure 1.1A). The exocrine and endocrine 
functions of the prostate primarily derive from the actions of its epithelial luminal 
secretory cells that express androgen receptor (AR) and  produce and secrete a 
spectrum of small molecules and enzymes in response to signalling by androgens 
(Sun, et al., 2009). In contrast, the basal and NE cells do not express AR and their 
functions in the prostate epithelium are not well characterized (Sun, et al., 2009). NE 
cells have hybrid epithelial, neural and endocrine features. They secrete cytokines 
and peptides/neuropeptides (Huang & diSant'Agnese, 2002), the receptors for which 
can be found in the surrounding prostate cells, such as calcitonin receptor (Wu et al., 
1996) and somatostatin receptor (Dizeyi et al., 2002; Hansson, Bjartell, Gadaleanu, 
Dizeyi, & Abrahamsson, 2002). Thus, paracrine signalling by the prostatic NE cells 
is likely and possibly plays important, yet undefined, regulatory roles of growth, 
differentiation and secretory activity of the benign prostatic epithelium. However, 
NE cells are very rare, constituting ~1% of the total epithelial cell population (Sun, et 
al., 2009; Vashchenko & Abrahamsson, 2005; Yuan, Veeramani, & Lin, 2007). NE 
cells are generally non-proliferative (Huang et al., 2006). Basal cells are thought to 
function as reserve cells that can differentiate into luminal secretory cells if needed 
(Sun, et al., 2009).  
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The prostate is, thus, a highly differentiated organ with very specific secretory 
functions. These functions and differentiation of the prostate epithelium cells are 
controlled by AR signalling.  Differentiation of the prostate into its two 
compartments and various cell types depend heavily on paracrine signalling. During 
prostate development, the mesenchyme differentiates into the stromal compartment 
(Hayward et al., 1998), while the epithelium differentiates into the epithelium 
compartment (Cunha, Lung, & Reese, 1980). Pre-differentiation, the AR is expressed 
only in the mesenchyme, induces the epithelium to differentiate into prostate 
secretory glandular structures through paracrine signalling (Cunha, et al., 1980). This 
paracrine signal is thought to include FGF1, FGF10 and IGF1, receptors for which 
are expressed on the epithelium (Le, Arnold, McFann, & Blackman, 2006; Lu, Luo, 
Kan, & McKeehan, 1999; Tenniswood, 1986; Thomson, 2008; Yan, Fukabori, 
Nikolaropoulos, Wang, & McKeehan, 1992). Without androgen signalling in the 
mesenchyme, the epithelium instead develops as in a female (Cunha, 2008). 
Differentiation causes the luminal epithelium cells to begin AR expression, which 
then becomes essential for its secretory abilities and maintenance of differentiation 
(Cunha & Young, 1991). The mesenchyme differentiates into the stroma, which still 
provides the AR regulated paracrine signal to prostate epithelial cells (FGF1, FGF10, 
IGF1), but instead of inducing differentiation, it now acts to regulate survival and 
proliferation of secretory luminal cells (Isaacs, 2008). In fact, AR in benign luminal 
epithelial cells signals suppression of the cell growth (as it is a terminal 
differentiation signal) through expression of p27 (Chen et al., 1996; Tsihlias et al., 
2000; Waltregny et al., 2001) and acts as a tumour suppressor (Niu et al., 2008).  
Interestingly, insulin signalling appears to be crucial for proper development of the 
prostate. In type I diabetic mice, rat and human children, the prostatic epithelium 
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failed to differentiate properly into secretory glandular structures, and instead 
showed diminution in secretory granules and presence of autophagic vacuoles. 
Circulating IGF1 and insulin are both decreased in type I diabetes, and as IGF1 is an 
essential hormone for prostate differentiation (mesenchymal secretion), it is tempting 
to assume that low circulating levels of IGF1 in type I diabetes causes improper 
differentiation. However, treatment with insulin recovered the normal prostate 
epithelial development (Angervall, Hesselsjo, Nilsson, & Tisell, 1967; Sufrin & 
Prutkin, 1974; Suthagar et al., 2009). Thus, insulin signalling is specifically crucial 
for proper prostate development and differentiation.  
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Figure 1.1. Cellular composition of normal and cancerous prostate tissue. (A) 
Pictorial representation of normal prostate epithelial glandular structure. The prostate 
tissue consists of stromal cells (capillary, nerves, fibroblast, immune cells, 
connective tissue, smooth muscle cell) surrounding a two-layered epithelial 
compartment (secretory luminal cell, basal cell, neuroendocrine cell). Picture from 
Barron and Rowley (Barron & Rowley, 2012). (B) Immunohistochemistry (IHC) of 
benign and cancerous prostate tissue showing neuroendocrine cells (brown staining) 
with anti-chromogranin A antibody. The rest of the cells are luminal secretory cells. 
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Number of NE cells increase with cancer progression. Scale bar520 mm. Figure from 
Li et al. (Li et al., 2013) 
1.2 Prostate cancer 
Prostate cancer accounts for 9.6% of all new cancers in men worldwide and is the 
second leading cause of cancer death in men (NIH, 2017). In Australia, around 18, 
000 men are diagnosed with PCa each year, accounting for 25% of all cancers 
diagnosed in Australian men. Over 90% of primary human prostate tumours are 
adenocarcinomas, where ~99% of the tumour is composed of androgen dependent 
(AR+) luminal secretory cells undergoing uncontrolled proliferation (Li, et al., 2013). 
There is a distinct lack of basal cells in adenocarcinomas. Basal cell initiating 
cancers evolve to luminal adenocarcinomas (Goldstein, Huang, Guo, Garraway, & 
Witte, 2010; Stoyanova et al., 2013; Wang et al., 2009; Wang et al., 2013). Within 
these tumours a small proportion of cells (~1%) is comprised of cells with a 
neuroendocrine (NE) phenotype (Li, et al., 2013) (Figure 1.1B). Cancerous NE cells 
are different from their non-cancerous counterparts as they show more luminal than 
basal characteristics with up regulation of cytokeratin 18 protein and down regulation 
of cytokeratin 5 (van Bokhoven et al., 2003; Vashchenko & Abrahamsson, 2005). 
Rare small cell neuroendocrine carcinomas in the prostate composed entirely of NE 
cells (Li, et al., 2013), have been postulated to be derived from this NE 
subpopulation, however these account for only around 1% of all localized prostate 
tumours (Acosta et al., 2008; Brown, Wieczorek, Shaffer, & Salgia, 2003; Chen et 
al., 2012; Li, et al., 2013; van Bokhoven, et al., 2003).   
Unlike in normal luminal cells, in the cancerous luminal cells AR regulates genes for 
cell cycle progression, cell survival and growth (Claessens et al., 2008; Huggins C, 
1941; Massard & Fizazi, 2011) in addition to maintaining PSA secretion. The AR is 
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a ligand-dependent transcription factor that binds ligand at the cytosol, undergoes 
conformational change, dimerizes, becomes activated and translocates to the nucleus, 
where it progresses to bind DNA in a sequence specific manner at the Androgen 
Response Elements (AREs) found within the promoter regions of target genes 
(Hsieh, Small, & Ryan, 2007). Both binding affinity to ligand and ARE affect the 
regulation of gene expression by the AR, facilitated through separate DNA-binding 
and ligand binding domains (Chmelar, Buchanan, Need, Tilley, & Greenberg, 2007). 
The ligand binding domain of the AR can accommodate up to five types of 
androgens, namely testosterone, dihydrotestosterone (DHT), dehydroepiandrosterone 
(DHEA), DHEA-sulfate and androstenedione, although DHT retains the highest 
affinity for AR binding (Culig et al., 1996; Hellerstedt, 2003; Tan et al., 1997). These 
androgens are normally synthesized from cholesterol by the testes and adrenals via a 
steroid biogenesis pathway (Figure 2B). Key enzymes in this pathway include 5 α-
reductase and the cytochrome P450 enzyme CYP17A1. CYP17A1 catalyzes two 
important steps in the steroidogenesis pathway – the conversion of progestagens to 
androgen precursors through its 17- α hydroxylase activity and next, the conversion 
of the androgen precursors to androgens (cortisol, DHEA and androstenedione) 
through its 17,20 lyase activity. The testes further convert DHEA and 
androstenedione to testosterone via 17 β-hydroxysteroid dehydrogenases, and 
testosterone is converted to DHT via 5 α-reductase activity. The conversion of other 
androgens to testosterone and DHT does not take place within the adrenals, which 
release non-testosterone androgens s such as aldosterone, cortisol, DHEA, DHEA-S 
and androstenedione into circulation. Thus, androgen ligand secretion by the testes 
and adrenals bring about AR signalling in the both malignant and non-malignant 
luminal prostate epithelial cells. The oncogenic transformation of the AR in luminal 
 26 Chapter 1: Background 
cancer cells is not well defined. Mutations in the AR which promote proliferation 
have been reported (Gao, Arnold, & Isaacs, 2001; Vander Griend et al., 2010), 
however these account for less than 10% of prostate adenocarcinomas (Buchanan et 
al., 2001).  
Both genetic and environmental factors can be attributed to prostate carcinogenesis. 
PCa is more prevalent in the West (Marugame & Katanoda, 2006), however the 
prevalence of PCa in migrant populations increases to match the prevalence in 
western populations within two years, indicating that environmental factors such as 
diet and lifestyle play an important role (Lee, Demissie, Lu, & Rhoads, 2007). 
Additionally, men with first-degree relatives diagnosed with PCa have a four times 
higher diagnostic risk than the general population (Johns & Houlston, 2003) and 
monozygotic twins have 50% higher risk of PCa than dizygotic twins (Gronberg, 
Damber, & Damber, 1994; Hemminki & Vaittinen, 1998; Lichtenstein et al., 2000), 
indicating underlying genetic causes of the disease. Genome-wide association studies 
have also identified 77 rare single nucleotide polymorphisms (SNPs) that confer 
moderate risk and account for 30% of the genetic risk of PCa. Another 5% of the 
genetic risk can be accounted for by rare mutations in BRCA2 (Kote-Jarai et al., 
2011), BRCA1 (Leongamornlert et al., 2012), DNA repair genes MMR, NBS1 and 
CHEK2 (Cybulski et al., 2004; Cybulski et al., 2006; Erkko et al., 2007; Hebbring et 
al., 2006; Kote-Jarai et al., 2009), and homeobox gene HOXB13 (Ewing et al., 
2012).     
Several clonal genetic aberrations have been recently identified that allow 
classification of subtypes of PCa. 50-60% of localized PCa tumours in Caucasian 
men contain ETS-gene fusions, where the 5’untranslated region of an androgen 
regulated gene such as TMPRSS2, is fused with the coding sequence of an ETS 
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transcription factor such as ERG (Tomlins et al., 2007). These tumours also need 
PTEN loss, activating the PI3K/Akt pathway, for carcinogenesis (Carver et al., 2009; 
King et al., 2009). Also, chronically activated Akt can lead to uncontrolled 
proliferation of the prostate luminal epithelial cells both in the presence and absence 
of AR (Memarzadeh et al., 2011), showing that chronically active Akt pathway is 
dominant over the AR signalling in prostate cancer. Early-onset tumours typically 
have high proportions of ETS gene fusions (Berger et al., 2011).  A second distinct 
subtype of PCa, detected in 5-15% of localized tumours, have no ETS gene fusions 
and are PTEN wild type, but have simultaneous mutations in SPINK, SPOP and 
CHD1 genes (Attard et al., 2016). More rare subtypes, detected in 1-2% of tumours, 
show activation of RAS/RAF pathway, with no ETS fusions or PTEN loss (Attard, et 
al., 2016). Lower grade localized PCa is relatively homogeneous, displaying cells of 
only one subtype of PCa. As aggressiveness increases, so does heterogeneity of the 
tumour cells, with multiple subtypes of PCa existing within the same tumour, 
indicating several clonal origins (Attard, et al., 2016).   
The 5-year survival for localised PCa is 94%, which is in part attributable to early 
detection rates made possible with the use of serum PSA, as a screening biomarker. 
PCa is diagnosed using a combination of elevated PSA, digital rectal examination 
and confirmation biopsy. If diagnosed early, prostate tumours are readily treated by 
radical prostatectomy or radiation therapy.  However somewhere between 10 and 
50% of men will experience a secondary rise in their serum PSA levels post 
intervention, indicative of cancer recurrence (Figure 1.2).  
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Figure 1.2: Prostate cancer disease progression. Following primary diagnosis via 
high tumour volume / elevated serum PSA levels (red line, Y axis), patients are 
treated with surgery or radiation therapy. Despite treatment, PCa recurs often with 
bone and lymph node metastases within a median time of 5 years (primary PSA 
failure). At this stage, tumours are treated with first line ADT drugs such as goserelin 
acetate, a major side effect of which is hyperinsulinaemia. However, patients will 
often progress to Castrate Resistant Prostate Cancer accompanied by secondary PSA 
failure, despite low serum androgen levels.  Tumours are generally treated with AR-
targeted therapies (ATTs) such as bicalutamide, enzalutamide and abiraterone acetate 
which extend survival but ultimately cannot prevent death of patient.  
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1.3 Recurrent PCa  
Recurrent PCa is signalled by a secondary rise in serum PSA (Figure 1.2). Treatment 
options capitalise on the dependence of the tumours on AR activity for growth and 
survival, with androgen deprivation therapy (ADT) as the primary treatment. ADT 
suppresses testicular testosterone production using luteinizing hormone releasing 
hormone (LHRH) agonists such as goserelin acetate (Denmeade & Isaacs, 2002). 
This typically results in reduced tumour burden, reduced secretion of PSA 
(Kuriyama et al., 1982; Papsidero, Wang, Valenzuela, Murphy, & Chu, 1980; Sadar, 
Hussain, & Bruchovsky, 1999), used as a biomarker of tumour response and a 
reduction in the number of circulating tumour cells (CTCs) (Attard, Richards, & de 
Bono, 2011; Ferraldeschi, Pezaro, Karavasilis, & de Bono, 2013). However, despite 
the initial therapeutic response from ADT, many patients recur (50%), with 
increasing PSA, despite a lack of circulating androgens.  This stage of the disease is 
termed castrate resistant prostate cancer (CRPC) and is often accompanied by 
increase of intratumoral androgens, increased CTCs, and frank metastases (mCRPC) 
(Eisenberger et al., 1998; Pagliarulo et al., 2012; Schroder, Crawford, Axcrona, 
Payne, & Keane, 2012). CRPC carries a worse prognosis with an average survival 
time of 16-18 months (Attar, Takimoto, & Gottardis, 2009; Marques, Dits, Erkens-
Schulze, van Weerden, & Jenster, 2010). Originally, it was thought this heralded the 
emergence of an androgen independent tumour, however, it has now been established 
that a number of mechanisms are used by the tumour to amplify AR signalling in this 
low androgen environment. Understanding the mechanisms of ADT resistance has 
helped rationalise new treatment options. 
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1.4 Mechanisms of ADT resistance 
Research efforts over the last ten to fifteen years have identified a number of 
mechanisms by which the AR can be re-activated to drive cancer progression. These 
include: (1) development of a hypersensitive AR through overexpression that can 
respond to extremely low levels of androgens present in men undergoing ADT (Chen 
et al., 2004); (2) de novo synthesis of androgens in the face of ADT by the prostate 
cancer cells (Leon et al., 2010; Locke et al., 2008; Montgomery et al., 2008);  (3) 
gain-of-function mutations or alternative splicing of AR that allow ligand 
independent activity (Dehm, Schmidt, Heemers, Vessella, & Tindall, 2008), or 
activation by non-canonical ligands (Buchanan et al., 2004; Taplin et al., 1995; 
Veldscholte et al., 1990). The re-activation of AR has been recognized as the 
predominant mechanism for recurrence. PSA production returns, indicating that AR 
continues to play a large role in the development and progression of prostate cancer 
even after ADT (Fowke et al., 2008; Group et al., 2008; Montgomery, et al., 2008; 
Small et al., 2004; Small & Srinivas, 1995). The discovery that treatment resistant 
tumours remain largely dependent on AR signalling played a critical role in the 
development of second line therapies for CRPC with post-ADT therapeutic strategies 
mostly focussed on enhanced inhibition of androgen signalling (Figure 1.3). Second 
generation androgen targeting therapies (ATT) includes the use of direct inhibitors of 
the AR (antagonists e.g. finasteride, enzalutamide), molecules in androgen signalling 
(e.g. co-regulators such as Hsp90 inhibitor OGX-427) or biosynthesis pathway (e.g. 
CYP17A1 inhibitor, abiraterone) (Ahmed, Ali, & Sarkar, 2014; Attard et al., 2009; 
Clegg et al., 2012; Vasaitis et al., 2008). These therapies are often combined with 
traditional chemotherapies such as docetaxel (Berthold et al., 2008; Tannock et al., 
2004) and cabazitaxel (de Bono et al., 2010).  
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However, despite these advances, these therapies still offer only modest 
improvements in survival.  The recently FDA approved drugs abiraterone and 
enzalutamide show survival benefits of only 4.6 months (Fizazi, Scher, Molina, & 
Investigators, 2012) and 4.8 months (Scher et al., 2012a), respectively, in the post-
docetaxel setting. In the pre-chemotherapy setting, abiraterone treatment offers an 
increased time to biochemical recurrence of 11.1 months (Fizazi, et al., 2012; Ryan 
et al., 2012). Early trial results show that enzalutamide provided an extra 5.3 months 
to biochemical recurrence compared to chemotherapy alone (Scher, et al., 2012a).  
AR activation by residual ligands(Richards et al., 2012) and increased CYP17A1 
expression (Cai et al., 2011; Mostaghel et al., 2011) may contribute to resistance to 
abiraterone. Mechanisms underlying resistance to enzalutamide include expression of 
mutant AR that can be activated by enzalutamide(Balbas et al., 2013), increased 
androgens that can outcompete enzalutamide(Richards, et al., 2012), and signalling 
by other nuclear glucocorticoid receptors(Arora et al., 2013). Presence of AR splice 
variant 7 (AR V7) can also contribute to resistance to both abiraterone and 
enzalutamide and may explain why response rate to combining abiraterone with 
enzalutamide is low (Antonarakis et al., 2014).   
Thus, even aggressive attempts to inhibit AR signalling are unable to prevent cancer 
progression.  This underscores the importance of considering alternative mechanisms 
which may contribute to the development of resistance in the face of ATT including 
physiological or micro-environmental signalling cues which arise in the androgen-
free environment.  
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Figure 1.3. Mechanisms of action of second generation of drugs targeting 
androgen signalling axis in PCa. Androgen signalling contributes to the 
development of CRPC via mechanisms including AR amplification, mutations in the 
LBD allowing activation by non-canonical ligands such as progesterone, and 
intratumoral steroidogenesis. Androgen targeted therapies (ATT) can be classified 
into two categories, those that are direct antagonists of the androgen receptor, such as 
bicalutamide and enzalutamide, and those that are inhibitors of DHT de novo 
synthesis by PCa cells, such as abiraterone.  
1.5 ADT induced metabolic dysfunction  
The significant role of AR signalling in PCa progression has led to therapies which 
continue to target androgens, and which ultimately result in continued androgen 
deprivation in the patient. However, there are numerous, predictable negative side-
effects to androgen deprivation including bone loss, the development of anaemia, 
depression and loss of libido. There have also been well-documented effects of a 
decline in metabolic function resulting in changes to the endocrine profile. Evidence 
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suggests this is led by the rapid development of insulin resistance resulting in 
hyperinsulinemia, but altered metabolism in ADT also includes changes to 
circulating levels of ghrelin (Seim et al., 2013), leptin (Onuma, Bub, Rummel, & 
Iwamoto, 2003; Samuel-Mendelsohn et al., 2011) and adiponectin. The endocrine 
changes are accompanied by altered cholesterol and lipid profiles including increased 
HDL and LDL cholesterol and raised triglycerides. In addition, testosterone 
deficiency causes patients to develop sarcopenic obesity, with increased fat mass at 
the expense of muscle mass (Karzai, Madan, & Dahut, 2016; Redig & Munshi, 2010; 
Smith et al., 2008). Second generation ATTs exacerbate these metabolic 
perturbations (Conteduca et al., 2015).  
Many of the ADT induced metabolic side effects overlap with the definition of 
Metabolic Syndrome (MS) by the World Health Organization (WHO).  The WHO 
defines MS as the presence of three or more risk factors among increased waist 
circumference (abdominal obesity), increased circulating triglycerides, decreased 
HDL, raised blood pressure or increased fasting glucose (Table 1.1).  While the 
WHO figures for increased waist circumference can be used for people of European 
origin, for people of non-European origin, the International Diabetes Federation 
(IDF) has lower thresholds for increased central obesity: ≥37in in men and ≥31.5in in 
women (Alberti et al., 2009). MS associates with increased risk of hypertension, 
cardiovascular disease, and significant to this thesis, cancer related mortality (Jaggers 
et al., 2009; Pothiwala, Jain, & Yaturu, 2009); approximately 20% of all new cancers 
can be attributable to obesity (Russo, Autelitano, & Bisanti, 2008), the majority of 
whom will meet the MS criteria. 
Thus, although ADT metabolic dysfunction inadvertently reduces patients’ quality of 
life, more gravely, it might also contribute to PCa recurrence.  
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Table 1.1. Metabolic Syndrome: diagnosed by the presence of 3 or more of these 
risk factors 
 
 
 
  
Risk Factor Defining label
1. Abdominal Obesity Waist circumference
Men >40 in
Women >35 in
2. Triglycerides (mg/dl) ≥ 150
3. HDL-C (mg/dl)
Men <40
Women <50
4. Blood pressure (mmHg) ≥130/≥85
5. Fasting glucose (mg/dl) ≥100
 Chapter 1: Background 35 
1.6 ADT induced hyperinsulinaemia  
There are several lines of evidence that demonstrate a relationship between the 
testosterone and insulin axes. In conditions of insulin resistance such as type 2 
diabetes, there is an association with low testosterone levels (Biswas, Hampton, 
Newcombe, & Aled Rees, 2011; Dandona & Dhindsa, 2011; Grossmann et al., 2008; 
Haffner, Valdez, Mykkanen, Stern, & Katz, 1994; Halmenschlager, Rhoden, & 
Riedner, 2011; Laaksonen et al., 2003; Laaksonen et al., 2004; Rohrmann et al., 
2011). Circulating insulin levels increase in type 2 diabetes occurs due to the 
development of insulin resistance in muscles and other classically metabolic tissues 
such as liver and adipose tissue, whereby cells are unable to transduce the desired 
metabolic signal in response to normal blood insulin levels. Blood insulin levels thus 
rise to compensate to ensure glucose homeostasis. Hypo gonadal men exhibit insulin 
resistance.  
In prostate cancer patients, patients exhibit metabolic dysfunction within 12 weeks of 
commencing ADT with elevated serum triglycerides and cholesterol, and elevated 
insulin levels, contributing to reduced insulin sensitivity index (ISI) and HOMA 
scores, in the absence of significant changes to blood glucose or BMI. In further 
studies, elevated circulated insulin levels, (hyperinsulinemia), as a result of decreased 
insulin sensitivity has been found to be one of the most rapid metabolic responses to 
ADT, developing in PCa patients within two weeks (Yialamas et al., 2007) of 
commencing treatment as a direct consequence of decreased serum testosterone 
levels (Gunter, Lubik, McKenzie, Pollak, & Nelson, 2012; Yu, Lin, Sparks, Yeh, & 
Chang, 2014), providing evidence of a direct inverse co-regulation of the testosterone 
and insulin physiology. Increased insulin levels (hyperinsulinaemia) in type 2 
diabetes are associated with low testosterone levels in several studies (Biswas, et al., 
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2011; Dandona & Dhindsa, 2011; Grossmann, et al., 2008; Haffner, et al., 1994; 
Halmenschlager, et al., 2011; Laaksonen, et al., 2003; Laaksonen, et al., 2004; 
Rohrmann, et al., 2011). Rubinow et al. demonstrated that testosterone is a direct 
inducer of insulin resistance in men, by manipulating both testosterone and oestradiol 
levels in young to middle-aged healthy men and showing that only reduced 
testosterone led to increased insulin resistance (Rubinow, Snyder, Amory, 
Hoofnagle, & Page, 2011), independent of age and disease. While low testosterone 
leads to insulin resistance and hyperinsulinaemia, conversely, high testosterone 
levels are associated with better insulin sensitivity and lowered insulin levels (He, 
Tu, Lee, & Yeung, 2011; Pitteloud et al., 2005). The mechanisms linking 
testosterone levels to insulin sensitivity in men remain poorly understood (Cohen, 
2008; Dhindsa et al., 2011; Tajar et al., 2010; Vermeulen, Kaufman, Deslypere, & 
Thomas, 1993). But given the rapid development of insulin resistance, 
hyperglycaemia, raised body mass index (BMI), fat mass or age do not seem to be 
causal factors (Basaria, Muller, Carducci, Egan, & Dobs, 2006; Dhindsa et al., 2004; 
Yannucci, Manola, Garnick, Bhat, & Bubley, 2006). Despite evidence of the 
development of insulin resistance in metabolic tissue, there is no evidence of to 
suggest that insulin signalling is affected in PCa cells, however, diet-induced 
hyperinsulinemia in mouse models is known to increase insulin receptor expression, 
Akt activation and proliferation in LNCaP xenografts, potentially resulting in 
increased insulin signalling (Venkateswaran et al., 2007). 
1.7 Hyperinsulinaemia as a risk factor for PCa 
Men with diabetes have lower risk of getting PCa, perhaps due to also reduced 
testosterone levels. However, men with type 2 diabetes have more aggressive 
progression of PCa, indicating mechanisms of cancer progression are affected in men 
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with metabolic dysfunction more than initial carcinogenesis. This is also reflected in 
breast cancer studies, where type 2 diabetes increases breast cancer risk moderately 
(12-20%), but impact on breast cancer related mortality much more significantly (30-
100%), suggesting type 2 diabetes is a more potent promoter of tumour progression 
and/or metastases (Barone et al., 2008; Bianchini, Kaaks, & Vainio, 2002; Calle, 
Rodriguez, Walker-Thurmond, & Thun, 2003; Renehan, Tyson, Egger, Heller, & 
Zwahlen, 2008; Xue & Michels, 2007). Hyperinsulinaemia has been identified as a 
specific risk factor for faster progression and increased PCa related mortality 
(Basaria, et al., 2006; Call et al., 2010; Faris & Smith, 2010; Flanagan et al., 2010; 
Fowke, et al., 2008; Hammarsten & Hogstedt, 2005; Ma et al., 2008; Onitilo et al., 
2012). Thus, these observations suggest that insulin signalling might be playing an 
important role in PCa progression.  
1.8 Insulin signalling pathway  
Insulin is part of the insulin like growth factor (IGF) family of signalling molecules 
which consists of the hormonal ligands insulin, insulin like growth factor 1 (IGF1) 
and insulin-like growth factor 2 (IGF2) and three receptors, namely, insulin receptor 
(IR), IGF1 receptor (IGF1R) and IGF2 receptor (IGF2R). The IR and IGF1R are 
transmembrane receptors can exist either as homodimers or heterodimers. Moreover, 
IR has two isoforms, where IR isoform A (IR-A) has exon 11 spliced out compared 
to IR isoform B (IR-B). Importantly, insulin can signal through homodimers of IR-A, 
homodimers of IR-B, or heterodimers of IR-A and IR-B. Insulin can also signal 
through heterodimers of IR-A or IR-B with IGF1R, but not through homodimers of 
IGF1R (Belfiore, 2007).   
Conversely, IGF1 can signal through homodimers of IGF1R or heterodimers of 
IGF1R with either isoform of IR, but not with homodimers of IR. IGF2 can signal 
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through all the different combinations of receptors. IGF2R can bind IGF2, but acts as 
a quencher of IGF2 signalling, where it binds the IGF2 but does not cause a 
downstream signalling cascade, effectively blocking IGF2 function in the cell. 
Insulin binds with greater affinity to IR-A than IR-B, and does not bind to IGF1R 
under physiological conditions (Table 1.2) Belfiore, Frasca, Pandini, Sciacca, and 
Vigneri (2009). 
The predominant isoform of IR (A or B) shifts with age. During development, IR-A 
is normally expressed in fetal tissue. Insulin signalling through IR-A is important for 
normal development and differentiation of many organs, such as pancreatic β-cells, 
bone, neurons and retina (Dudek et al., 1997; Hellstrom et al., 2001; Lupu, 
Terwilliger, Lee, Segre, & Efstratiadis, 2001; Pete et al., 1999; Withers et al., 1998). 
Notably, insulin is also crucial for the development of the prostate (Angervall, et al., 
1967; Sufrin & Prutkin, 1974; Suthagar, et al., 2009) although receptors involved or 
mechanisms are unknown.  
While IR-A is considered to be mitogenic, IR-B is primarily metabolic in function 
(Belfiore, et al., 2009; Giudice, Leskow, Arndt-Jovin, Jovin, & Jares-Erijman, 2011) 
and is the predominant isoform in adult metabolic tissues. Insulin signalling through 
IR-B in classic metabolic tissue such as muscles, adipose and liver involves 
translocation of glucose transporter, GLU4 to the cell surface in response to blood 
glucose levels. IR-B signalling is better characterized than IR-A. Downstream 
signalling commonly involves phosphoionosidite-3-kinase (PI3K) and mitogen 
activated protein kinases (MAPK) pathways, leading to increased gene transcription, 
protein synthesis, lipogenesis and proliferation. Insulin signalling is thus a 
physiological marker of an energy excess state, engaging anabolic mechanisms and 
growth.   
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Table 1.2 IC50 values (nM) of insulin, IGF1 and IGF1R to the different 
receptors in the insulin/IGF signalling pathway. The lower the IC50 value, the 
higher the affinity of the ligand for the receptor. Values taken from (Belfiore, et al., 
2009). 
  Insulin IGF1 IGF2 
IR-A 0.2-0.9 9.0-41 2.2-2.5 
IR-B 0.5-1.6 
90.0-
390 10.0-20 
IGF1R 
30.0-
1000 0.2-50 0.5-4.4 
IR-A/IR-B hybrid 
receptor 1 50 10 
 
1.9 Insulin signalling in cancer 
The role that elevated insulin levels play in cancer is an emerging area of research 
(reviewed in (Malaguarnera & Belfiore, 2014)). Recently, hyperinsulinaemia has 
been specifically reported to promote metastasis to the lung in a mouse model of 
Her2-mediated breast cancer (Ferguson et al., 2013) as well as in breast cancer 
xenografts studies (Ferguson et al., 2012). Several recent studies suggest that insulin 
mediated cancer progression seems to occur due to a switch in the composition of 
insulin receptor isoforms expressed in adult cells. 
IR-A expression in adults have been recognized as a key mediator for progression of 
several cancers (Malaguarnera & Belfiore, 2014). In thyroid cancers, anaplastic 
cancer cells express higher levels of IR-A compared to more differentiated thyroid 
cancer histotypes (Vella et al., 2002). Increasing IR-A expression in hepatoblastoma 
cell lines also correlate with increasing mesenchymal phenotype and epithelial-to-
mesenchymal transition (EMT, further discussed section 1.9) (Zhao et al., 2012). IR-
A transfection in HepG2 hepatoblastoma cells increased proliferation and migration 
in response to insulin, while transfection with IR-B decreased both biological effects 
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(Pandini et al., 2002). Transfection of IR-B, but not IRA, in colon cancer cells 
(Andres et al., 2013) and 32D cells (Sciacca et al., 2003) also increased biomarkers 
of differentiation. In fact, the ratio of IR-A:IR-B might be an important regulator of 
cellular plasticity. Induction of differentiation in progenitor/stem cells from human 
thyroid was associated with a dramatic decrease in both absolute IR-A content and in 
IR-A:IR-B ratio (Malaguarnera et al., 2011). Induction of differentiation and 
epithelial phenotype in human liver cancer HepG2 cells showed marked decrease of 
IR-A:IR-B ratio from 80:20 to 20:80 (Kosaki & Webster, 1993; Pandini, et al., 
2002). Additionally, mouse intestinal stem cells and progenitors are characterized by 
high IR-A:IR-B ratio (Andres, et al., 2013).  
IGF1 signalling is well established to be crucial for cancer progression, however 
clinical trials with anti-IGF1R antibodies show disappointing results (Baserga, 2013).  
Several recent studies of breast, prostate and bone cancers show that presence of IR-
A increases with development of resistance to IGF1R blockade (Garofalo et al., 
2011; Weinstein, Sarfstein, Laron, & Werner, 2014; Yang & Yee, 2012). Thus, IR-A 
may play an important role in mediating cancer progression and may help in 
conferring treatment resistance.  
Additionally, in PCa, cross talk exists between PI3K, MAPK and AR signalling 
pathways that could contribute to ATT resistant progression. The AR can be 
phosphorylated independently of ligand binding via the PI3K/AKT and MAPK 
pathways (Malinowska et al., 2009a; Robinson, Zylstra, & Williams, 2008; Seaton et 
al., 2008). Conversely, MAPK can be directly activated by AR (Bunone, Briand, 
Miksicek, & Picard, 1996; Migliaccio et al., 2000; Migliaccio et al., 1996; Peterziel 
et al., 1999; Zhu, Li, Liu, & Funder, 1999) to rapidly stimulate proliferation (within 2 
minutes) in prostate cancer cells (Kousteni et al., 2001; Migliaccio, et al., 2000; 
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Peterziel, et al., 1999), distinct from the transcriptional actions of AR. It is 
hypothesized that cells with mutated AR or those with transient/low access to 
androgens exhibit such MAPK activation, making this particularly relevant to ATT 
and PCa (Kousteni, et al., 2001). Importantly, current anti-androgens, which target 
the ligand binding domain of AR, are unable to inhibit this activation of MAPK 
(Peterziel, et al., 1999). Moreover, MAPK is able to phosphorylate AR and allow 
androgen-dependent gene activation in the absence of DHT ligand (Ueda, Mawji, 
Bruchovsky, & Sadar, 2002; Yeh et al., 1999). Constitutively active MAPK was 
shown to directly stimulate and transcribe AR-regulated genes without androgens, 
while dominant negative MAPK impaired the ability of AR to be activated by 
androgens (Abreu-Martin, Chari, Palladino, Craft, & Sawyers, 1999). c-JUN, 
downstream of MAPK, enhances AR DNA binding and gene transcription (Bubulya, 
Wise, Shen, Burmeister, & Shemshedini, 1996; Bubulya, Zhou, Shen, Fisher, & 
Shemshedini, 2000). Transfection of a constitutively active Akt maintains prostate 
cancer survival in an androgen-poor or growth factor-poor environment (Graff et al., 
2000; Murillo, Huang, Schmidt, Smith, & Tindall, 2001). It is well documented that 
activated Akt phosphorylates AR to promote prostate cancer survival (Campbell et 
al., 2001; Carson, Kulik, & Weber, 1999; Davies et al., 1999; Graff, et al., 2000; 
Kimura, Markowski, Bowen, & Gelmann, 2001; Li, Nicosia, & Bai, 2001; Lin, Yeh, 
Kang, & Chang, 2001; Manin et al., 2002; Nelson & Carducci, 2000; Sharma, 
Chuang, & Sun, 2002; Sun et al., 2001; Wen et al., 2000; Wilding, Gelmann, & 
Freter, 1990). AR binding to FOXO1 inhibits AR signalling (Melnik, 2010; Melnik 
& Schmitz, 2009). Akt, through phosphorylation of FOXO1, might reverse its 
inhibition of AR and thus amplify androgen signalling (Melnik, 2010; Melnik & 
Schmitz, 2009).  
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As PI3K and MAPK pathways can be activated downstream of insulin signalling, 
these observations suggest that the insulin and AR signalling pathways might not be 
mutually exclusive, especially in a low androgen context. Existence of such 
horizontal signal transduction between insulin and AR might promote ATT 
resistance in PCa cells. 
Insulin signalling, through phosphoinositide 3-kinases (PI3K) and mitogen activated 
protein kinase (MAPK) pathways, can also modulate several processes which might 
be relevant to cancer progression such as lipogenesis, steroidogenesis, protein 
synthesis and anti-apoptotic survival (Belfiore, et al., 2009; Mounier & Posner, 
2006b). 
1.10 Insulin receptor in prostate cancer 
Expression of insulin receptor in PCa tumours has been identified and characterised 
in several studies (Figure 1.4). Insulin receptor gene (INSR) expression was found to 
be increased in PCa and in adjacent prostate tissue immediately surrounding the 
tumour, but not benign prostate tissue (Heni et al., 2012) (Figure 1.4A). This 
suggests an association of insulin signalling in the tumour microenvironment that 
might be specific to tumour pathogenesis. Moreover, the INSR-A isoform is 
increased over INSR-B and IGF1R suggesting a selective upregulation of pathways 
downstream of INSR-A such as mitosis.  
Increased IR expression has also been identified as a mechanism contributing to the 
development of resistance to therapies targeting IGF1R (Weinstein, et al., 2014) 
(Figure 1.4E), potentially allowing cells to maintain similar signalling pathways. And 
IR transcripts were increased by AR activation in C42B and PC3 cells (negligible 
endogenous AR expression) engineered to express wild-type AR, suggesting AR 
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activation can at least partially regulate IR transcription.  (Weinstein, et al., 2014) 
(Figure 1.4F). 
Previous studies from this laboratory have shown that insulin receptor protein (IR) 
expression increased with PCa progression in tumours from radical prostatectomy 
compared to tumours from patient with CRPC  (Cox et al., 2009). Additionally, in an 
in vivo LNCaP CRPC model, tumours from mice that developed biochemical 
recurrence increased INSR mRNA in parallel with increased PSA compared to mice 
that did not have re-expression of PSA, and did not display changes to INSR 
expression (Lubik et al., 2011) (Figure 1.4B and C). Most interestingly, our previous 
results also indicate that increasing length of treatment with ADT is associated with 
elevated IR expression in our PCa tissue specimens (Lubik, Gunter, Hollier, Fazli, et 
al., 2013) (Figure 1.4D). Thus, ATT possibly induces a positive feedback loop of 
insulin signalling, where circulating ligand (insulin) is increased due to 
hyperinsulinaemia and receptor (IR) is also increased, causing amplification of 
insulin signalling, although this has not been specifically tested in ADT induced 
hyperinsulinaemic patients.   
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Figure 1.4: Insulin receptor expression is up-regulated in prostate cancer. (A) 
Radical prostatectomy samples from 65 prostate cancer patients and 23 healthy 
volunteers, showing the expression of insulin receptor isoform A as a ratio of the 
expression of isoform B (Heni, et al., 2012).  (B) Immunohistochemistry of prostate 
cancer tumours with increasing Gleason grades show increasing IR (brown) with 
disease progression (Cox, et al., 2009). (C) LNCaP xenografts collected 28 days- 
post castration when mice experience biochemical recurrence. PSA, INSR-A and 
IRS2 mRNA increased in mice with recurrence (blue) but not in mice that did not 
progress to CRPC (red) (Lubik, et al., 2011). (D) IR (brown) in prostate cancer 
patient tissue increased with neo adjuvant hormone therapy (NHT) duration and 
advancing disease (Lubik, Gunter, Hollier, Fazli, et al., 2013). (E) IGF1R inhibitor 
AR12 decreases IGF1R but not IR levels in C42B cells (F) Stimulation of DHT in in 
C42B and PC3cells overexpressing wild type AR show increased promoter activity 
at the insulin receptor.  
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1.11 Metastatic PCa 
The fatal form of PCa is metastatic disease (De et al., 2003; Konishi, Shimada, 
Ishida, & Nakamura, 2005; Swanson, Thompson, & Basler, 2006), with a mean 
overall survival of 16-18 months (Marques, et al., 2010). The metastatic cascade 
begins with gain of invasion and migration of tumour cells, followed by 
extravasation into blood or lymphatic vessels for circulation throughout the body, 
after which surviving cells may extravagate into distant organs and seed metastatic 
tumours (Pantel & Brakenhoff, 2004). Metastatic disease is also clonal, and 
evolution of different subtypes of PCa cells under ADT and ATTs is under 
investigation (Attard, et al., 2016). Neuroendocrine prostate cancers also become 
more common in CRPC, accounting for 10-30% of recurrent PCa (Aggarwal, Zhang, 
Small, & Armstrong, 2014). Along with the mentioned reactivation of AR, genetic 
alterations of PI3K/Akt (100% in metastasis verses 42% in primary) and MAPK 
(90% in metastasis verses 43% in primary) have been identified as major pathways 
of disease progression(Karantanos, Corn, & Thompson, 2013). As these pathways 
are also frequently activated downstream of IR, insulin signalling may play key roles 
in metastatic development of PCa.  
In fact, several studies have reported that insulin signalling can increase cancer 
invasion and migration. Insulin has been directly shown to induce invasion of 
endometrial cancer and pancreatic cancer cells (Wang et al., 2010; Wang et al., 
2012). Insulin’s emerging role as a modulator of cell invasion phenotype is further 
supported by a recent study showing insulin signalling promotes the activity of 
discoidin domain receptor (DDR),  receptor tyrosine kinases that interact with the 
extracellular matrix and play important roles in cell invasion, migration and adhesion 
(Iwai, Chang, & Huang, 2013). Moreover, serum from obese mice has been shown to 
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induce migration in melanoma and prostate cancer cell lines (Kushiro & Nunez, 
2011a; Price, Cavazos, De Angel, Hursting, & Degraffenried, 2012b) suggesting 
metabolic changes associated with obesity, including elevated insulin, may drive 
metastatic progression. Insulin also induces migration and proliferation in 
endometrial cancer (Wang, et al., 2012). Furthermore, hyperinsulinaemia has been 
shown to increase breast cancer metastasis in xenograft models (Ferguson, et al., 
2013; Ferguson, et al., 2012), is reduced when IR is knocked down in the grafted 
breast cancer cells (Zelenko et al., 2016) .   
1.12 Research structure 
Hypothesis: In the absence of androgens, insulin signalling is altered in PCa cells 
and elevated insulin levels enhance disease progression in prostate cells.  
AIM 1 Characterize the expression and localization of insulin receptors 
in clinical samples and in response to manipulation of the 
androgen axis in PCa cells. 
AIM 2    Characterize insulin-induced proliferation, migration and 
invasion in prostate cancer cells in the context of ADT and ATTs. 
AIM 3 Identify the molecular mechanisms of insulin-induced migration 
and invasion. 
Significance: This thesis sets out to characterise current, and establish new models 
which allow manipulation of insulin signalling or manipulation of androgen 
signalling.  Using these models, this thesis explores pathways activated downstream 
of insulin that contribute to disease progression and the failure of current therapies.  
This thesis presents the case for better understanding the mechanisms by which 
insulin may drive critical pathways of progression which lead to the aggressive 
tumour phenotype observed in epidemiological studies. The first aim addresses the 
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relationship between IR and AR and in so doing, establishes models required for 
further analysis in aims 2 and 3. My following aim uncovers a critical pathway 
contributing to the development of an invasive phenotype within the context of 
androgen signalling. My final aim attempts to define the molecular mechanisms 
underpinning this pathway.  
Together, my data establishes that insulin does directly affect PCa progression and 
provides data to rationalise the clinical management of metabolic side effects, and 
the potential use of metabolic therapies to extend the efficacy of androgen 
deprivation therapy.  
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2.1 Cell lines and culture  
A variety of PCa cell lines with a spectrum of AR responsiveness and AR expression 
were used in various assays of this thesis to study insulin driven processes in both the 
AR responsive/positive state and the AR unresponsive/negative state. AR 
responsiveness is stated based on the cell’s PSA expression in response to DHT 
treatment. Reasoning of the different cell lines used in various assays is provided in 
the individual chapters of the thesis that discuss the results of the assays. The PCa 
cell lines LNCaP, 22RV1, C42B, VCAP, DU145 and PC3 were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA, USA) and were 
maintained in phenol red-free Gibco© Roswell Park Memorial Institute (RPMI)-1640 
medium containing 1mM L-Glutamine (Life Technologies, Carlsbad, CA, USA) 
supplemented with 10% foetal bovine serum (FBS; Invitrogen). LNCaP shAR cells 
were generated by Dr. Gregor Tvez of APCRCQ via the same method detailed in 
section 2.3 and kindly gifted. These were also cultured in phenol red-free RPMI 
containing 1mM L-Glutamine supplemented with 10% FBS. DUCAP PCa cells were 
provided by Matthias Nees from the VTT Technical Research Centre of Turku, 
Finland, and were maintained in phenol red-free Gibco© RPMI-1640 medium 
containing L-Glutamine with 10% FBS.  
HEK293T cells (ATCC) and Chinese Hamster Ovary cells engineered to stably 
overexpress the insulin receptor (CHO.IR), (kind gift from Jon Whitehead, Mater 
Medical Research Institute, TRI), were maintained in Gibco© Dulbecco’s Modified 
Eagle Medium (DMEM) with L-Glutamine and 2.438g/L sodium bicarbonate (Life 
Technologies), supplemented with 10% FBS.  
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All cells were grown at 37˚C in a humidified atmosphere of 5% CO2 and 95% air. 
Cell lines were confirmed by STR analysis and tested regularly to confirm the 
absence of mycoplasma. 
Table 2.1 AR and PTEN status of parental prostate cancer cell lines used.  
Cell line AR status PTEN status 
LNCaP 
AR positive and responsive (PSA 
expression)
Loss-of-function 
mutation 
22RV1 AR positive and mildly responsive PTEN+/+ 
C42B AR positive and responsive
Loss-of-function 
mutation 
VCAP AR positive and highly responsive PTEN+/+ 
DUCAP AR positive and highly responsive PTEN+/+ 
DU145 AR negative and unresponsive PTEN+/- 
PC3 AR negative and unresponsive PTEN-/- 
2.2 Treatment with hormones and inhibitors  
Different cell lines were used in different assays, as detailed further along this 
chapter. Various hormones and inhibitors were used in different combinations in 
different assays, which is explained in greater detail in the results sections of the 
following chapters.  
To stimulate androgen deprivation context, assays were performed on cell cultured in 
androgen deprived condition. Androgen deprivation was performed for both AR 
positive and negative cells (e.g. PC3, DU145), for consistency, as well as to study 
response of AR negative cells in androgen deprived context because prevalence of 
AR negative cells increase in patients under chronic hormone therapy. Cells were 
seeded in appropriate FBS-supplemented media and incubated overnight to allow 
cells to adhere. The following day, the media was changed to media containing CSS 
and incubated for 48 hours, to simulate androgen deprivation. After this time, cells 
underwent treatment with hormones and inhibitors outlined in Table 2.1. 
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For functional studies hormone treatment was performed in media supplemented 
with 10% CSS, however, for molecular studies (qRT-PCR, Western blotting and 
Immunofluorescence) hormone treatment was performed in serum-free media 
supplemented with 0.2% Bovine Serum Albumin (BSA, Sigma-Aldrich, St. Louis, 
MO, USA).  
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Table 2.2 Drugs and hormones.  Table listing concentrations of hormones, growth 
factors and inhibitors used in experiments.  
Hormone/Inhibitor Final 
concentration 
Description Optimization of final 
concentration 
Insulin 10nM Endogenous hormone 
produced by pancreatic β-
cells
Used previously in 
published literature 
(Lubik, et al., 2011)
Insulin-like growth 
factor-1 (IGF-1) 
100ng/mL Endogenous growth 
factor and member of 
insulin family of proteins, 
with high homology to 
insulin 
Used previously in 
published literature 
(Watson, O'Brien, 
Coffey, & Fitzpatrick, 
2000) 
Insulin-like growth 
factor-2 (IGF-2) 
80ng/mL Endogenous growth 
factor and member of 
insulin family of proteins. 
Structural similarity to 
insulin 
Used previously in 
published literature 
(Lubik, Gunter, 
Hollier, Ettinger, et al., 
2013) 
Epidermal growth 
factor (EGF) 
50ng/mL Endogenous growth 
factor that stimulates 
proliferation and cell 
migration
Used previously in 
published literature 
(Cai et al., 2008) 
Dihydrotestosterone 
(DHT) 
10nM Androgen, steroid 
hormone and potent 
activator of the androgen 
receptor (AR) 
Used previously in 
published literature 
(Lubik, et al., 2011) 
Bicalutamide 10μM AR antagonist Used previously in 
published literature 
(Lin et al., 2013)
Enzalutamide 
(MDV-3100) 
10μM AR antagonist.  Used previously in 
published literature 
(Lin, et al., 2013)
Apalutamide 
(ARN509) 
10μM AR antagonist Used previously in 
published literature 
(Clegg, et al., 2012)
BMS 745804-07 500μM Small molecule 
antagonist of IR and 
IGF1R 
Optimized in house, 
(supplementary figure 
4.1 and discussed in 
chapter 4, section 
4.2.2) 
CP 751871 5ug/mL Monoclonal antibody 
against IGF1R and 
inhibits function of 
IGF1R. 
Optimized in house, 
(supplementary figure 
4.1 and discussed in 
chapter 4, section 
4.2.2) 
PD 98059 10μM PD98059 is a non-
competitive small 
molecule inhibitor of 
MAPK (MEK1 and 
Used previously in 
published literature 
(Xie, Li, Dang, Chang, 
& Li, 2016) 
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MEK2). 
UO 126 10μM UO126, is a small molecule 
inhibitor of MAPK (MEK1 
and MEK2)  
Used previously in 
published literature 
(Freeman, Kim, 
Lisanti, & Di Vizio, 
2011) 
LY 294002 5μM LY294002 is a morpholine-
containing chemical 
compound that is a potent 
inhibitor of 
phosphoinositide 3-kinases 
(PI3K)
Used previously in 
published literature 
(Lane et al., 2013) 
Metformin 30μM Biguanide drug, widely 
used in the treatment of 
type 2 diabetes mellitus. 
Binds Complex 1 of 
electron transfer chain 
and activates AMPK. 
Optimized in house 
(Discussed in 
Appendix, section 
A1.2 and Figure A1.2) 
Phenformin 30μM Potent biguanide, not in 
clinical use 
Optimized in house 
(Discussed in 
Appendix, section 
A1.2 and Figure A1.2) 
Mitomycin C 
(MMC) 
10μg/mL Anti-mitotic agent; DNA 
cross-linker 
Optimized in house 
(Discussed in Chapter 
4, section 4.2.3 and 
Supplementary Figure 
4.2)
Nocodazole 100ng/mL Antineoplastic agent; 
inhibits polymerization of 
microtubules 
Optimized in house 
(Discussed in Chapter 
4, section 4.2.3 and 
Supplementary Figure 
4.2)
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2.3 Generation of inducible INSR knockdown LNCaP cells 
pTRIPZ lentiviral inducible shRNA containing one of three microRNA-adapted 
shRNA (shRNAmir) targeting the insulin receptor gene (INSR) or one of four 
shRNA constructs targeting the IGF1R gene were obtained (Thermo Scientific). The 
pTRIPZ construct is designed with Tet-inducible shRNA expression that allows 
controlled timing and reversible expression (Figure 2.1). The vector has been 
engineered to be tetracycline (TET)-On and produces tightly regulated induction of 
shRNA in the presence of doxycycline.  In addition, TRIPZ design incorporates a red 
fluorescent protein (RFP)-reporter to allow for easy discrimination of doxycycline 
activation. Agar plates supplemented with 100ug/ml carbenicillin were streaked with 
e.coli containing each construct and incubated at 37˚C for 16 hours. Single colonies 
were picked from each plate and expanded at 37˚C overnight, shaking, in 5mL of 
nutrient broth/LB medium supplemented with carbenicillin (100ug/ml) and DNA 
purified using QIAGEN miniprep spin column (QIAGEN, Hilden, Germany). DNA 
was quantitated using the Nanodrop. 
 
Figure 2.1 pTRIPZ Vector Map. Map of the major cassettes within the pTRIPZ 
vector. Reverse tetracycline-transactivator 3 (rtTA3) and puromycin resistance genes 
are downstream of the human ubiquitin C (UBC) promoter. Turbo RFP (tRFP) and 
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shRNA to target are cloned downstream of the tetracycline inducible promoter 
(TRE). Source: Dharmacon GE Life Sciences 
 
HEK293T cells were 1.5x106 plated onto 10cm dishes in 10 ml DMEM with 10% 
heat inactivated (55°C for 1 hour) FBS without antibiotics. After 12-20 hours, or 
when they are about 50-60% confluent, the cells were co-transfected with pTRIPZ 
vectors and MISSION RNAi Lentiviral Packaging Mix (Sigma-Aldrich) containing 
packaging and envelope vectors (pUMVC and pCMV-VSVG) for production of viral 
particles. Transfections were carried out according to the manufacturer’s instructions 
to create high-titre pseudo-typed lentiviral particles containing the shRNAmir 
sequences. Three pTRIPZ vectors were used, each containing a different shRNAmir 
sequence targeting INSR (clone ID V3THS_319895, V3THS_319891, 
VSTHS_319890). Briefly, 185ul of serum-free DME was mixed by pipetting with 
2ul of transfection reagent FUGENE, 1.8ug of pCMV gag/pol (pUMVC), 0.2ug of 
pCMV-VSVG and 2.0ug of pTRIPZ containing shRNAmir targeting INSR. This 
mixture was incubated at room temperature for 15 minutes and then dripped onto the 
HEK293T cells using a pipetman. After 24 hours the HEK293T cells were switched 
to 7mL fresh serum free DME media. Viral particles were allowed to accumulate in 
the media for a further 48 hours before it was collected and filter sterilised through a 
0.45 um filter. Another fresh 7mL of serum free DME media was added to the 
transfected HEK293T cells for further viral accumulation, which was collected after 
24h and filter sterilized through a 0.45um filter. The 7mL of virus containing media 
each collected 48 hour and 72 hour post transfection were both combined into one 
lot. 
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Meanwhile, LNCaP cells were seeded in 6-well plates at a 30-50% confluence. Once 
attached, lentivirus-containing media was added directly to LNCaP cells (passage 
30). After 24 hours, cells were changed into RPMI (5% FBS) and supplemented with 
2μg/mL puromycin (Invitrogen) to select transduced cells. Once the cells had 
undergone selection, they were maintained in RPMI (5% FBS) supplemented 
1μg/mL puromycin. Transduced LNCaP cells displayed some TET-off RFP 
expression. After selection with puromycin, transduced LNCaP cells were sorted for 
RFP low expression using the MoFlow Astrios Sorter (Flow Cytometry Core 
Facility, TRI). Optimal knockdown of gene expression was confirmed using QRT-
PCR and Western blot. 
 
2.4 Cell proliferation assays 
Cell proliferation was assessed by quantification of PrestoBlue® assay (Thermo 
Fisher Scientific), according to the manufacturer’s instructions. Cells were seeded at 
approximately 20% density in 96-well plates. Cells were treated as per experimental 
protocol and at the end of the treatment period 10ul of Presto Blue reagent was added 
to each well. Cells were incubated at 37°C, in a humidified incubator for a further 4-
6 hours. PrestoBlue® is a resazurin-based solution that undergoes a colour change 
based on metabolic reduction by living cells. Metabolism of reagent was detected 
using the PHERAstar FSX Plate Reader (BMG Labtech) with absorbance readings at 
570nM and 600nM. 
To overcome treatment-induced metabolic changes, proliferation was also assessed 
by quantitating cellular DNA content through the Cyquant® assay (Thermo Fisher 
Scientific), according to the manufacturer’s instructions. Briefly, at the end of the 
assay, media was removed and replaced with 200 μl cell lysis solution containing 
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CyQUANT®GR dye, which exhibits high fluorescence when bound to DNA. Cells 
were frozen at -80°C to enhance lysis and thawed before analysis using the Omega 
plate reader at 480 nm excitation and 520 nm emission.  
2.5 Wound-healing migration assay 
To test the effect of insulin on a range of AR responsive cells LNCaP, 22RV1 and 
DU145 cells were chosen and were seeded at 10 000, 5000 and 18 000 cells per well, 
respectively in 96-well Image Lock plates (Essen Biosciences, Ann Arbor, MI, USA) 
and grown to confluence. The cells underwent 48 hours incubation in 5% CSS RPMI 
to simulate androgen deprivation and were treated with 10μg/mL mitomycin C 
(MMC) to prevent proliferation 2h prior to treatment with hormones and inhibitors. 
Scratch wounds were created down the centre of the wells using the Incucyte Wound 
Maker (Essen Biosciences) as per the manufacturer’s instructions. Wells were 
imaged and quantitated every 2h at x20 magnification using the Incucyte and 
associated software (Essence Biosciences). Insulin and DHT were topped up every 
24 hours. Experiments typically contained 6-12 technical replicates. At least three 
independent sets of experiments have been performed for each treatment in LNCaP, 
22RV1 and DU145 cell lines. 
 
2.6 Transwell migration assay 
Transwell migration assays were performed in sterile 24-well plates (Corning, NY, 
USA) using Millicell culture inserts with 8 μm pore size polycarbonate filters of 
12mm diameter (Merck Millipore, Billerica, MA, USA). LNCaPs were androgen 
deprived for 48h and then pre-treated with desired hormones and inhibitors for 24 
hours in serum free RPMI-1640, before being detached, resuspended in serum-free 
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RPMI containing appropriate treatment, and seeded in triplicate at 2.5x105 cells per 
insert. The outside of the inserts contained RPMI-1640 supplemented with 10% FBS, 
as the chemo-attractant. Cells were incubated at 37˚C for 48h. At the end of this 
time, cells adhering to the lower surface of the inserts were fixed in 100% methanol 
for 1 min at room temperature and differentially stained using Dip Quick stain 
(Fronine, Thermo Scientific, Waltham, MA, USA) according to manufacturer’s 
protocol. Dye I contains eosin, staining basophilic cellular elements and Dye II 
contains methylene blue which stains acidophilic cellular elements including the 
nucleus. The cells remaining on the inside (top) of the insert were removed using wet 
cotton buds, leaving behind only the fixed and stained cells that had migrated across 
the pore to the lower side of the insert. The inserts were imaged in five representative 
fields at X10 magnification using the Eclipse Ti microscope (Nikon Instruments Inc., 
Melville, NY, USA) and the cells counted manually using the counting tool of Adobe 
Photoshop. The counts from all five images were totalled to provide the number of 
migrating cells in the total area imaged per insert.  
2.7 Transwell invasion assay 
Transwell invasion assays were performed in Modified Boyden Blind Well 
Chambers with 13 mm diameter 12 μM pore size PVP free polycarbonate filter 
(Neuro Probe Inc, Gaithersburg, MD, USA). Filters were coated with 50µL (0.50 
mg/mL) of growth-factor reduced phenol-red free Matrigel™ (BD Biosciences, 
Becton Drive Franklin Lakes, NJ, USA). Androgen deprived and pre-treated LNCaP 
cells (3x105 cells/well) were seeded in the upper chamber containing serum-free 
RPMI-1640 with appropriate treatments. The lower chambers were filled with 
RPMI-1640 containing 10% FBS as the chemo-attractant. Invasion was followed for 
24h at 37˚C. Cells adhering to the lower surface of the filter were fixed by 100% 
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methanol and stained with Dip Quick stain as described, above. The total number of 
invading cells was acquired in five representative fields at X10 magnification by 
using Eclipse Ti microscope as above. 
2.8 3D MatrigelTM cell culture 
Cells were grown between two layers of growth-factor reduced phenol-red free 
Matrigel (BD Biosciences, Becton Drive Franklin Lakes, NJ, USA) on uncoated 
sterile 96-well plates (Corning, NY, USA): bottom layers were formed with 35μL of 
Matrigel: culture medium (3:1; 75%; 7.35mg/mL of Matrigel) and polymerized at 
37°C for 30 min. Cells were then seeded at a density 10,000 cells/ml (1000 
cells/well), resuspended with Matrigel: culture medium (1:39, 2.5%; 0.245mg/mL of 
Matrigel) and incubated overnight at 37°C. Culture medium (RPMI-1640, 10% 
FBS), and was changed every second day. Single cells within the Matrigel layers 
were allowed to proliferate into small spheroidal colonies for 3-7 days, after which 
the culture medium was switched to RPMI-1640, 5% CSS with additional treatments. 
The colonies were cultured for another 14 days with periodic imaging. Insulin and 
DHT treatments were topped up every 24h, and all media of all samples changed 
every second day. 
2.9 Microarray 
To assess the effect of insulin on PCa cells, in the presence and absence of androgen, 
LNCaP cells, plated on 10cm dishes, were incubated in 5% CSS RPMI (Sigma-
Aldrich) for 48hr, followed by 24h incubation in in 5% CSS RPMI with 10nM 
R1881 or equal volume 20% EtOH (vehicle). Cells were next transferred to serum 
free RPMI with treatments maintained for 24hr. 10nM insulin was then added in the 
final 10hr before TriReagent (Sigma-Aldrich) extraction of RNA. All treatments 
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were done in triplicate. A custom designed microarray was used (GEO platform ID 
GPL17236, Agilent Technologies, Wilmington, DE, USA). The total RNA quality 
was assessed using the Agilent RNA 6000 Nano Kit (Agilent) on an Agilent 2100 
Bioanalyzer for RIN >8. One-colour microarray-based gene expression analysis was 
performed following Agilent's Quick Amp Labelling Kit (Agilent) using 500 ng of 
total RNA according to manufacturer’s instructions. Scanning was performed using 
Agilent High Resolution Microarray Scanner, and data was processed with the 
Agilent Feature Extraction 10.5.1 software (Agilent). Data was normalized using the 
quantile normalization method in LIMMA (Ritchie et al., 2015). Results were 
submitted to GEO (GSE47622).  
The above experimentation and subsequent bioinformatics analysis was performed 
by groups within the APCRC-Q.  
Pathway analysis on available data was performed using Ingenuity Pathway Analysis 
(Qiagen, San Francisco, USA) against a compiled list of genes associated with 
epithelial and mesenchymal phenotypes from published literature. Heatmap 
visualisation was performed using GenePattern software (Reich et al., 2006). Data 
was also visualized using browser extensible data (BED) tracks, available within the 
general laboratory, using UCSC Genome Browser (Kent et al., 2002) 
(http://genome.ucsc.edu/) on the RefSeq human GRCh38/hg38 Assembly (Lander et 
al., 2001).      
2.10 Gene expression in RNA-Sequence samples 
mRNAseq was performed in the following three experiments:  
1. PDX samples, where the method is detailed in (Conway et al., 2012) 
2. LNCaP cells were cultured under androgen deprived conditions (5% CSS 
containing RPMI) for 48 hrs and treated with DHT (10nM), and AR 
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inhibitors ARN509 (10μM), bicalutamide (10μM) and enzalutamide (10μM) 
for another 48hrs in androgen deprivation. 
3. LNCaP cells were cultured under androgen deprived conditions (5% CSS 
containing RPMI) for 48 hrs and treated with metformin (500μM) with and 
without DHT (10nM) for 48hrs in androgen deprivation. 
For experiments 2 and 3 mRNAseq, total cellular RNA was extracted using the 
Norgen RNA Purification PLUS kit #48400 (Norgen Biotek Corp., Thorold, Canada) 
according to the manufacturer's instructions, including DNase treatment. RNA 
quality and quantity were determined on an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, USA) and Qubit®. 2.0 Fluorometer (Thermo Fisher 
Scientific Inc, Waltham, USA). Library preparation and sequencing was done at the 
Kinghorn Centre for Clinical Genomics (KCCG, Garvan Institute, Sydney) using the 
'Illumina TruSeq Stranded mRNA Sample Prep Kit' with an input of 1 ug total RNA 
(RIN>8), followed by paired-end sequencing on an Illumina HiSeq2500 v4.0 
(Illumina, San Diego, USA), multiplexing 6 samples per lane and yielding about 
30M reads per sample. Raw data was processed through a custom designed pipeline. 
Raw reads were trimmed using 'TRIMGALORE', followed by parallel alignments to 
the genome (hg38) and transcriptome (Ensembl v77) using the 'STAR' aligner and 
read quantification with 'RSEM'. Differential expression between two conditions was 
calculated using 'edgeR' and is defined by an absolute fold change of >1.5 and a 
corrected p-value <0.05. Quality control of raw data included sequential mapping to 
the ERCC controls, rRNA and a comprehensive set of pathogen genomes as well as 
detection and quantification of 3'bias. 
The above experimentation and subsequent bioinformatics analysis was performed 
by groups within the APCRC-Q.  
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Detailed information on all the transcripts investigated in the RNA-Seq data for the 
genes INSR-A, INSR-B IGF1R, IGF1, IGF2 and IGF2R was accessed using the 
associated ensembl77 transcript name in the ensembl website 
(http://www.ensembl.org) (Yates et al., 2016). The main transcript for each gene 
within the cell was chosen based on the description of the transcript on ensemble 
dataset as well as the counts per million for that transcript. RNA-Seq data were also 
visualized using browser extensible data (BED) tracks, available within the general 
laboratory, using UCSC Genome Browser (Kent, et al., 2002) 
(http://genome.ucsc.edu/) on the RefSeq human GRC h38/hg38 Assembly (Lander, 
et al., 2001). Bar graphs and one-way ANOVA for the differences in counts per 
million across the relevant treatments for the chosen genes were generated using 
GraphPad Prism (6.00 for Windows, GraphPad Software, La Jolla California USA).      
2.11 In vivo experiment with LNCaP shAR cells 
LNCaP shAR cells were generated by Dr. Gregor Tvez of APCRCQ with the same 
protocol detailed in section 2.3. In vivo experiment was performed by Dr. Elizabeth 
Williams and Ms. Ellca Rather of APCRC-Q. 106 of these cells were injected 
subcutaneously in 100μL of cell suspension in serum free RPMI (Life Technologies) 
mixed 1:1 with MatrigelTM (BD Biosciences) in 4-5 week old NOD/SCID mice 
(Animal Resource Centre, Perth, Australia). Tumour volume was measured three 
times per week with a calliper and serum PSA was measured weekly with ELISA 
total PSA kit (Genway, San Diego, CA, USA). At 200mm3 tumour volume mice 
were treated with or without 625mg/kg of chow containing doxycycline. At 600mm3 
tumour volume mice from both doxycycline treated and non-treated groups were 
further subdivided into castration group and non-castration group. Mice were 
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euthanized at 1000mm3 tumour volume. mRNA was extracted from harvested 
tumours with the  Norgen RNA Purification PLUS kit #48400 (Norgen Biotek) and 
cDNA was produced with SensiFASTTM kit (Bioline, Alexandria, NSW, Australia) 
and the C1000TM Thermal Cycler (BioRad, Hercules, CA, USA). Quantitative RT-
PCR was performed with a SYBR Green ER qPCR kit (Invitrogen) in a 7900HT Fast 
Real-time PCR System (Applied Biosystems). In vivo experiment, mRNA extraction 
and qRT-PCR was performed by Ms Ellca Rather. qRT-PCR data was analysed by 
me.  
2.12 RNA isolation and quantitative Real Time PCR (qRT-PCR) analysis 
LNCaP and 22RV1 cells were seeded in triplicate, androgen starved for 48h and then 
treated with hormone and drug combinations for 6-48 hours in serum-free RPMI-
1640. Cells were harvested in Trizol Reagent (Invitrogen) and RNA purified using 
the Direct-ZolTM RNA Miniprep kit (Zymo Research, Irvine, CA, USA) according to 
the manufacturers’ instructions.  Treatment with RNase-free DNase was incorporated 
into the protocol to remove contaminating DNA.  RNA yield and purity were 
determined by spectrophotometry. Using 1 μg of RNA for each sample, reverse 
transcription was performed with SuperScript III First-Strand Synthesis system 
(Invitrogen) and the C1000TM Thermal Cycler (BioRad). The targeted gene and 
primer sequences are listed in Table 2.  
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Table 2.3.   Primers used for qRT-PCR  
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
RLP32 CCCCTTGTGAAGCCCAAGA GACTGGTGCCGGATGAACTT
FOXC2 GCCTAAGGACCTGGTGAAGC TTGACGAAGCACTCGTTGAG
Zeb1 CAACTACGGTCAGCCC GCGGTGTAGAATCAGAGTC
Vimentin ACCAGCTAACCAACGACAAA
G
GCTTCCTCTCTCTGAAGCAT 
SNAIL CCTCCCTGTCAGATGAGGAC CCAGGCTGAGGTATTCCTTG
CDH-1  GAACGCATTGCCACATACAC ATTCGGGCTTGTTGTCATTC
DSP  
INSR-A CTGCACAACGTGGTTTTCGT ACGGCCACCGCACATTC
INSR-B CGTCCCCAGAAAAACCTCTT
C
ACGGCCACCGTCACATTC 
IGF1R GAAAGTGACAGTCCTGCATT
TCA 
CCGGTGCCAGGTTATGATG 
IGF2 CTGTGCTACCCCCGCCAAG ACGTTTGGCCTCCCTGAACG
PSA AGTGCGAGAAGCATTCCCAA
C
CCAGCAAGATCACGCTTTTGT
T
AR CTGGACACGACAACAACCAG CAGATCAGGGGCGAAGTAGA
MMP9 CTGGGGAAGGAGCCAGTTTG AAAAACAAAGGTGAGAAGAG
AGGG
VTN GTGGCTGTCCTTGTTCTCCAG AAGACACTCTGGATGGGTTC
AC
EPCAM TGCTCAAAGCTGGCTGCCAA
ATG 
GTGCCGTTGCACTGCTTGGC 
CHG-A TCCCTGTGAACAGCCCTATG
AATAA   
AAAGTGTGTCGGAGATGACC
TCAA
NCAM TGCGACCATCCACCTCAAAG CCAGAGTCTTTTCTTCGCTGC
TUBB3 AGCAAGGTGCGTGAGGAGTA
T
TGGACAGCGTGGCGTTGTAG 
SST CTGAACCCAACCAGACGGAG AGCCGGGTTTGAGTTAGCAG
NTS GAACAGCCCAGCTGAGGAAA CCAGTGTTGAAAAGCCCTGC
NEURO
G1 
GCCTTTCTATCTGTCCGTCG GTCTGGCACAGTCTTCCTC 
FUZ ACAGACATGGGGCTGTTAGC AAGCACAGAGGGGAGAGGG
SYP GGCTCTGGCCACCTACATCTT
C
CCGATGAGCTAACTAGCCAC
ATGA
SOX8 CCACAAGAGTGCCCCGTC CTGCAGGAACCGTAGTCGG
STY1 AACATGGGGTTGGCTGTTT CGGCAGACGGTTATTTTCCT
NEURO
D1 
ACTCCAAGACCCAGAAACTG
TC 
ACTGGTAGGAGTAGGGATGC
AC
RPL32 GCACCAGTCAGACCGATATG ACTGGGCAGCATGTGCTTTG
ASCL1 TGGTGCGAATGGACTTTGG TAAAGATGCAGGTTGTGCGA
TCA
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Quantitative RT-PCR was performed with a SYBR Green ER qPCR kit (Invitrogen) 
in a 7900HT Fast Real-time PCR System (Applied Biosystems). The relative 
expression levels of target genes were normalized to the housekeeping RPL32. 
Amplification specificity was confirmed by dissociation curve analysis. Each gene 
was measured in triplicate and the average ΔCt was taken from the three replicate 
wells before fold change was calculated using the ΔΔCt method.   
 
2.13 Preparation of protein lysates, subcellular fractionation and Western 
blotting 
Whole cell protein extracts were collected by rinsing cells, on ice, with chilled 
phosphate-buffered saline (PBS) and lysing with TK buffer containing 50 mM 
HEPES (pH 7.4), 150 mM NaCl, 1% TritonX-100, 1mM Na3VO4, 30 mM NaF, 10 
mM Na4P2O7, 10 mM EDTA, 0.5 mM AEBSF and cOmplete protease inhibitor 
tablet (Roche, Basel, Switzerland) for 20 min on ice. Lysates were spun for 20 
minutes, 13000g at 4°C. Supernatant was collected and the protein content 
determined with a commercially available kit (Pierce BCS Protein Assay, Thermo 
Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. 
Nuclear and cytoplasmic protein extracts were collected using the NE-PER®Nuclear 
and Cytoplasmic Extraction Reagents (Thermo Scientific, Waltham, MA, USA), 
according to the manufacturer’s instructions. Proteins were separated by 
electrophoresis in 10% SDS–polyacrylamide gels (PAGE) and transferred to PVDF 
membranes. Membranes were blocked in 1% fish skin gelatin (FSG; Sigma-Aldrich) 
in tris-buffered saline (TBS) or in Odyssey blocking buffer (Thermo Scientific) in 
PBS then incubated with primary antibodies overnight at 4°C. Primary antibodies 
used are listed in Table 3. Blots were washed for 3 times 5 minutes, with 0.1% TBS-
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Tween (TBS-T) or in 0.1% PBS-Tween and incubated with the appropriate 
secondary antibodies in 1% FSG in TBS-T or PBS-T for 1 hour at room temperature. 
Secondary antibodies used were different based on the imaging system. For 
Odessey® imaging system, secondary antibodies were diluted 1 in 25,000 of stock 
and included anti-mouse IgG 800 (926-32213, LI-COR Biosciences, Lincoln, NE, 
United States), anti-rabbit 680 (926-68072, LI-COR Biosciences), and anti-goat 700 
(926-68074, LI-COR Biosciences). For ECLTM, secondary antibodies were diluted 1 
in 1000 of stock, and included anti-mouse IgG linked to horseradish peroxidase 
(HRP) (NA931V, GE Healthcare, Little Chalfont, United Kingdom), anti-rabbit IgG-
HRP (NA934V), anti-goat IgG-HRP (sc-2020, Santa Cruz). Membranes were 
washed (3 times) a second time in TBS-T or PBS-T and protein bands were 
visualised with Odyssey® CLx infra-red imaging system (Li-cor, Lincoln, NE, USA) 
or ECL (Merck Millipore) according to the manufacturer’s instructions. 
  
 68 Chapter 2: Materials and Methods 
Table 2.4.    Primary antibodies used in various experiments.  
Target Company 
Catalogue # 
Species kDa 
Dilution 
WB IF 
IR ABCAM ab983 Mouse 95/70 - 50 
IR ABCAM Ab131238 Rabbit 95 1000 - 
IGF1R Santa-Cruz sc-713 (C20) Rabbit 95 1000 50 
AR Santa-Cruz 441 Mouse 110 1000 - 
AR Cell Signalling 5153S Rabbit 110 1000 - 
FOXC2 Santa-Cruz sc-31734 Goat 62 500 - 
FOXC2 Cell Signalling 13974S Rabbit 62 1000 - 
EPCAM Cell Signalling 2626 Rabbit 40 1000 - 
Vimentin Sigma-Aldrich V66-30 Mouse 58 - - 
ZEB1 Cell Signalling 3396 Rabbit 200 1000 - 
CDH1 BD 610181 Mouse 120 1000  -  
PI3K Cell Signalling 4257 Rabbit 85 1000 - 
pPI3K Cell Signalling  4228 Rabbit 85 1000  - 
MAPK Cell Signalling 4696 Mouse 44,42 1000 - 
pMAPK Cell Signalling 4377S Rabbit 44,42 1000 - 
AMPK Cell Signalling 2793S Mouse 62 1000  
pAMPK Cell Signalling 2535S Rabbit 62 1000  
GAPDH Cell Signalling 5174S Rabbit 37 10,000 - 
GAPDH Santa-Cruz sc-32233 Mouse 37 10,000 - 
PARP Cell Signalling 9542S Rabbit 130 10,000 - 
γ-tubulin Sigma T5326 Mouse 48 1000 - 
 
2.14 Immunofluorescence and confocal microscopy 
Cells were grown on glass coverslips in 24-well plates (Corning, NY, USA), 
androgen deprived for 72h and then treated for 48h with various hormones and 
inhibitors. Cells were washed in PBS and fixed in 4% paraformaldehyde in PBS for 
20 minutes at room temperature, permeabilized for 15 minutes in PBS containing 
0.1% Triton X-100, and autofluoresence quenched with PBS containing 0.3M 
glycine for 15 minutes at room temperatures. Non-specific epitopes were blocked in 
PBS containing 1% bovine serum albumin (BSA) for 20 minutes. Next, the cells 
were treated for 1 hour at room temperature with primary antibodies (Table 3) in 1% 
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BSA/PBS, washed three times in 0.1% BSA/PBS, and incubated, for a further 20 min 
at room temperature with AlexFluor 647-conjugated Phalloidin (A22287, Invitrogen) 
and appropriate fluorescently-conjugated secondary antibodies, AlexaFluorTM anti-
mouse 448 (A11001, Life Technologies), AlexaFluorTM anti-rabbit 448 (A11008, 
Life Technologies), AlexaFluorTM anti-goat 647 (A21245, Life Technologies)  
diluted in 1% BSA/PBS either 1 in 100 or 1 in 200 dilution. Cells were protected 
from light during this incubation and for the remainder of the procedure. After three 
washes in 0.1% BSA/PBS, cell nuclei were counterstained with DAPI (D3571, 
Invitrogen), diluted 1 in 40,000 of a 5mg/mL stock, or 125ng/mL, for 15 min at room 
temperature.  Finally, cells were washed three more times in 0.1% BSA/PBS and 
coverslips placed onto microscope slides with a layer of anti-fade MoviolTM and 
incubated at room temperature until dry. The coverslips were further sealed with nail 
polish, and images were taken with the Zeiss confocal microscope (Core Microscope 
Facility, TRI). Images of control and experimental cells were acquired under 
identical exposure conditions for comparative analysis.  
2.15 Gene expression in clinical prostate cancer samples 
Clinical datasets were accessed using OncomineTM (Compendia BioscienceTM, part 
of Life TechnologiesTM, Ann Arbor, MI, USA) and used to analyse expression of 
INSR and FOXC2 genes in normal, primary and metastatic PCa tumour tissue. 
Linear regression and associated statistical analyses were performed using GraphPad 
Prism (6.00 for Windows, GraphPad Software, La Jolla California USA). 
2.16 Statistical analyses 
All in vitro experiments had three biological replicates (n=3), including proliferation, 
wound-healing, transwell, qRT-PCR and immunoblotting, unless otherwise specified 
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in the figure legends. T-tests and one-way ANOVA were performed, as  suitable, 
using GraphPad Prism (6.00 for Windows, GraphPad Software, La Jolla California 
USA).   The original single step Dunnette test was performed post-hoc to compare 
means to the control group, and multiplicity adjusted p-values are reported.  
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3.1 Introduction 
PCa patients who undergo ADT experience rapid development of insulin resistance 
in classically metabolic tissues such as muscle, liver and adipose tissue. Typically, 
insulin binds the IR-B, which activates a signalling cascade via PI3K and Akt that 
results in the efficient translocation of glucose transporter GLUT4 to the cell surface, 
allowing glucose uptake into cells from the blood (Belfiore, et al., 2009; Giudice, et 
al., 2011), however disruptions in this pathway lead to inefficient glucose clearance.  
To compensate for slowed glucose clearance, the pancreas secretes increased 
amounts of insulin which leads to higher levels of circulating insulin 
(hyperinsulinemia). 
Hyperinsulinemia correlates with higher mortality and aggressiveness in PCa 
(Basaria, et al., 2006; Call, et al., 2010; Faris & Smith, 2010; Flanagan, et al., 2010; 
Fowke, et al., 2008; Hammarsten & Hogstedt, 2005; Ma, et al., 2008; Onitilo, et al., 
2012). Simultaneously, increased IR expression in PCa clinical samples correlate 
with increased Gleason grade, or disease staging. This suggests that insulin signalling 
through IR may be important for PCa progression. Insulin can signal through both 
receptor isoforms A and B, as well as through heterodimeric IGF1R and IR ‘hybrid’ 
receptors (Figure 3.1). IR has also been reported to increase in PCa cells upon IGF1R 
inhibition (Weinstein, et al., 2014). 
Interestingly, clinical studies have also shown that PCa tumours contain higher IR-A 
compared to IR-B (Heni, et al., 2012). IR-A is commonly expressed in foetal tissue 
during development and has different functional roles to IR-B. IR-A is considered to 
activate more mitogenic pathways than IR-B, activating similar downstream 
pathways to IGF1R (Belfiore, et al., 2009). As tumour cells express IR-A as the 
predominant isoform, it is possible that IR regulation in PCa may be different to that 
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of metabolic tissues. Although ADT results in insulin resistance in metabolic tissues, 
insulin signalling in PCa tumours has not been examined. The composition of insulin 
receptor expression in PCa tumour cells is important to understand as the 
downstream cellular effects can vary greatly based on whether insulin ligand is 
binding to homodimers of IR-A, IR-B or heterodimers of IR-A:IR-B or heterodimers 
of IR-A:IGF1R (Pandini, et al., 2002) (Figure 3.1). Since IR-B levels are expected to 
be low in cancer cells (Malaguarnera & Belfiore, 2014), it was anticipated that 
insulin in PCa tumours will most probably signal through a combination of 
homodimers of IR-A and heterodimers of IR-A:IGF1R. The formation of 
heterodimers is regulated by simple stoichiometry (Belfiore, et al., 2009). IGF1R 
levels are increased by androgens in PCa (Pandini, Genua, Frasca, Vigneri, & 
Belfiore, 2009), and are also generally increased in cancer (Samani, Yakar, LeRoith, 
& Brodt, 2007). In the presence of androgens, IGF1R can promote proliferation in 
PCa cells (Sayeed, Fedele, Trerotola, Ganguly, & Languino, 2013). Androgen 
deprivation has been shown to reduce overall IGF1R levels, but may cause the cells 
to become more sensitive to IGF1 (Krueckl et al., 2004). Previous work in this 
laboratory identified that IR expression in PCa tumours is increased with duration of 
ADT (Lubik, Gunter, Hollier, Fazli, et al., 2013), which was complimented by in 
vivo studies whereby LNCaP xenograft models of CRPC showed a concomitant 
increase in INSR gene expression with biochemical recurrence, measured by 
increasing tumour PSA expression (Figure 1.2).  This suggests that the capacity for 
insulin signalling in PCa may in fact rise upon androgen deprivation as a result of 
increased circulating ligand and tumour receptor expression.  However, IR regulation 
by androgens in PCa is unknown, as is IGF1R regulation in the absence of androgens 
and with AR inhibitors.  
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Thus the concurrent regulation of INSR and IGF1R by insulin and androgens was 
investigated in clinical samples of advanced PCa, patient derived xenografts (PDXs), 
and in vivo and in vitro models of prostate cancer. Examining the concurrent 
regulation of IR and IGF1R by androgens, and insulin in an androgen deprived 
environment, is important to understanding insulin signalling in PCa and how PCa 
cells adapt to ADT and AR inhibitors to produce recurrent tumours. Better 
knowledge of changes in receptor expression on tumour cells as cells undergo 
androgen deprivation or experience ADT induced hyperinsulinaemia will also 
provide refined biomarkers for targeting PCa treatments to specific patient 
populations.  
 
Figure 3.1 Insulin/IGF receptor signalling pathways. The IGF pathway has three 
receptors through which a signal can be propagated within cells, namely insulin 
receptor isoform A (IR-A), insulin receptor isoform B (IR-B) and IGF1 receptor 
(IGF1R). These receptors function as dimers whose formation depends on the 
Figure 3.1 
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stoichiometry of receptor expression. Insulin can signal through both isoforms of 
IRs, as well as hybrid receptors with IGF1R. Insulin cannot signal through 
homodimers of IGF1R. The downstream pathways activated by insulin depend on 
which receptor combination it is signalling through. Most common pathways 
triggered are the PI3K/Akt and Ras/MAPK pathways, however, some pathways are 
specific to certain receptors. For example, insulin activation of homodimers of IR-B 
specifically activates the TC10 pathway, which acts in concert with the PI3K/Akt 
pathway to control glucose intake by the cells.  
3.2 Results 
3.2.1 INSR expression is increased more frequently than IGF1R in human 
metastatic PCa tumours and patient-derived xenografts 
INSR expression is increased in the LNCaP xenograft CRPC model of biochemical 
failure; however, it is unknown whether this also occurs in clinical samples. 
Comparison of all the clinical study datasets available on OncomineTM that report 
expression of INSR and IGF1R for primary and metastatic tumours (Figure 3.2A) 
show that INSR is more commonly increased in PCa metastases (significantly 
increased in 78% of the datasets). By comparison, IGF1R transcripts were increased 
in PCa metastases in only 33% of the datasets with available data. Similarly, analysis 
of transcript levels in RNA-sequencing from a range of PCa patient derived 
xenografts (PDXs) indicate considerably higher transcript levels of INSR-A 
compared to INSR-B and IGF1R (Figure 3.2B), suggesting signalling through IR-A 
may be more prominent than through IGF1R.  
It is important to keep in mind that the vast majority of metastatic PCa patients are 
likely to have undergone ADT, however this data has not been examined with 
respect to therapy or duration of treatment. Nevertheless, this high concordance 
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amongst datasets prompted further investigation of the relationship between 
androgen and insulin signalling in PCa cells.  
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Figure 3.2. Androgen deprivation is associated with increased INSR 
transcription in human clinical tumours and patient derived xenografts. (A) All 
datasets available in OncomineTM that reported significant change of INSR and 
IGF1R mRNA expression in metastatic tissue relative to primary tissue. Yellow 
denotes up-regulation; blue denotes down-regulation and darker shading denotes 
greater magnitude of fold-change. INSR was up-regulated in 7/8 datasets, while 
IGF1R was downregulated in 6/8 of the data sets where IGF1R or INSR transcripts 
was reported to undergo significant change in expression. (B) Analysis of transcripts 
per million of RNAseq data of PCa patient-derived xenografts (PDX). PDXs 
extracted from two mice are shown separately as tumour from mouse 1 (black bars) 
Figure 3.2 
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and mouse 2 (grey bars). A range of AR levels are observed across the PDXs. INSR-A 
transcripts are consistently higher than IGF1R and INSR-B transcripts, expect for 
mice 2 of LUCaP 35, 105 and 141.  
3.2.2 AR and IR levels inversely correlate in our models 
The expression of INSR and IGF1R was then examined in a range of PCa cell models 
(Figure 3.3A). DUCaP cells expressed the highest level of AR mRNA expression, 
followed by LNCaP and then 22RV1 cells (Figure 3.3A). AR expression in these 
cells inversely correlated with expression of both INSR isoforms A and B (Figure 
3.3A) whereby 22RV1 cells had the highest INSR expression followed by LNCaP 
and the least amount in DUCaP cells (Figure 3.3A). IGF1R transcript expression, on 
the other hand, correlated positively with AR expression in these cells (Figure 3.3A). 
Protein expression show similar results. In an expanded panel of PCa cell lines, AR 
protein expression correlated inversely with IR expression. IGF1R was difficult to 
detect in these cell lines, but with the exception of DU145 cells, receded with AR 
expression (Figure 3.3B), highlighted by VCAP cells, which have lower AR levels 
than DUCaP cells, and showed lower IGF1R expression. It is important to note that 
baseline AR expression correlated with the known AR responsiveness of the cell 
lines (Figure 3.3B).  
Protein expression of IR was also investigated with immunofluorescence imaging. IR 
antibody was optimized in Chinese hamster ovary cells overexpressing IR-A 
(CHO.IR) for immunofluorescence (Supplementary Figure 3.1A). IR internalization 
upon insulin stimulation could be observed over a 30 minute period (Supplementary 
Figure 3.1A). Surprisingly, IR protein was not concentrated at the plasma membrane 
in PCa cells, despite serum starvation overnight, compared to positive control 
CHO.IR cells where plasma membrane localization of IR is clearly evident with little 
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cytoplasmic IR staining (Figure 3.3C). Some punctate IR positive immunoreactivity 
was also observed in the nucleus.  This is in contrast to IGF1R localization in 
DUCaP cells which was prominently at the plasma membrane, and as expected, 
internalizes with IGF1 treatment (Supplementary figure 3.1B). Thus, IR subcellular 
localization in PCa cells appears to be dysregulated compared to IGF1R.  This is 
similar to observations in clinical tissue which report cytoplasmic IR staining in 
prostate tumours (Cox, et al., 2009). 
Together these data indicate that expression and localization of IR and IGF1R in PCa 
cell lines differ greatly, especially with respect to the androgen receptor status of the 
cell. The expression and localization of IR was further investigated in in vitro 
experiments using a range of PCa cell lines with differing AR responsiveness and 
under advanced PCa contexts of androgen deprivation and AR inhibitors in order to 
illuminate how tumours could adapt to ADT and ATT treatments in advanced PCa 
through changes in their IR levels and subcellular localization. 
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Figure 3.3. IR levels inversely correlate with AR in PCa cells. (A) Transcript 
levels in a range of PCa cells cultured in normal conditions were measured by qRT-
PCR.  AR transcript levels are highest in DUCaP, then LNCaP and the lowest in 
22RV1 cells, with a similar expression profile for IGF1R. IR-A and IR-B transcript 
levels exhibit the opposite pattern of expression (n=3, mean± standard error of the 
mean, SEM). (B) Immunoblotting of AR, IGF1R and IR proteins in several PCa 
cells, cultured in normal conditions, were investigated with 40 g of protein per 
lane. Correlated to their AR levels, IGF1R protein is also reduced across the cell 
lines, except in DU145 cells where IGF1R protein is higher despite lack of AR 
expression. IR levels across the cell lines correlate inversely with AR protein 
expression and AR responsiveness (n=3). (C) Confocal immunofluorescent 
microscopy of IR (antibody ab983, 1:50) in positive control CHO.IR cells and in PCa 
cell lines LNCaP, 22RV1 and PC3 cultured under in 5% FBS containing media and 
serum starved overnight. IR protein (green) is primarily cytoplasmic across all PCa 
cell lines, with 22RV1 cells showing more plasma membrane IR than LNCaP and 
PC3 cells. Nuclear localization of IR is also observed (n=3, scale bars show 50μm). 
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3.2.3 Androgen deprivation can alter IGF1R to IR stoichiometry 
RNAseq and qRT-PCR of the PCa cell lines was used to examine the relative 
expression of INSR-A, INSR-B and IGF1R following manipulation of the AR axis. 
Cells had been treated for 48 hours in the absence or presence of 10nM DHT and 
10μM bicalutamide (BIC), enzalutamide (ENZ) or ARN-509 (ARN). RNASeq data 
in LNCaPs showed high levels of IGF1R and INSR-A, while INSR-B transcript levels 
were extremely low (Figure 3.4A). This data confirmed that all three cell lines 
express INSR-A as the predominant isoform, consistent with the PDX data (Figure 
3.1B) and literature (Figure 1.4A).  
It is known that DHT upregulates IGF1R (Pandini, et al., 2009). This was also 
observed in the LNCaP RNASeq data, but interestingly, upon androgen deprivation, 
it was observed IGF1R transcript levels fall below that of INSR-A transcript levels 
(Figure 3.4A). In the qRT-PCR data, it was also observed that IGF1R transcript 
levels were increased by DHT, and fell upon androgen deprivation. However, by 
qRT-PCR, IGF1R transcript levels reached equivalency to that of INSR-A transcript 
levels, in contrast to RNASeq (Figure 3.4B). INSR-A transcript levels did not change 
significantly in the LNCaP RNASeq or qRT-PCR. Further validation of these 
observations were performed in DUCaP (Figure 3.4C) and 22RV1 cells (Figure 
3.4D) by qRT-PCR. Like LNCaP cells, IGF1R transcript levels fell significantly in 
DUCaP cells upon androgen deprivation and with AR inhibitors, but remained higher 
than that of INSR-A. Like in LNCaP cells, INSR-A values did not change 
significantly in DUCaP cells with androgen deprivation or with AR inhibitors 
(Figure 3.4C). In 22RV1s, IGF1R levels did not alter significantly across the 
treatments, and consistently remained higher than INSR-A levels. INSR-A levels 
increased only slightly and significantly increase with AR inhibitor enzalutamide 
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treatment in the absence of DHT (Figure 3.4D). Lack of IGF1R reduction in 22RV1 
cells upon androgen deprivation could be due to muted DHT responsiveness of this 
cell line. IGF1R expression induced by DHT correlated well with PSA expression 
across the cell lines; both genes are increased in DUCaP and LNCaP cells, but not in 
22RV1 cells (Supplementary Figure 3.2). Thus, IGF1R expression could be 
considered a proxy for DHT responsiveness. DHT reduced the transcript levels of its 
cognate receptor, AR only in DUCaP cells, which have high baseline of AR 
(Supplementary Figure 3.2).  
The effect of androgen deprivation on expression of INSR-A and IGF1R was also 
investigated in tumours from an in vivo experiment of LNCaP xenografts from nude 
mice castrated when tumour volume reached 600mm3. Mice were euthanized when 
tumour volume reached 1000mm3, with castration period ranging from 1 to 4 weeks. 
(Figure 3.4E). Castration lead to drop in serum PSA levels in all mice; however 
tumour volume continued to rise (data not shown). In contrast to their behaviour in 
vitro, LNCaP xenografts showed increased expression of INSR-A, and reduced their 
expression of IGF1R (Figure 3.4E). Together these results demonstrate a change in 
the transcriptomic stoichiometry between IGF1R and INSR-A in PCa cells upon 
androgen deprivation.  
Next, immunoblotting was used to see whether similar changes occurred to receptor 
protein. IR protein expression remained unchanged across DHT and androgen 
deprived conditions, as well as with AR inhibitors, across all three cell lines DUCaP, 
LNCaP and 22RV1 (Figure 3.5), reflecting mRNA data. IGF1R levels in DUCAP 
cells were increased with DHT (Figure 3.5), confirming that DHT increases both 
IGF1R transcripts and protein. IGF1R protein detection was only successful for 
DUCAP cells, as base levels were shown to be high only in DUCaP, VCaP and 
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DU145 cells (Figure 3.1B). IGF1R protein was probed for in LNCaP and 22RV1 
cells by western blotting and immunofluorescence with a range of antibodies, 
unsuccessfully (data not shown). Previous studies in LNCaP cells with the IGF1R 
antibody, C-20 (Santa-Cruz) also report significantly lower IGF1R protein detection 
compared to IR in LNCaPs (Weinstein, et al., 2014). Also reflecting mRNA, DHT 
dramatically reduced AR protein levels in DUCaP cells (Figure 3.5A), while LNCaP 
and 22RV1 cells, showed increased AR protein levels (may include both newly 
synthesize and stabilized proteins) with DHT (Figure 3.5B and C). As IGF1R protein 
levels fall in the absence of DHT, and IR protein levels remain steady, this data 
suggests increased probability of hybrid IGF1R:IR receptor signalling in PCa cells 
upon androgen deprivation.  
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Figure 3.4 IR transcription is maintained under androgen deprivation while 
IGF1R transcription. (A) RNASeq of LNCaP cells cultured under androgen 
deprived conditions or with addition of DHT (10nM) and AR inhibitors bicalutamide 
(BIC, 10μM) and enzalutamide (ENZ, 10μM) for 48hr. IGF1R expression decreased 
with androgen deprivation and AR inhibition (green bars), while IR-A (blue bars) 
remained stable across treatments (n=3, mean± SEM, ANOVA, **** = p<0.00005). 
Similar results were observed from qRT-PCR in (B) LNCaP and (C) DUCaP cells 
similarly treated with DHT, BIC, ENZ and 10μM ARN-509 (ARN). (D) In 22RV1 
cells, IGF1R levels did not fall significantly upon androgen deprivation and AR 
inhibition. INSR-A transcripts predominate over INSR-B transcripts (red) across all 
cell lines, with 22RV1 cells showing the greatest levels of INSR-B transcripts among 
these cells (n=3, mean± SEM, ANOVA * p=<0.05, ** = p<0.005, **** = 
p<0.00005). (E) Expression of IGF1R and INSR-A mRNA in LNCaP xenografts 
show INSR-A transcript levels were significantly increased with castration (n=3) 
compared to non-castrated mice (n=1), while IGF1R transcript levels were reduced 
with castration (mean± SEM, two-way ANOVA * = p<0.05). 
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Figure 3.5 IR protein is maintained in androgen deprivation but IGF1R protein 
is reduced. DUCaP (A), LNCaP (B) and 22RV1 (C) cells were cultured under 
androgen deprived conditions for 48hr and treated with DHT (10nM), with and 
without AR inhibitors ARN509 (10μM), bicalutamide (10μM) and enzalutamide 
(10μM) for 24hr. Immunoblotting of whole cell lysates (40g) show that IR protein 
levels remain steady under androgen deprivation across the cell lines. IGF1R protein 
falls in the absence of DHT in DUCaP cells but was undetectable in LNCaP and 
22RV1 cells. AR protein levels were reduced by DHT in cells highly expressing AR 
Figure 3.5 
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such as the DUCaP cells, but AR was increased by DHT in LNCaP and 22RV1 cells 
which have significantly lower levels of AR protein expression compared to DuCaP. 
DHT-stimulated changes in AR levels did not correlate with changes in IR protein 
expression across cell lines (n=3). 
3.2.4 Genetic knockdown of AR increases IR expression levels 
LNCaP cells expressing inducible shRNA targeting the AR (LNCaP shAR) and 
control shRNA with non-targeting sequence (LNCaP shNT) were established at the 
APCRC-Q by Dr. Tevz and Ms Ratther. These cells can be induced to express 
shRNA targeting the AR upon addition of 250ng/ml doxycycline, with concurrent 
expression of red fluorescent protein (RFP) (Figure 3.6A). Cells were cultured in 
normal media (5% FBS containing RPMI) with and without daily addition of 
doxycycline (250ng/mL) for 5 days, with addition of puromycin (250ng/mL) every 
alternate day for maintaining selection pressure. Doxycycline-induced knockdown of 
AR caused morphological changes in the LNCaP cells which were not seen in the 
control conditions of no doxycycline shAR LNCaPs, nor in the shNT cells (Figure 
3.6B). Knockdown of AR in these cells, cultured under androgen deprived conditions 
for 5 days with and without doxycycline, led to a rise in INSR-A mRNA levels by 
qRT-PCR, which was not observed in shNT cells (Figure 3.6C). Cells responded to 
DHT with increased expression of PSA, as expected, but this was not observed in 
shAR LNCaPs with doxycycline, indicating functional inhibition of DHT action 
(Figure 3.6C). AR protein knockdown was also observed in the shAR cells, which 
correlated with significantly increased IR protein expression (Figure 3.6D). INSR-A, 
AR and PSA mRNA expression was measured in xenografts of doxycycline 
inducible LNCaP shAR cells, where doxycycline infused chow was provided to nude 
mice when xenografts reached 200-300mm3. Mice were euthanized when tumours 
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reached 1000mm3, with length of doxycycline treatment ranging from 13 to 116 
days. Control mice were fed normal chow throughout experiment. In vivo xenografts 
with AR knockdown also showed increased INSR-A mRNA expression, with 
concomitant decreased PSA with doxycycline feeding (Figure 3.6E). Serum PSA 
levels remained low at end of experiment for these mice (data not shown). Together 
these data show that AR, through a mechanism undefined here, may supress IR 
expression in LNCaP cells.  
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Figure 3.6. Genetic knockdown of AR in LNCaP cells increases IR. LNCaP cells 
with doxycycline inducible AR knockdown (LNCaP shAR) and control LNCaP cells 
containing non-targeting shRNA (LNCaP shNT) were generated with red 
fluorescence protein as a reporter for doxycycline action. (A) Bright field and 
fluorescent images (10x magnification) show doxycycline addition stimulated RFP 
expression in both control LNCaP shNT and shAR6 cells (Scale bars - 800μm) (B) 
Figure 3.6 
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Bright field images showed cells with AR knockdown became thin and elongated, 
which was not observed in control LNCaP shNT cells or LNCaP shAR6 cells 
without doxycycline (Scale bars in upper panel = 200μm and for lower panel 
=100μm. (C) LNCaP shAR cells increased INSR-A transcription upon AR 
knockdown (red bar), but not in LNCaP shNT cells. PSA transcription was 
stimulated by DHT treatment in LNCaP shNT cells with and without doxycycline, 
but not in LNCaP shAR cells with doxycycline addition (n=3, mean± SEM, ANOVA 
** = p<0.005, *** = p<0.0005, **** = p<0.00005). (D) Immunoblotting of whole 
cell lysates (40g) of LNCaP shNT and shAR6 cells cultured in normal media for 5 
days, with and without doxycycline , showed increased IR protein expression with 
AR knockdown, which was not observed in controls (n=3, mean ± SEM, ANOVA * 
= p<0.05, ** = p<0.005). (E). INSR-A levels increase in xenografts with doxycycline 
induced AR knockdown (n=4), compared to control chow-fed mice (n=1).  
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3.2.5 Androgens increase nuclear IR localization in some PCa cells. 
Data from the shAR LNCaP cells suggest that androgens may regulate the IR. 
However, as INSR-A mRNA and IR protein levels were not affected by androgen 
deprivation and AR inhibitors, it was hypothesized that subcellular localization of IR 
may be under androgen regulation.   
IR localization in androgen deprived LNCaP cells was investigated with 
immunofluorescence microscopy, where again IR appeared primarily cytoplasmic 
and DHT appeared to increase IR translocation to the nucleus (Figure 3.7A). To 
explore this using a more quantitative method, immunoblotting of fractionated 
protein lysates in LNCaP and LNCaP derivative C42B cells was used and showed 
increased nuclear localization of IR by DHT (Figure 3.7B and C). Whole cell lysates 
were fractionated into nuclear protein fraction and cytoplasmic/plasma membrane 
protein fractions. PARP was used as a marker for nuclear protein enrichment and 
GAPDH a marker for cytoplasmic protein enrichment. The addition of enzalutamide 
prevented DHT stimulated IR nuclear translocation in LNCaP cells (Figure 3.7B). 
This result was also replicated with LNCaP shAR cells, where genetic knockdown of 
AR prevented DHT stimulated IR nuclear translocation (Figure 3.8D). LNCaP shAR 
and LNCaP shNT cells were cultured under normal conditions (5% FBS containing 
RPMI) and treated with and without doxycycline (250ng/mL, topped up daily) for 5 
days, and puromycine (250ng/mL, topped up every other day) to maintain selection 
pressure of cells containing shRNA sequence. At 5 days, cells were treated with and 
without insulin (10nM) and DHT (10nM) for another 20hr. Nuclear and cytoplasmic 
fractions were isolated as described.  
Immunoblotting of LNCaP whole cell lysate and cytoplasmic/plasma membrane 
fractions show enrichment of cytoplasmic proteins in fractions from LNCaP shAR 
and shNT cells compared to whole cell lysate. AR knockdown is also observed in 
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these cytoplasmic fractions with doxycycline addition in the shAR cells showing 
significantly reduced AR levels, but not in the control shNT cells (Figure 3.8A and 
B). Moreover, doxycycline induced AR knockdown correlated with non-significantly 
reduced cytoplasmic/plasma membrane accumulation of IR protein in the vehicle and 
insulin treated samples. The DHT treated samples also showed non-significantly 
decreased levels of cytoplasmic/plasma membrane accumulation of IR protein, 
however, AR knockdown combined with DHT treatment significantly reduced 
cytoplasmic/plasma membrane IR protein levels (Figure 3.8A and B). 
Immunoblotting of LNCaP whole cell lysate and nuclear enriched fractions from 
treated LNCaP shAR and shNT cells also showed enrichment of nuclear proteins 
compared to whole cell lysate, by PARP enrichment and reduction in GAPDH 
protein levels showing little cytoplasmic protein contamination in samples (Figure 
3.8C). AR knockdown observed with doxycycline addition in the shAR cells, but not 
in the shNT cells. DHT stimulated a significant rise in nuclear IR in shNT cells with 
and without doxycycline and in the shAR cells without doxycycline, which was 
curbed by AR knockdown (Figure 3.8C and D). Paradoxically, AR knockdown in the 
absence of DHT alone also triggered significantly increased IR nuclear translocation. 
Images of these cells show a clear morphological difference between vehicle and 
insulin treated shAR cells with doxycycline addition, compared to DHT treated shNT 
and shAR6 cells without doxycycline treatment (Supplementary figure 3.3, referred 
images are starred), yet all these cells demonstrate increased nuclear IR protein, 
indicating functionally either different mechanisms driving translocation of IR of 
different consequences of this translocation event. DHT stimulated IR translocation 
was not observed in other PCa cell lines such as VCaP and 22RV1 cells (Figure 3.9). 
Thus, together these data suggest that nuclear IR translocation can have varied 
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functional consequences in PCa cells and androgens can result in IR translocation to 
the nucleus in a subset of PCa cells, in particular seen here in LNCaP and LNCaP 
derivative C42B cells.  
As expected, nuclear localization of AR increased with DHT in all the PCa cell lines 
(Figure 3.7, 3.8 and 3.9), and the amount of AR in nucleus translocated following 
DHT treatment increased from 22RV1 (Figure 3.9D, 6-8 fold rise over control) and 
C42B (Figure 3.7E, 5 fold rise over control) to LNCaP (Figure 3.7C, 15-20 fold rise 
over control), consistent with the androgen responsiveness of these cells.  
Interestingly, insulin significantly increased cytoplasmic AR content in C42B and 
VCaP cells (Figures 3.7E and 3.9B). This could be because insulin drives non-
genomic, cytoplasmic actions of AR. Insulin treated cells looked morphologically 
different to DHT treated cells (Supplementary Figure 3.4), and thus, the functional 
effects of insulin in androgen deprived PCa cells are expected to be different to those 
of androgens.   
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Figure 3.7 Androgens increase nuclear IR localization in LNCaP and C42B 
cells. (A) Androgen deprived LNCaP cells were treated with insulin (10nM) and 
DHT (10nM) for 48hr and imaged with confocal microscopy for IR (green, ab983, 
1:50) and DAPI (blue). DHT showed increased nuclear localization of IR (n=3, scale 
bars = 50μM).  (B) LNCaP cells cultured under androgen deprived conditions for 
48hr were treated with and without insulin (10nM), DHT (10nM) and AR inhibitor 
enzalutamide (10μM) for 20hr. Clean nuclear and cytoplasmic protein enrichment 
Figure 3.7 
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was observed with immunoblotting (PARP and GAPDH), with increased nuclear AR 
(441) observed with DHT. Similarly, increased IR (ab131238) was observed with 
DHT (n=3). (C) Quantification of bands on the LNCaP immunoblots shown in panel 
(B) show significantly increased nuclear IR and AR observed with DHT treatments 
in LNCaP cells. (D) Androgen deprived C42B cells were also treated for 20hr with 
insulin (10nM) and DHT (10nM) and nuclear and cytoplasmic/plasma membrane 
protein fractions. Immunoblotting again shows good separation of nuclear and 
cytoplasmic proteins in respective fractions through PARP (nuclear marker) and 
GAPDH (cytoplasmic marker), and also shows increased nuclear IR and AR 
translocation with DHT treatment, similarly to LNCaP (n=3). (E) Densitometry of 
C42B immunoblots shown in panel (D) show significantly increased nuclear IR and 
AR with DHT treatments in C42B cells. Insulin significantly increases cytoplasmic 
AR protein levels. AR and IR band intensities were quantitated with Odyssey 
software and normalized to either PARP or GAPDH band intensities. (All graphs 
n=3, mean± SEM, SFM used as control for ANOVA * = p<0.05, ** = p<0.005, **** 
= p<0.00005)  
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Figure 3.8 AR knockdown hinders DHT stimulated IR nuclear localization.  (A) 
Immunoblotting of LNCaP whole cell lysate and cytoplasmic/plasma membrane 
fractions show AR knockdown with doxycycline addition in the shAR cells, but not 
in shNT cells. Both doxycycline induced AR knockdown and DHT treatments also 
reduced IR cytoplasmic/plasma membrane levels (B) Quantification of bands of the 
immunoblots shown in panel (A) confirm these results. AR and IR band intensities 
were quantitated with Odyssey software and normalized to either PARP or GAPDH 
band intensities. (C)  Immunoblotting of LNCaP whole cell lysate and nuclear 
fractions show AR knockdown with doxycycline treatment in shAR cells, but not 
shNT cells. (D) Quantitation of bands shown in panel (C) confirm AR knockdown 
with non-significantly reduced levels of AR in the nuclear fractions of DHT/insulin-
treated LNCaP shAR cells compared to controls. DHT significantly increased nuclear 
AR translocation, which was hindered with AR knockdown. AR knockdown 
correlated with significantly increased nuclear accumulation of IR protein in the 
vehicle and insulin treated samples. DHT-treated cells showed significantly 
increased nuclear IR, which was abrogated by AR knock down. (All graphs n=3, 
mean± SEM, vehicle treated, no doxycycline shNT cells used as control for ANOVA 
* = p<0.05, ** = p<0.005, *** = p<0.0005, **** = p<0.00005) 
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Figure 3.9 Androgens do not increase nuclear IR in other PCa cell lines. VCAP 
cells cultured under androgen deprived conditions and treated for 20hr with insulin 
(10nM) and DHT (10nM) were separated into nuclear and cytoplasmic fractions. (A) 
Immunoblots show PARP (nuclear marker) and GAPDH (cytoplasmic marker) 
enrichment with minimal cross contamination. DHT increases nuclear AR protein 
levels, while reducing cytoplasmic AR protein levels. Insulin increases cytoplasmic 
AR accumulation (n=3). (B) Quantitation of bands shown in (A) indicate 
significantly reduced IR cytoplasmic levels with both insulin and DHT treatments 
compared to vehicle treated cells. DHT also reduces nuclear IR levels. DHT 
increases nuclear AR levels and insulin significantly increases cytoplasmic AR 
levels. (C) 22RV1 cells cultured under androgen deprived conditions and treated for 
Figure 3.9 
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20hr with insulin (10nM) and DHT (10nM) were fractionated into nuclear and 
cytoplasmic fractions (C) Immunoblots show PARP (nuclear) and GAPDH 
(cytoplasmic) enrichment. DHT increases nuclear AR protein levels. (n=3) (D) 
Quantification of bands of immunoblots shown in (C) indicate significantly 
increased AR nuclear protein levels by DHT. DHT however did not affect nuclear IR 
levels. Insulin non-significantly reduced cytoplasmic/plasma membrane IR protein 
levels in 22RV1 cells. AR and IR band intensities were quantitated with Odyssey 
software and normalized to either PARP or GAPDH band intensities. (All graphs 
n=3, mean± SEM, vehicle treated, no doxycycline shNT cells used as control for 
ANOVA * = p<0.05, ** = p<0.005, *** = p<0.0005, **** = p<0.00005) 
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3.2.6 Insulin increases IR expression 
To study the overlap in the functional effects of insulin in PCa cells with androgen 
activity an existing microarray dataset of androgen deprived LNCaP cells, treated for 
10hr with insulin in the presence and absence of synthetic androgen R1881 was 
analysed (described in Chapter 2, section 2.9). Although transcriptional response by 
insulin and synthetic androgen R1881 was largely different, there was approximately 
10% overlap between insulin and androgen regulated genes, indicating some 
pathways may be co-regulated by both insulin and androgens, for instance both PSA 
and AR genes are represented in this subset, where insulin and androgens both up-
regulate PSA (Figure 3.10A) and down-regulate AR (Figure 3.10B). Importantly, 
insulin upregulated expression of its own receptor in this dataset (Figure 3.10A).  
Transcriptomic analysis of LNCaP cells by qRT-PCR showed increased INSR-A 
expression with insulin treatment, both alone and in the presence of DHT and AR 
inhibitor enzalutamide (Figure 3.10C). Enzalutamide also increased INSR-A 
expression (Figure 3.10C). Reflecting the microarray data, PSA levels were 
additively increased by insulin in combination with DHT over DHT alone, indicating 
both insulin and DHT can regulate this gene co-operatively (Figure 3.10C). Insulin 
also increased IR protein levels, and inhibition of PI3K and MAPK, downstream of 
IR, via PI3K inhibitor LY294002 and MAPK inhibitor UO0126, decreased the 
insulin driven rise in IR (Figure 3.10D). This shows that the effects of insulin on IR 
are specific as inhibitors of downstream signalling molecules reversed this effect. 
Together this data suggests that insulin can trigger a positive feedback regulation of 
its own receptor in PCa cells, different to what is expected in classically insulin 
responsive tissues such as liver and skeletal muscles.  
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Figure 3.10. Insulin increases IR in LNCaP cells. Venn diagrams showing 
distribution of differentially upregulated genes (A) and differentially down-regulated 
genes (B) in microarray analysis of LNCaP cells cultured under androgen deprived 
conditions, pre-treated with synthetic androgen R1881 (10nM) for 48hr followed by 
insulin (10nM) for 10hr. INSR transcript is significantly up-regulated with insulin 
alone. PSA is significantly up-regulated in all three conditions, while AR is 
significantly downregulated by insulin alone and insulin in the presence of R1881. 
(C) qRT-PCR analysis indicates that insulin and enzalutamide significantly increase 
Figure 3.10 
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INSR-A transcripts in androgen deprived LNCaP cells at 20hr treatments. PSA 
transcription was increased in DHT containing treatments. (n=3, mean± SEM, 
ANOVA *** = p<0.0005, **** = p<0.00005).  (D) Immunoblotting of whole cell 
lysates (40µg) of androgen deprived LNCaP cells treated for 24hr show insulin 
increases IR protein, which is reduced by PI3K inhibitor LY294002 (LY) and MAPK 
inhibitor UO0126 (UO). Bar graphs show quantification of IR bands normalized to 
GAPDH. (n=1) 
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3.3 Discussion 
Transcriptional analysis of advanced and metastatic PCa tumours showed INSR is 
upregulated more commonly than IGF1R, and INSR-A transcript levels are higher 
than IGF1R transcripts in patient-derived xenografts. Previous studies have also 
shown that while IGF1R levels are increased in primary PCa tissue compared to 
benign, in metastatic tissue IGF1R levels are largely decreased, especially in samples 
where a simultaneous PTEN deletion occurs (Hellawell et al., 2002). These results 
suggest that in advanced PCa, insulin signalling could play a prominent role, 
signalling through hybrid and increasingly homodimerized IR receptors. Analysis of 
PCa cell lines also provided evidence that within 24hr of androgen deprivation 
IGF1R transcript and protein levels fall in PCa cells, while INSR transcript and 
protein levels remain stable. Previous studies also confirm that IGF1R protein levels 
are reduced in PCa cells upon androgen deprivation, and that IR protein levels 
remain unchanged (Krueckl, et al., 2004). This would be expected to alter the 
stoichiometry of IGF1R and IR in the cells to favour greater capacity of insulin 
signalling through formation of hybrid IGF1R:IR-A receptors and homodimers of 
IR-A:IR-A. Testosterone increases insulin sensitivity in men, and thus androgens are 
expected to increase IR expression in classically metabolic tissues. One recent study 
showed DHT increased activity at the IR promoter in LNCaP cells after 24hr 
(Weinstein, et al., 2014). However, the data herein shows no change in overall IR 
protein levels with DHT treatments at 24hr, nor a change in INSR-A or INSR-B 
mRNA levels with DHT at 48hr. The in vitro experiments performed in this Chapter 
examined androgen deprived cells, which may partly explain the difference in the 
results.  
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In fact, the in vitro data presented in this Chapter provide evidence that IR expression 
in PCa cells is negatively correlated with AR expression. The cells with high AR, 
such as DUCaP exhibited low IR expression, while the 22RV1s, with high IR, 
exhibited low AR expression. LNCaP cells displayed moderate expression of both 
AR and IR. AR knockdown lead to increased levels of INSR-A transcripts both in 
vitro and in vivo and increased IR protein levels. Additionally, AR knockdown also 
resulted in increased IR nuclear translocation. These results suggest that AR 
inhibition can further enhance insulin action in PCa cells by increasing total IR 
protein levels as well as its nuclear translocation. In vitro experimentation with 
clinically relevant AR inhibitors enzalutamide, bicalutamide and ARN509 did not 
change expression of INSR-A or IR protein, and only showed modest, non-significant 
increase in nuclear translocation of IR. However, this could be due to the short 
treatment time of 24hr with these inhibitors, while AR genetic knockdown studies 
were performed for a period of five days. Thus, further studies with longer treatment 
times with AR inhibitors will help establish whether AR inhibitors are able to 
replicate the effects of AR knockdown. Nevertheless, the results provide evidence 
that IR expression increases with androgen deprivation and AR inhibition, while 
IGF1R levels are reduced , altering the receptor stoichiometry of PCa cells to favour 
insulin signalling (Figure 3.11).  
An unexpected finding was that, nuclear IR levels were also increased by DHT 
treatments, similarly to AR knockdown. This was not explored in this Chapter, 
however, we did observe dramatic differences in cell morphology in these different 
contexts. It would be interesting to examine the functional effects of IR when co-
localized to the nucleus with AR (by DHT) compared to nuclear localisation without 
AR (in the absence of DHT or with AR knockdown). Nuclear IR has been recently 
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shown to be part of the transcription machinery in hepatocytes to regulate insulin 
inducible genes erg-1 and Gck (Nelson, LeBoeuf, & Bomsztyk, 2011); several older 
studies had also reported nuclear IR in hepatocytes (Gletsu, Dixon, & Clandinin, 
1999; Gletsu, Field, & Clandinin, 1999; Podlecki et al., 1987) and it has been 
reported more recently in human corneal epithelial cells (Wu, Zhu, & Robertson, 
2012) and breast cancer cells (Sarfstein et al., 2012). Whether DHT drives IR to the 
nucleus in muscle, liver and adipose tissue would also inform how androgens 
regulate IR in classically metabolic tissues, which are expected to express high levels 
of both AR and IR, and would provide additional information to how PCa cell IR 
regulation may compare to IR regulation in metabolic tissues. It is also important to 
note that metabolic tissues typically expresses the IR-B isoform of IR in contrast to 
cancer cells, and IR-B drives different cellular functions than IR-A, thus it’s 
reasonable to expect its regulation will differ. Nuclear IGF1R has also been recently 
shown to be part of the transcriptional complex in human cells (Sehat et al., 2010).  
Nuclear IR could be involved in gene expression regulation, either by regulating 
transcription or by regulating histone modifications and epigenetic control of gene 
expression. That fact that DHT stimulates co-translocation of both AR and IR to the 
nucleus indicates that IR could associate with the AR transcriptional protein 
complex. Immunoblotting with IR of immunoprecipitated samples of AR bound 
nuclear proteins would confirm or rule out whether IR is directly bound to AR. 
Further, CHIP-Seq assays would identify whether nuclear IR is regulating expression 
of different genes in the context of AR inhibition compared to when nuclear AR is 
abundant in DHT replete conditions. Gel shift-assays as described by Sehat et al in 
their 2010 report (Sehat, et al., 2010) could confirm binding of nuclear IR to the key 
genes identified through CHIP-Seq. The microarray results provided here suggest 
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that insulin can have transcriptional actions in PCa cells both different and same to 
that of androgens. For example, insulin up-regulated expression of its own receptor 
only in the absence of androgens, while PSA transcription could be up-regulated by 
both insulin and androgens. Thus, further studies are required to better understand 
the role of nuclear IR and its effects on insulin and androgen stimulated transcription 
in PCa cells.  
Immunofluorescence also indicated that the majority of IR in PCa cells remain in 
cytoplasm, however IGF1R is at the plasma membrane in DUCAP cells. This is 
consistent with literaure of stained tumour tissue also showing membranous 
localisation of IGF1R and cytoplasmic localization for IR (Cox, et al., 2009; Lubik, 
Gunter, Hollier, Fazli, et al., 2013) . It has been reported that IR-A internalizes more 
rapidly than IR-B (Giudice, et al., 2011; Vogt, Carrascosa, Ermel, Ullrich, & Haring, 
1991; Yamaguchi et al., 1991). Thus, predominance of IR-A in PCa cells could also 
partly explain its increased cytoplasmic localization. IR in the cytoplasm could 
indicate prolonged/constitutive IR activation in multi-vesiclular bodies (MVBs) or 
that IR is being degraded in lysosomes. Co-staining for IR with markers of MVB or 
lysosomes would help clarify this; additionally staining for phosphorylated IR in 
insulin treated PCa cells and PDX samples would establish localization of activated 
IR within PCa cells.  
The evidence provided here show that in vitro, insulin treatment increases both 
INSR-A transcripts as well as IR protein levels, and that inhibition of PI3K and 
MAPK pathways downstream of the receptor blocked this process. Thus insulin 
action in androgen deprived PCa cells increased transcription and translation of IR 
through activation of PI3K and MAPK pathways. Interestingly, AR has also been 
known to have non-genomic actions by activating PI3K and MAPK pathways 
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(Malinowska et al., 2009b; Peterziel, et al., 1999; Zhu, et al., 1999). Insulin treatment 
increased accumulation of cytoplasmic AR, suggesting that some non-genomic AR 
action may be triggered by insulin in PCa cells. Further studies investigating the 
mechanisms of AR and IR direct regulation would be illuminating, although a 
completed signalling networking involvement of PI3K and MAPK signalling is 
likely. Importantly, this data suggests that insulin in PCa cells may be triggering a 
positive feedback regulation of its own receptor, causing the PCa cells that initially 
respond to insulin to become more and more sensitive to the ligand over time. As 
PCa patients become hyperinsulinaemic upon ADT treatment, paired with increased 
IR expression in tumour cells, insulin action in PCa cells may play crucial functions 
in activating process of cancer progression and recurrence in patients. The PDX and 
in vitro results here confirm that IR-A is the predominant isoform of IR in PCa, in 
line with other cancers (Malaguarnera & Belfiore, 2014). It is more mitogenic than 
IR-B, and may also be involved in cell migration and invasion processes (Pandini, et 
al., 2002; Zhao, et al., 2012). Insulin can regulate numerous pathways in cells 
(Belfiore, et al., 2009; Lubik, Gunter, Hollier, Fazli, et al., 2013; Mounier & Posner, 
2006a; Pandini, et al., 2002), resulting in different functional outcomes. However, 
the functional effects of insulin signalling in PCa are not well characterized (Figure 
3.11). Better understanding the roles insulin signal through IR-A or hybrid 
IGF1R:IR-A receptors can play in PCa is needed to grasp how PCa progression 
occurs in patients, especially in those that develop ADT induced hyperinsulinaemia. 
This will also provide evidence to better target treatments towards patient 
populations that are at risk of PCa recurrence after ADT. Thus, these results compel 
more investigation into the functional relevance of insulin signalling in PCa.   
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Figure 3.11 Androgen deprived PCa cells increase expression of receptors for 
insulin signalling. Schematic showing composition of insulin receptors expected in 
androgen deprived PCa cells, which lower their IGF1R expression and increase IR-A 
expression, leading to formation of homodimers of IR-A, or hybrid IGF1R:IR-A 
receptors. Insulin also activates the PI3K/Akt and Ras/MAPK pathways, which can 
positively regulate IR-A expression, further increasing its expression in PCa cells. 
The functional effects of insulin action in PCa cells are however not wholly 
understood. 
 
Figure 3.11 
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4.1 Introduction 
Findings from the previous Chapter identified a negative correlation between 
IR and AR levels across PCa cell lines. Additionally, inhibition of AR activity using 
androgen withdrawal, AR inhibitors or AR knockdown, resulted in decreased IGF1R 
and increased IR levels. This was reflected in vitro, in vivo, in metastatic tumour 
samples and in patient derived xenografts (PDXs). Thus, these observations reflect 
the in vivo adaptive response suggesting insulin may play a more significant role in 
patients undergoing ADT than previously appreciated.  
IGF1 signalling in PCa has been shown to stimulate proliferation, invasion, 
migration and metastasis in vivo (Wu & Yu, 2014). However, with this new 
information about increased insulin signalling potential in androgen deprived cells, 
understanding the functional effects of insulin in advanced PCa becomes pertinent. 
However, these effects are ill defined. Our team had shown that insulin can increase 
de novo steroidogenesis in PCa in vitro (Lubik, et al., 2011), but, its regulation of 
proliferation and cell migration/invasion processes in PCa is unknown. These 
processes are crucial to PCa hormone therapy resistance and metastasis. Studies 
showing serum from obese mice or obese humans, which would be expected to be 
hyperinsulinaemic, increase cell migration of PCa cells (Kushiro & Nunez, 2011b; 
Price, Cavazos, De Angel, Hursting, & deGraffenried, 2012a) suggest that insulin 
may affect PCa cell migration.  To test this hypothesis, the direct effect of insulin on 
proliferation, migration and invasion was tested on a range of androgen deprived PCa 
cells and its interactions with androgens and AR inhibitors were studied.  
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4.2 Results  
4.2.1 Insulin stimulated proliferation in PCa cells corresponds to their PTEN 
status  
Cell proliferation in a range of androgen deprived PCa cells was measured through 
quantitating DNA content with the Cyquant assay (Figure 4.1) as well as through 
measuring mitochondrial activity with Presto Blue assay (Figure 4.2). Both assays 
show largely the same trends across the cell lines, although some differences are 
seen, especially in VCAP, DU145 and PC3 cells where insulin stimulated rise in 
DNA content (Figure 4.1B, E and F) did not correlate with similarly increased 
mitochondrial activity (Figure 4.2B, E and F); and in C42B cells where DHT 
stimulated rise in DNA content (Figure 4.1G) also did not correlate with increased 
mitochondrial activity (Figure 4.2G). It is possible that mitochondrial activity does 
not always associate with increased proliferation as measured through rise in DNA 
content. In fact, treatments showed more apparent changes in DNA content (Figure 
4.1E, F and G) than mitochondrial activity (Figure 4.2E, F and G) in several of the 
less androgen responsive cell lines, including C42B, DU145 and PC3 cells.  
As expected, androgens stimulated significant proliferation (Figure 4.1A, B, C and 
D) and increased mitochondrial activity (Figure 4.2A, B, C and D) in the androgen 
responsive cell lines DUCAP, VCAP, LNCaP and 22RV1, while the AR negative 
cell line DU145 and PC3 cells did not respond to DHT with significant change in 
proliferation (Figure 4.1 E and F) or mitochondrial activity (Figure 4.2 E and F). 
C42B cells, which are an androgen independent derivative of LNCaP cells 
(Horoszewicz et al., 1983; Wu et al., 1994), also did not respond to DHT with 
significant rise in proliferation (Figure 4.1G) or mitochondrial activity (Figure 4.2G).  
Interestingly, while insulin stimulated proliferation in all the cell lines (Figure 4.1), 
in some cell lines, the rise in insulin stimulated proliferation was equal to (DUCAP 
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and 22RV1, Figure 4.1A and D) or higher than that stimulated by androgens (VCAP, 
Figure 4.1B). This indicates that insulin can be as potent a stimulator of cell 
proliferation in a subset of cells as DHT. DUCAP (Gravina et al., 2011), VCAP 
(Hodgson et al., 2011) and 22RV1 (Fraser et al., 2012) cell lines are all PTEN+/+, 
while the other cell lines studied have dysfunctional PTEN through loss-of-function 
mutations (LNCaP, C42B, frameshift mutations of PTEN (Vlietstra, van Alewijk, 
Hermans, van Steenbrugge, & Trapman, 1998)) or deletions (DU145 cells have 
heterozygous deletion (Fraser, et al., 2012), and PC3 cells have homozygous 
deletions (Fraser, et al., 2012)).  Thus, the most dramatic changes in insulin induced 
proliferation associated with PTEN positive cell lines.  
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Figure 4.1 Insulin induces significant cell proliferation in PTEN positive PCa 
cell lines. DUCaP (A), VCaP (B), LNCaP (C), 22RV1 (D), DU145 (E), PC3 (F) and 
C42B (G) PCa cell lines were cultured under androgen deprived conditions for 48hr 
and treated for 48hr with insulin (ins, 10nM), DHT (10nM), in the presence and 
Figure 4.1 
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absence of AR inhibitors bicalutamide (bic, 10µM) and enzalutamide (enz, 10µM) 
and with tyrosine kinase inhibitor to IR and IGF1R BMS 745804-07 (bms, 500µM) 
and monoclonal antibody inhibitor of IGF1R CP751871 (cp, 5mg/mL) in media 
containing charcoal stripped serum. The AR sensitivity of the cell lines are labelled 
at the top, and their PTEN mutation status is labelled at the top left or bottom left 
corner of the graph of each cell line.  Y-axis range of all graphs are the same for easy 
comparison of magnitude of change across cell lines. Cell proliferation was 
measured by quantitating cellular DNA content with the Cyquant® assay. Insulin 
induced proliferation in PTEN homozygous positive cell lines DUCaP (A), VCaP 
(B) and 22RV1 (D) to the same or greater levels to that by androgens. DHT 
stimulated proliferation in all AR sensitive cell lines (A-D), but not in the AR 
independent cell lines (E-G). Insulin stimulated proliferation was blocked by pan-
inhibitor BMS 745804-07 in all cell lines, and reduced with IGF1R inhibitor 
CP751871 in DUCaP (A) and VCaP (B) cells. AR inhibitors bicalutamide and 
enzalutamide inhibited proliferation across the AR sensitive cell lines, and reduced 
DHT stimulated proliferation in VCaP (B) and LNCaP (D) cells. Insulin treatment 
increased cell proliferation despite presence of AR inhibitors in DUCaP (A), VCaP 
(B) and 22RV1 (D) cells, as well as non-significant rise in proliferation in AR 
independent cell lines (E-G). (all graphs n=3, One-way ANOVA ± SEM with 
vehicle treatment as control, * = p<0.05, ** = p<0.005, *** = p<0.0005, **** = 
p<0.00005) 
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Figure 4.2 Insulin increases mitochondrial activity in PTEN positive PCa cell 
lines. DUCAP (A), VCAP (B), LNCaP (C), 22RV1 (D), DU145 (E), PC3 (F) and 
C42B (G) PCa cell lines were cultured under androgen deprived conditions for 48hr 
and treated for 48hr with insulin (ins, 10nM), DHT (10nM), in the presence and 
Figure 4.2 
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absence of AR inhibitors bicalutamide (bic, 10µM) and enzalutamide (enz, 10µM) 
and with tyrosine kinase inhibitor to IR and IGF1R BMS 745804-07 (bms, 500µM) 
and monoclonal antibody inhibitor of IGF1R CP751871 (cp, 5mg/mL) in media 
containing charcoal stripped serum. The AR sensitivity of the cell lines are labelled at 
the top, and their PTEN mutation status is labelled at the top left corner of the graph 
of each cell line. Mitochondrial activity of cells was measured by quantitating colour 
change in PrestoBlue
®
, indicating metabolic reduction by living cells. Insulin 
induced significant rise in mitochondrial activity in PTEN homozygous positive cell 
lines DUCAP (A) and 22RV1 (D) to the same or greater levels as androgens. DHT 
also stimulated mitochondrial activity in all AR sensitive cell lines (A-D), but not in 
the AR independent cell lines (E-G). Insulin-stimulated mitochondrial activity was 
blocked by pan-inhibitor BMS 745804-07 in all cell lines, and reduced with IGF1R 
inhibitor CP751871 in DUCaP (A) and VCAP (B) cells. AR inhibitors bicalutamide 
and enzalutamide inhibited or reduced mitochondrial activity across the AR sensitive 
cell lines, but did not reduce DHT stimulated mitochondrial activity. Insulin 
treatment allowed significant increase in mitochondrial activity despite presence of 
AR inhibitors in DUCaP (A), VCaP (B) and 22RV1 (D) cells, as well as non-
significant rise in proliferation in AR independent cell lines (E-G) (all graphs n=3, 
One-way ANOVA ± SEM with vehicle treatment as control, * = p<0.05, ** = 
p<0.005, *** = p<0.0005, **** = p<0.00005). 
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Figure 4.3 Insulin causes survival against AR inhibitors in DUCaP cells. Bright 
field images of DUCaP cells cultured under androgen deprived conditions for 48hr 
and treated for 48hr with insulin (ins, 10nM), DHT (10nM), in the presence and 
absence of AR inhibitors bicalutamide (bic, 10µM) and enzalutamide (enz, 10µM) 
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and with tyrosine kinase inhibitor to IR and IGF1R BMS 745804-07 (bms, 500µM) 
and monoclonal antibody inhibitor of IGF1R CP751871 (cp, 5mg/mL) in media 
containing charcoal stripped serum. Presence of pan-inhibitor BMS 745804-07 lead 
to significant cell death, as well as with AR inhibitor enzalutamide. Some cell death 
is also evident with IGF1R inhibitor CP751871 and AR inhibitor bicalutamide. 
Presence of insulin in combination with bicalutamide and enzaluamide rescued cells 
from dying (n=3, scale bars indicate 100μm) 
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4.2.2 Insulin is associated with increased resistance to AR inhibitors in PCa cells 
Insulin can signal through IR homodimers or form hybrid receptors with IGF1R. The 
effects of insulin / IGF-1 receptor inhibitors on insulin induced proliferation using 
BMS 745807-04 (a pan-insulin/IGF1R small molecule inhibitor) and CP751871 
(IGF1R-specific blocking monoclonal antibody) was assessed. Inhibitor doses were 
based on loss of receptor phosphorylation, assessed by Western blot (Supplementary 
Figure 4.1).  Treatment with BMS 745807-04 led to significant suppression of 
insulin induced proliferation and mitochondrial activity in all cell lines (Figure 4.1 
and 4.2), and the addition of CP751871 reduced proliferation in LNCaP, C42B and 
DU145 (Figure 4.1C, E and G) and reduced mitochondrial activity in DU145 cells 
(Figure 4.2E). As CP751871 targets the IGF1R, this suggests there is at least some 
role of the hybrid receptors in these cells lines. Together this data suggests that 
insulin acts through homodimer IR or hybrid IGF1R:IR receptors to produce 
proliferation in PCa cells. 
Importantly, insulin induced significantly proliferation in the PTEN wild-type 
DUCaP, VCaP and 22RV1 cells lines despite the presence of AR inhibitors 
bicalutamide and enzalutamide (Figure 4.1A, B, D and Figure 4.2A, B and D). 
Images of treated DUCaP cells also confirm this (Figure 4.3), showing AR inhibitor 
treated cells in combination with insulin are more adherent to culture place than with 
AR inhibitor alone. This suggests that insulin can confer greater cell survival in the 
face of AR inhibitors in PTEN-positive cell lines.   
4.2.3 Insulin increases migration in androgen deprived PCa cells via insulin 
receptor 
Migration responses were not studied across all the given cell lines, but a 
combination of AR dependent and independent and PTEN positive and negative cell 
lines were chosen for migration experiments to capture the effect of insulin in a 
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range of PCa cell models. LNCaP (androgen dependent, dysfunctional PTEN), 
22RV1 (androgen responsive but not dependent, PTEN+/+) and DU145 cells 
(androgen independent, PTEN -/+) were cultured under androgen deprived conditions 
and treated with 10nM insulin in the presence and absence of 10nM DHT. To ensure 
proliferation was not measured, cells were treated with optimized concentration of 
anti-mitogenic agent mitomycin C (Supplementary Figure 4.2), as treatment with 
nocodazole led to cell death. The presence of insulin in androgen deprived conditions 
led to significant gains in migration in all three cell lines (Figure 4.4A). LNCaP, 
22RV1 and DU145 cells treated with insulin all displayed increased sheet migration 
(Figure 4.4A) measured by calculating the increased % wound confluency using the 
Incucyte Live Cell analysis system (Supplementary Figure 4.3) and graphing the % 
increase over vehicle. LNCaP cells showed a 20% greater wound confluency 
compared to vehicle, 22RV1 were 50% more confluent and DU145 30% more 
confluent than their vehicle controls. Similar results were observed with insulin 
increasing single cell migration of LNCaP cells through transwell filters (Figure 
4.4B).  Thus, again the largest effect is seen in PTEN +/+ 22RV1 cells. 
The effects of receptor inhibitors on insulin induced migration using BMS 745807-
04 and CP751871 were assessed. Treatment with BMS 745807-04 led to significant 
suppression of insulin induced migration in all 3 cell lines (Figure 4.4A and B), and 
replicating the proliferation data, the addition of CP751871 reduced migration in 
LNCaP and DU145 (Figure 4.4A), again suggestive of at least some role of the 
hybrid IGF1R:IR receptors in these cells lines. The 22RV1s, again, were not 
sensitive in this assay to the monoclonal antibody (Figure 4.4A).  
Both inhibitors available to us lacked specificity of the IR alone. To overcome this, 
LNCaP cells with doxycycline inducible shRNA against the IR were generated 
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(Supplementary Figure 4.4). Doxycycline-induced expression of shRNA decreased 
insulin-induced migration to vehicle levels, which was not observed in cells carrying 
the control non-targeting vector (Figure 4.4D). Together, these data suggest that 
insulin increases migration in AR-dependent and independent cell lines and these 
migratory effects of insulin are specific to the action of insulin through IR and hybrid 
receptors.   
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Figure 4.4: Insulin induced migration in PCa cells is reduced with addition of 
receptor inhibitors. Change in wound confluency quantitated relative to vehicle at 
48hrs (A). Insulin (10nM) accelerated wound closure in LNCaP, 22RV1 and DU145 
which was reduced by the pan insulin/IGF1R inhibitor BMS 745807-04 (10uM). The 
monoclonal antibody to IGF1R, CP 751871 (5ug/ml) reduced insulin-induced 
migration in LNCaP and DU145 cells, but not in 22RV1 cells. (B) BMS 745807-04 
and CP 751871 also reduced insulin accelerated transwell migration of LNCaP cells. 
Figure 4.4 
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Scale bars = 100μm(C) LNCaP cells transduced with doxycycline (dox)-inducible 
shRNA against the insulin receptor (INSR) resulted in decreased INSR RNA and IR 
protein after 3, 5 and 7 day dox induction compared to non-targeting control (NT). 
Reduction of insulin induced migration was observed in LNCaP cells with dox-
induced knockdown of insulin receptor, but not in the control cells with non-
targeting small-hairpin RNA (scale bars = 100 μm , n=3, One-way ANOVA, ± SEM, 
* = p<0.05, ** = p<0.005, *** = p<0.0005, **** = p<0.00005) 
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4.2.4 Androgens regulate insulin-induced migration in PCa cells 
Androgens regulate prostate cell differentiation and previous studies have 
demonstrated that androgen deprivation promotes epithelial de-differentiation in 
prostate cancer cells and increases cell motility (Bishop, Davies, Ketola, & Zoubeidi, 
2015; Li, Yang, & Gao, 2014; Nouri et al., 2014). The addition of 10nM 
dihydrotestosterone (DHT) suppressed wound healing migration of LNCaP cells 
induced by both ADT and insulin (Figure 4.5A). In the relatively less AR-dependent 
22RV1 cells, DHT alone and in combination with insulin, also reduced migration, 
but did not ablate it (Figure 4.5B), consistent with their reduced sensitivity to DHT 
and high basal AR activity. Insulin-induced migration in AR independent DU145 
cells was unaffected by the addition of DHT (Figure 4.5C). In the LNCaP cells, 
treatment with the AR antagonist, bicalutamide, was not able to reverse the 
suppression of insulin-induced migration by DHT (Figure 4.5D), in contrast to 
enzalutamide, which reversed the effects of DHT (Figure 4.5E) and, in accordance 
with recent reports, induced sheet migration with comparable potency to insulin. The 
combination of insulin and enzalutamide did not have an additive effect on 
migration, indicating potential activation of a common pathway, or that the cells may 
have reached a maximal threshold for migration. Similar results with both 
bicalutamide and enzalutamide were observed in transwell migration studies, (Figure 
4.5F). Enzalutamide promoted migration in the presence and absence of DHT and 
prevented the inhibition by DHT in insulin treated cells. Bicalutamide again 
appeared to inhibit migration which may be in part due to bicalutamide acting as an 
AR agonist in cells which harbour the AR mutation T877A, including LNCaP cells 
(Sun et al., 2006). Taken together, these observations suggest that insulin driven 
migration in PCa cells is sensitive to AR activity.  
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Figure 4.5: Insulin induced migration is inhibited by androgens. Change in 
wound confluency captured by Incucyte real-time imaging (line graph), and 
quantitated relative to vehicle at 48hrs (bar graph). (A) 10nM DHT reduced ADT 
(blue) and insulin-induced (orange) wound closure in LNCaP cells, DHT reduced 
wound closure in 22RV1 cells (B), but not to statistically significant levels. And 
DHT had no effect in AR negative DU145 cells (C). In LNCaP cells, bicalutamide 
(10uM) inhibited migration, imitating the effects of DHT (D). Conversely, the 
addition of enzalutamide (10uM) induced migration as potently as insulin (E). 
Similar results were observed in transwell migration experiments, where insulin 
Figure 4.5 
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induced migration, and both DHT and bicalutamide block this effect (F). (scale bars 
= 200 μm) n=3, One-way ANOVA, ± SEM, * = p<0.05, ** = p<0.005, *** = 
p<0.0005, **** = p<0.00005) 
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4.2.5 Insulin increases invasion in PCa cells 
Invasion was measured by quantitation of spheroid sprouting in 3D culture in 
Matrigel and counting cells passing through Matrigel-coated transwell inserts. 
Insulin increased the rate of spheroid sprouting in androgen deprived LNCaP (Figure 
4.6A) and 22RV1 cells (Figure 4.6B) in 3D culture, where single cells were observed 
sprouting from insulin-treated spheroids after 3 days and invading into the 
surrounding Matrigel by six and five days, respectively. This increase was blocked 
by the addition of receptor inhibitors, BMS 745807-04 and CP 751871 in both 
LNCaP and 22RV1 cell lines. Invasion did not occur for vehicle-treated spheroids at 
the same time point; however, sprouting spheroids in vehicle conditions did become 
invasive by day 12-14 post treatment (data not shown). These results are consistent 
with previous reports that androgen deprivation is capable of inducing migration and 
invasion in prostate cancer cells (37), but indicating that exposure to insulin 
significantly enhances invasive properties. Again, magnitude of insulin induced 
invasion was higher in PTEN+/+ 22RV1 cells than in LNCaP cells with dysfunctional 
PTEN. Insulin treatment also resulted in a dramatic increase in the number of cells 
undergoing transwell invasion in androgen deprived LNCaP cells relative to vehicle 
(Figure 4.6C) which was again blocked by insulin/IGF1 receptor inhibitors, DHT and 
bicalutamide, consistent with our migration data. Together, these data suggest that 
insulin induced invasion, like migration, is due to activation of IR/IGF1R and 
negatively regulated by androgens.  
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Figure 4.6: Insulin induced invasion in PCa cells. In 3D Matrigel assays, insulin 
promoted spheroid sprouting and invasion in LNCaP cells (A) and 22RV1 cells (B), 
which was blocked with CP 751871 (CP) and BMS 745807-04 (BMS). Images show 
degree of sprouting after 3 days of insulin treatment. Sprouting was not observed in 
vehicle-treated cells (VEH) at the same time point, but was apparent in LNCaP cells 
by day 12-14 (not shown). DHT-treated cells showed no evidence of sprouting over 
Figure 4.6 
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this time (Scale bars = 300μm, inset = 75μm). (C) Insulin promoted cell invasion 
through MatrigelTM coated transwell. The addition of DHT completely prevented cell 
invasion and bicalutamide failed to reverse the inhibitory effect of DHT. BMS 
745807-04 also inhibited insulin induced transwell invasion.  (Scale bars = 200 μm 
n=3, One-way ANOVA, ± SEM, * = p<0.05, ** = p<0.005, *** = p<0.0005, **** = 
p<0.00005) 
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4.2.6 Insulin induced rise in IGF2 
Insulin induces migration in androgen deprived PCa cells through IR signalling. 
However, along with insulin, IGF1 and IGF2 can also signal through IR and hybrid 
IR:IGF1R receptors. IGF1 and IGF2 are both established mediators of EMT. Thus 
expression of these molecules was also investigated.  
In Chapter 3, expression of IR in PCa metastasis was shown to be commonly up-
regulated (Figure 3.1). In PCa metastases, tumour level IGF2 is also preferentially 
increased over IGF1, indicating that IGF2 signalling may be of relevance in 
metastases related mechanisms in PCa (Table 4.1). LNCaP cells have greater 
amounts of IGF2 transcripts than IGF1 (Figure 4.7A), and IGF2 is increased by 
androgen deprivation and anti-androgens. IGF2 receptor (IGF2R), which is a non-
membrane bound receptor that sequesters IGF2 to prevent it signalling in cells is also 
reduced in androgen deprivation in LNCaP cells (Figure 4.7B). Doxycycline induced 
AR knockdown in LNCaP cells, introduced in Chapter 3, also increases IGF2 with 
AR knockdown, not seen in cells expressing non-targeting shRNA (Figure 4.7C).  
Importantly, insulin further increases IGF2 in LNCaP cells (Figure 4.7D). Rise in 
IGF2 to levels like that induced by insulin was also observed for AR inhibitor 
enzalutamide. IGF2 treatment is a potent driver of migration of LNCaP cells (Figure 
4.7E). Together, these results suggest IGF2 is increased in response to insulin 
signalling in LNCaPs and has the potential to also signal through IR and IGF1R.  
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Table 4.1: IGF2 is increased in clinical datasets comparing metastatic to 
primary tissue.  
Among clinical studies in OncomineTM, reporting differential gene expression of 
IGF1, IGF2 and IGF2R for primary and metastatic PCa patient tumours, IGF2 
expression is commonly increased in metastasis (89% of the datasets), whereas IGF1 
is commonly decreased (100%). Coloured cells represent significant differential 
expression, with p-value reported within the cells. Yellow for overexpression and 
blue for reduced expression in metastases relative to primary tumour tissue.   
Dataset Name Journal, Year
n 
(primary)
n 
(metastasis) IGF2 IGF2R IGF1
3.54E-08 0.004 1.36E-07
1.93E-06
Yu Prostate J Clin. Onco., 2004 64 24 0.004 5.60E-06
Chandran Prostate BMC Cancer, 2007 10 21 8.01E-10 6.90E-06
Taylor Prostate 3 Cancer Cell, 2010 131 19 0.023 0.012
Tamura Prostate Cancer Res, 2007 23 12
LaTulippe Prostate Cancer Res, 2002 23 9 0.023 0.002 0.015
LaPointe Prostate PNAS, 2004 62 9 0.047 5.40E-06
Holzbeierlien Prostate Am J Pathol., 2004 40 9 0.04
Vanaja Prostate Cancer Res, 2003 27 5 0.019
Varambally Prostate Cancer Cell, 2006 7 6 0.041 4.57E-04 1.13E-08
Ramaswamy multi-cancer PNAS, 2001 10 4 0.02
Ramaswamy multi-cancer 2 Nat. Genet. 2003 10 3 0.035
Magee Prostate Cancer Res, 2001 8 3 0.02
89% 33% 0%% of datasets in which overexpressed
Grasso Prostate Nature, 2012 59 35
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Figure 4.7: IGF2 increases in androgen deprivation and with insulin in PCa (A) 
RNA-Seq data from 48hr androgen deprived LNCaP cells treated with DHT (10nM) 
and AR inhibitors bicalutamide (bic, 10µM) and enzalutamide (enz, 10µM) show 
that while IGF1 transcript levels fall in the absence of androgens and with AR 
inhibitors, IGF2 transcript levels remain high, and predominate over IGF1 transcript 
levels. Additionally, IGF2R transcript levels are decreased in ADT (B), freeing up 
more active IGF2. (C) qRT-PCR of LNCaP shAR and shNT cells cultured under 
androgen deprived conditions for 5 days with and without 250ng/mL doxycycline 
stimulation indicate increased IGF2 transcription upon AR knockdown (red bar), 
which was not observed in control LNCaP shNT cells. DHT stimulation suppressed 
Figure 4.7 
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IGF2 transcript levels in shNT and in the shAR cells without doxycycline, but with 
dox induced AR knockdown in the shAR cells, the DHT induced suppression of 
IGF2 transcript was relived (n=3, mean± SEM, ANOVA * = p<0.05, ** = p<0.005, 
*** = p<0.0005, **** = p<0.00005) (D) LNCaP cells cultured under androgen 
deprived conditions for 48hr were treated with insulin (10nM), DHT (10nM) and 
enzalutamide (10µM) for 20h. qRT-PCR shows insulin significantly increased IGF2 
transcription in LNCaP cells (n=3, One-way ANOVA, ± SEM, * = p<0.05) (E) 
Androgen deprived LNCaP cells were treated overnight with IGF2 (80ng/mL) and 
insulin (10nM) and 2hrs of mitomycin c (10µg/mL). Transwell migration assay of 
cells show IGF2 is a more potent inducer of migration in LNCaP cells than insulin 
alone (Scale bars = 200μm, n=3, One-way ANOVA, ± SEM, * = p<0.05, *** = 
p<0.0005) 
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4.3 Discussion 
• Insulin and androgens activate similar and unique functions in advanced PCa 
In this chapter, it is seen that insulin and androgens can have both similar and 
contrary effects in PCa cells. Androgens are required for malignant luminal secretory 
cells to maintain their prostatic differentiation (PSA secretion) and proliferation. 
Thus, as expected, the in vitro data here show that DHT (10nM) increased cell 
proliferation in all the AR responsive cell lines, but supressed migration and invasion 
in LNCaP cells both in the presence and absence of insulin.  Insulin, however, 
activated both proliferation and migration/invasion processes in androgen deprived 
PCa cells. This indicates that insulin can activate both unique and mutual responses 
to that seen with androgens in advanced PCa (Figure 4.8), consistent with the 
microarray data presented in Chapter 3 (Figure 3.9A). However, insulin signalling in 
low androgen conditions may still be acting in concert with AR, as AR activation in 
low androgen has been shown to cause PCa cells to display gain of migratory and 
invasive properties (Zhu & Kyprianou, 2010) (Frigo et al., 2011), along with 
increased survival, proliferation and PSA secretion (Claessens, et al., 2008; Huggins 
C, 1941; Massard & Fizazi, 2011). Insulin can also enhance de novo androgen 
synthesis in the face of low androgen levels, contributing to a slight increase in 
androgen levels in the cellular microenvironment (Lubik, et al., 2011). 
Physiological levels of DHT (10nM) driven suppression of 
migration/invasion responses were stronger than insulin (10nM) driven activation of 
these pathways, as in the AR responsive LNCaP cells, DHT suppressed migration 
and invasion even in the presence of insulin. DHT also reduced insulin induced 
migration and invasion in 22RV1 cells, but did not supress migration to the same 
degree as in LNCaP cells, reflecting their mild AR responsiveness. Insulin induced 
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migration in DU145 cells both in the presence and absence of DHT, again consistent 
with DU145 cells lacking an AR and being unable to respond to DHT.  However, for 
proliferation, insulin in combination with DHT often had an additive effect.  
• AR inhibitors promote invasion and migration in PCa   
The AR antagonist bicalutamide and the more potent enzalutamide, both of 
which directly bind to the AR to prevent transcriptional activation, independently 
promoted invasive properties (Figure 4.8). These findings are also supported by 
recent literature suggesting that both bicalutamide and enzalutamide cause prostate 
cancer cells to invade, while inhibiting proliferation and PSA secretion (Lin, et al., 
2013). This could be because when AR is directly inhibited with these anti-
androgens, the luminal cells lose their epithelial differentiation and proliferation 
signal. This raises the possibility that patients under treatment with these anti-
androgens may experience regression of cancer, but the lack of AR activity might 
increase metastatic potential and warrants further research to better understand 
cellular plasticity in ATT-treated tumours. Interestingly, the combination of AR 
inhibitor and insulin treatment did not have an additive effect on in vitro migration, 
perhaps indicating that the cells have reached their maximum migratory/invasive 
capability. It might also be that anti-androgens and insulin both act through a 
common pathway.  
Not all anti-androgens increase invasion, as ASC-J9®, newly developed 
antagonist, lead to suppression of both proliferation and invasion in prostate cancer 
cells (Lin, et al., 2013). This highlights the more optimistic notion that AR inhibitors 
can have differential effects on the development of invasive characteristics. 
Identifying pathways through which cellular plasticity is being modulated by insulin 
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and AR inhibitors is thus crucial to overcome issues of treatment resistance and 
ensure greater benefits for patients.  
These observations indicate that both low androgenic situations as well as 
complete lack of AR can promote the acquisition of invasive characteristics in PCa 
cells, which are exacerbated by insulin signalling. Thus, in the absence of androgens, 
insulin signalling may cause PCa cells to become both proliferative and invasive, 
activating key pathways of cancer progression. Insulin signalling through IR-A has 
been shown to activate both proliferation and invasion/migration pathways in other 
cancers (Belfiore, et al., 2009), and this is the isoform expressed in the cell lines 
studied (Chapter 3). 
• Presence of hybrid insulin receptors in prostate cancer 
At the concentration used in these experiments, insulin is able to signal 
through either homodimers of IR (IR:IR) or hybrid heterodimers of insulin receptor 
and IGF1R (IR:IGF1R) (Belfiore, et al., 2009). Insulin is unable to bind and signal 
through homodimers of IGF1R (Belfiore, et al., 2009). Inhibitors to these receptors 
were used in the experiments. BMS 745807-04 is a small molecule that blocks 
homodimers of IR and IGF1R, as well as hybrid receptors, while CP751871 is an 
antibody with the ability of blocking ligand binding to IGF1R homodimers and 
hybrid receptors. The concentration CP 751871 used in these experiments were 
optimized to block IGF1R activation in LNCaP cells (Supplementary Figure 4.3). 
Reduction of insulin-driven proliferation and migration/invasion with CP 751871 
was seen in PTEN negative LNCaP, C42B and DU145 cells. This indicates that 
signalling in these cells occurs, at least partially, through hybrid receptors. Hybrid 
receptors form by stoichiometry (Bailyes et al., 1997), whereby if less IR is present 
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compared to IGF1R, IR will heterodimerise primarily as hybrid receptors (Siddle, 
2012). 
Notably, CP751871 was unable to suppress insulin-enhanced migration and 
proliferation in PTEN-positive cell lines 22RV1, DUCaP and VCaP.  These cells 
could have higher levels of IGF1R than PTEN negative cell lines, as PTEN deletion 
is associated with decreased IGF1R (Hellawell, et al., 2002). In fact, Chapter 3 data 
shows DUCaP and VCaP cells having higher IGF1R levels compared to the other 
cell lines, however, IGF1R levels also fall dramatically with androgen deprivation. 
IGF1R protein could not be detected in 22RV1 cells. LNCaP and 22RV1 cells were 
shown to express similar levels of IGF1R transcripts at baseline (Figure 3.2) and 
with androgen deprivation (Figure 3.3). Thus, failure of CP751871 in PTEN-positive 
cell lines could mean that these cells have greater levels of hybrid receptors or the 
concentrations of CP751871 used in the experiment were not optimal for this cell 
line. It could also mean that they may primarily possess IR homodimers. 
Comparative levels of hybrid receptors could be assessed by immunoprecipitation 
experiments with IR antibody and then immunoblotting samples for IGF1R.  The 
composition of insulin receptors is unlikely to be homogenous in PCa tissue and 
would be expected to include a proportion of hybrid receptors. 
• IGF2 may account for some of the insulin induced rise in migration 
Like insulin, IGF2 also can signal through the IR and hybrid IR:IGF1R receptors. 
Insulin increased IGF2 expression. When used independently, IGF2 induced a strong 
migration response in LNCaPs compared to insulin. It is possible that that part of the 
migration effects observed due to insulin treatment could be due to secondary 
increase in IGF2 signalling through IR. As genetic knockdown of IR prevented 
insulin-induced migration, any insulin-induced IGF2 must be primarily signalling 
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through IR in these cells. Thus measuring IGF2 induced migration in IR knocked 
down LNCaP cells will be illuminating. Whether blocking IGF2 prevents insulin 
driven migration would also show if insulin induced IGF2 is driving migration in 
these cells. It is noteworthy that IR and IGF2 are both commonly increased in PCa 
metastatic tumours compared to primary tumours, suggesting that IGF2 signalling 
through IR may be an important means of driving pathways to metastatic 
progression. 
• Insulin acts through the PI3K/Akt pathways to regulate proliferation, migration 
and invasion 
Insulin stimulated the greatest magnitude of rise in proliferation, migration 
and invasion in PTEN+/+ cell lines. PTEN is an inactivator of PI3K and lack of 
functional PTEN causes constitutive activation of the PI3K/Akt pathway (Bitting & 
Armstrong, 2013). The fact that insulin produced muted effects in cell lines with 
PTEN loss-of-function or deletion, suggests that in cell lines with constitutive 
PI3K/Akt signalling, insulin activation of its receptors has minimal additive effects, 
especially for proliferation responses. Additional stimulation by insulin only 
produced a slight and non-significant rise in proliferation as seen in the LNCaP, 
C42B, DU145 and PC3 cell lines; migration/invasion responses were also higher in 
PTEN positive 22RV1 cell line compared to PTEN mutated LNCaP and DU145 cells 
with heterozygous PTEN deletion. This indicates that the proliferation, migration and 
invasion effects of insulin, downstream of its receptor activation is occurring through 
activating of the PI3K/Akt pathway (Figure 4.8). Investigating whether insulin 
treatment in the PTEN positive DUCAP, VCAP and 22RV1 cells leads to 
downregulation of PTEN would provide further information on the mechanisms of 
insulin action in these cell lines.  
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 However, there is evidence of activation of additional pathways by insulin 
downstream of its receptor in these cells (Figure 4.8). Insulin significantly increased 
migration and invasion responses in PTEN negative LNCaP and DU145 cells. This 
indicates that pathways may be activated by insulin in addition to the PI3K/Akt 
pathway to produce functional effects in androgen deprived PCa cells, especially in 
regards to cell migration and invasion (Figure 4.8). In Chapter 3, it was seen that in 
addition to PI3K/Akt pathway, activation of Ras/Raf/MAPK pathway downstream of 
insulin receptors allowed up-regulation of IR protein levels. Thus, MAPK pathway 
may also be involved in insulin induced migration and invasion.  
The in vitro effects of insulin induced proliferation may be muted compared 
to in vivo responses, as the in vitro data here show a non-significant rise in 
proliferation by insulin in LNCaP cells, but diet induced hyperinsulinemia has been 
shown to significantly increase LNCaP xenograft growth (Venkateswaran, et al., 
2007). Again, insulin may act through pathways other than the PI3K/Akt pathway in 
vivo to activate proliferation, thus producing an additive effect over the constitutively 
activated PI3K/Akt pathway in LNCaP cells.   
• Hyperinsulinemia may cause resistance to AR inhibitors and increase metastatic 
potential to advance PCa 
PCa is a heterogeneous disease, where tumour heterogeneity increases with 
recurrent cancer and metastatic disease (Attard, et al., 2016). Cells with no AR such 
as the PC3 and DU145 cells, AR insensitive cells such as C42B, and cells with a 
PTEN loss-of-function leading to constitutive proliferation signal through PI3K/Akt 
pathways such as LNCaP, C42B, PC3 and DU145 cells are likely to survive ADT 
and ATT treatments due to these mutations. Cells that would be most affected by 
androgen deprivation and AR inhibitors were modelled in the in vitro experiments 
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here using AR responsive and PTEN intact cell lines such as DUCaP, VCaP and 
22RV1 cells. It was observed that insulin could stimulate proliferation in these cell 
lines to the same magnitude as androgens, even in the presence of AR inhibitors 
bicalutamide and enzalutamide. Thus, ADT induced hyperinsulinemia can provide 
the necessary stimulation for PCa tumours to grow even in ADT and with second 
line ATT drugs such as bicalutamide and enzalutamide. This might partly explain 
how AR responsive cells continue to survive in patients under ADT and ATT 
conditions and might also explain increased recurrence in patient populations with 
ADT induced hyperinsulinemia, as shown through multiple epidemiological studies 
(Faris & Smith, 2010; Flanagan, et al., 2010; Hammarsten & Hogstedt, 2005; Ma, et 
al., 2008). 
Insulin treatment in androgen deprived PCa cells also increased both 
migration and invasion. It is hypothesized that gain of invasive and migratory 
properties is the first step in cancer metastasis (Bitting, Schaeffer, Somarelli, Garcia-
Blanco, & Armstrong, 2014). The metastatic ‘cascade’ shows that cells lose their 
epithelial phenotype and strong cell to cell adhesion, invade local surrounding tissue, 
then intravastate into blood vessels to travel through the body to distant organs, 
where they can extravasate to re-seed secondary metastatic tumours (Bitting, et al., 
2014). In PCa, metastases are usually found in bones and lymph nodes. Metastatic 
PCa is also the fatal form of the disease (Attard, et al., 2016). Elevated insulin levels 
at diagnosis have been linked to higher mortality rates and decreased 5-year survival 
(Faris & Smith, 2010; Flanagan, et al., 2010; Hammarsten & Hogstedt, 2005; Ma, et 
al., 2008). This data begins to shed a light on pathways that may underpin these 
epidemiological observations. That insulin increases migration and invasion suggests 
that hyperinsulinemia in patients undergoing ADT is potentially increasing the risk 
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of metastatic CRPC driven by elevated insulin. Identifying the molecular 
mechanisms of insulin induced migration/invasion would allow deeper 
understanding of this process and may also uncover novel biomarkers and drug 
targets.  
 
 
Figure 4.8 Schematic of proliferation, migration and invasion induced by insulin 
and AR in PCa cells. Androgens stimulated cell proliferation, while preventing 
migration and invasion, while AR inhibitors did the reverse. Data in this chapter 
proves that insulin stimulates both proliferation and migration/invasion processes in 
PCa cells in the absence of androgens or with AR inhibitors bicalutamide and 
enzalutamide. Magnitude of change activated by insulin in these functions were 
greatest in cell lines with functional PTEN, indicating involvement of the PI3K/Akt 
pathways in producing these effects downstream of the insulin receptors IR-A and 
Figure 4.8 
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hybrid IR-A: IGF1R. However, significant migration and invasion was still observed 
in LNCaP cells with dysfunctional PTEN, and non-significantly increased 
proliferation was observed in PTEN negative cell lines, indicating that insulin may 
activate other, yet uncharacterized, additional pathways in the presence of a 
constitutively active PI3K/Akt pathway to produce additional rise in proliferation, 
migration and invasion.  
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5.1 Introduction 
The previous chapter showed that insulin caused gain of invasive and migratory 
properties in androgen deprived PCa cells. A molecular understanding of this process 
is lacking and would aide in identifying biomarkers or treatment targets in advanced 
PCa patients.  
To gain motility, cells have to transition from a stationary state. ‘Epithelial’ cells 
display intact cell to cell adhesion and apical/basal polarity, dependent on the 
function of E-cadherins, EPCAM and other transmembrane proteins. However, when 
this adhesion and polarity is lost, cells with characteristic expression of proteins 
including vimentin, N-cadherin and others are said to have a ‘mesenchymal’ 
phenotype. In vitro, cancer cells can undergo epithelial-to-mesenchymal transition 
(EMT), the term for the process where cells lose epithelial features and gain 
mesenchymal features. EMT is a developmental process, aberrant activation of 
which in cancer has been associated with increased migration and invasion and 
metastasis (Chaffer & Weinberg, 2011). Molecular changes in EMT include increase 
in transcription factors (e.g. SNAI1, FOXC2, Zeb1) and decrease in cell adhesion 
molecules (e.g. E-cadherin, desmoplakin, occludin), among others (reviewed in (Lee, 
Dedhar, Kalluri, & Thompson, 2006)). However, the molecular changes associated 
with EMT can occur over a spectrum, with some cell models undergoing complete 
EMT, and others undergoing partial EMT (Christiansen & Rajasekaran, 2006; 
Gavert, Vivanti, Hazin, Brabletz, & Ben-Ze'ev, 2011; Paez-Ribes et al., 2009; Wicki 
et al., 2006). 
Cancer cells that undergo partial EMT, display collective migration, with retention of 
gap junctions and cadherin expression alongside gain of expression of integrins and 
proteases with which to digest, invade and navigate extracellular matrix (ECM). 
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Collective migration describes cells moving as a group where cell to cell contacts are 
largely maintained, while cells on the leading edge of the direction of movement 
display more migratory characteristics, dragging the rest of the cell mass along. 
Single cell migration occurs when tumour cells lose all cell to cell contacts and move 
out of the tumours individually. Cells that undergo complete EMT display no 
cadherin expression, but have high expression of integrins and proteases, especially 
MMPs. These cells travel individually and are said to display mesenchymal 
migration. Cancer cells can also display amoeboid migration, where change in cell 
shape is used to navigate the ECM, rather than integrin based adhesion and protease 
based degradation. Thus, cells displaying amoeboid migration generally have no 
cadherins, integrins or protease expression. Unlike the mesenchymal cells that are 
elongated and fibroblast like, amoeboid cells have a circular morphology. Thus, the 
molecular profile of migration can define the method of tumour cell migration from a 
range (Friedl & Alexander, 2011; Friedl & Wolf, 2003) (Figure 5.1). 
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Figure 5.1. Differences between the types of cancer cell movement. As cells move 
from collective to individual migration, there is a range of expression of cadherins, 
integrins and proteases that result in varied mechanisms of cell migration. Adapted 
from (Friedl & Wolf, 2003). 
 
Invasive and migratory cancer cells are a hallmark of aggressive disease, and are 
hypothesized to begin the ‘metastatic cascade’(Pantel & Brakenhoff, 2004). Insulin 
regulation of these processes is thus especially crucial to investigate, as the majority 
of PCa deaths are a result metastatic progression (De, et al., 2003; Konishi, et al., 
2005; Swanson, et al., 2006). Moreover, the deadliest subset of metastatic PCa 
tumours are composed entirely of neuroendocrine  (NE) cells, accounting for 10-30% 
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of recurrent PCa (Aggarwal, et al., 2014), with a 5-year overall survival of a dismal 
12.6% (Parimi, Goyal, Poropatich, & Yang, 2014). NE tumours are also extremely 
invasive. As discussed in Chapter 1, NE PCa cells are AR-negative cells within the 
tumour that usually compose 1% of PCa primary tumours. Thus, the proportion of 
NE cells in PCa tumours increase with increasing PCa progression and ADT (Figure 
5.1); as well as metastasis (Bostwick et al., 2002; Jin et al., 2004; Roudier et al., 
2003). NE PCa cells are non-prolific, and may also be stemlike in nature (Nouri et 
al., 2017). Classical markers of NE in PCa include expression of neural cell adhesion 
molecule (NCAM), as well as neuropeptides such as chromogranin A (CHGA) and 
somatostatin (SST) (Parimi, et al., 2014).  
 
 
Figure 5.2. NE cells in cancerous prostate tissue. Immunohistochemistry (IHC) of 
benign and cancerous prostate tissue showing NE cells (brown) with anti-
chromogranin-A (CHGA) immunoreactivity surrounded by luminal secretory cells. 
Number of NE cells increase with cancer progression. Scale bar 520 mm. Figure 
from Li et al. (Li, et al., 2013) 
 
Insulin action in a low androgen or AR suppressed environment is particularly 
relevant to modelling actions of ADT induced hyperinsulinaemia. Androgens confer 
an epithelial differentiation signal in prostate cells, which is lost upon AR 
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suppression.  This leads to cellular de-differentiation and trans-differentiation, 
resulting in the expression of a plethora of epithelial-to-mesenchymal transition 
(EMT) (Bishop, et al., 2015; Li, et al., 2014; Nouri, et al., 2014)  and NE markers 
(Burchardt et al., 1999; Yang et al., 2005). PCa cells have been shown to co-express 
markers of EMT and NE (McKeithen, Graham, Chung, & Odero-Marah, 2010) and 
this is associated with increased stemness (Nouri, et al., 2017; Paranjape et al., 
2016); however, interplay between the EMT and NE phenotype is the subject of 
ongoing research. 
Although other studies have shown insulin driving invasion and migration in 
endometrial cancer cells (Wang, et al., 2012), there have been few attempts in the 
literature to define the molecular profile driving insulin induced gain of migration 
and invasion (Ferguson, et al., 2013; Ferguson, et al., 2012; Zelenko, et al., 2016). 
This chapter explores the hypothesis that insulin may function through activating 
both EMT and NE mechanisms in androgen deprived PCa cells to promote migration 
and invasion.  
 
5.2 Results 
5.2.1 Insulin increases EMT and NE markers in PCa cells 
To identify the molecular profile underlying insulin-enhanced gain of invasion and 
migration, the microarray data shown in Chapter 3, from LNCaP cells treated with 
insulin with and without synthetic androgen R1881 was probed further. Ingenuity 
Pathway Analysis identified transcriptomic changes consistent with insulin-treated 
LNCaP cells undergoing an EMT (Figure 5.3A) and NE differentiation (Figure 
5.3B). These transcriptional changes were cross-referenced in an existing RNA-Seq 
data (detailed in Chapter 2) at the APCRC-Q to determine base level expression (not 
shown) to eliminate for further validation by qRT-PCR genes with negligible 
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transcript levels which may have exaggerated fold change values. Primer sequences 
for candidate genes were sourced from literature of designed de novo and validated 
with RNA from cell lines positive for given genes (Supplementary figure 5.1). 
qRT-PCR showed insulin and enzalutamide increased transcription of hallmark 
EMT-associated transcription factors (Figure 5.3C), mesenchymal transcripts (Figure 
5.3D), NE-associated transcription factors (Figure 5.3E) and several markers of NE 
phenotype (Figure 5.3F). Specifically for key EMT markers such as FOXC2, ZEB1 
and VIM, both insulin and enzalutamide modulated gene expression with similar 
potency and inversely to DHT (Figure 5.3C and D). Transcription factors for both 
EMT (FOXC2, ZEB1) and NE (SOX8, NEUROG1) phenotypes showed an early 
transcriptional peak at 20h post insulin treatment (Figure 5.4), compared to their 
levels at 48h (Figure 5.3C and E), indicating that an early rise in these transcription 
factors may be driving subsequent transcription of EMT and NE markers. Markers 
such as MMP9, VTN and SST were increased with insulin after 20h (Figure 5.5), but 
no change was observed with enzalutamide or DHT at this time point. Other markers 
such as VIM remained unchanged by insulin at 20h, suggesting that MMP9, VTN and 
SST might be under more direct insulin regulation. Probing the same markers in 
22RV1 and DUCAP RNA (Figure 5.5) revealed a similar transcriptomic profile for 
both EMT and NE associated markers, with increased expression observed with 
insulin and enzalutamide treatments and the reverse with DHT treatments. Some 
cell-line related differences were observed, where VIM and MMP9 levels did not rise 
significantly in 22RV1 cells with insulin treatment at 48h (Figure 5.4B). For the 
same period of treatment, magnitude of transcriptional change in DUCaP cells were 
also similar, but slightly lower than LNCaP cells, especially for SOX8, VIM, MMP9, 
VTN and SST (Figure 5.5 compared to 5.3). Interestingly, although there was some 
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increase in RNA of epithelial transcripts by androgens across the different cell lines, 
their protein levels remained stable across all treatments (Figure 5.6). Nuclear 
FOXC2 and Zeb1 protein was also increased by insulin in 22RV1 cells 
(Supplementary Figure 5.2). Together these data indicate that plasticity mechanisms 
such as EMT and NE are activated by insulin in androgen deprived PCa cells, with 
common regulation by transcription factors such as FOXC2.  
 
 
Figure 5.3 
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Figure 5.3: Insulin increases EMT and NE transcriptional changes in LNCaP 
cells. Gene expression heatmap comparing LNCaP cells treated with 10nM insulin in 
the presence or absence of 1nM R1881 of typical epithelial and mesenchymal genes 
(A) and NE genes (B) from LNCaP microarray. Quantitative reverse transcription 
PCR (qRT-PCR) results of LNCaP cells showing that 48h insulin treatment up-
regulated key EMT associated transcriptional factors (C), mesenchymal markers (D), 
NE associated transcriptional factors (E) and NE markers (F). 48hr insulin (10nM) 
significantly increases levels of transcription factors in LNCaP cells to levels similar 
to those observed for enzalutamide (10μM) treatment. DHT (10nM) suppresses 
expression of these transcription factors. DHT inhibited EMT-like changes, while 
enzalutamide induced changes as potently as insulin (n=3, *p<0.05, ***p<0.001, 
One-way ANOVA, ± SEM).  
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Figure 5.4: Early transcriptional response to insulin in LNCaP cells. In androgen 
deprived LNCaP cells, 20h of insulin (10nM) treatment increased expression of  
several EMT associated transcripts such as FOXC2, Zeb1, Snail,  MMP9 and VTN, 
as well as NE associated transcripts such as NEUROG1, FUZ, SOX8 and SST. With 
the exception of SYP transcript up-regulation with insulin (10nM) and DHT (10nM) 
co-treatment, there was no significant concomitant change in the other molecules 
Figure 5.4 
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investigated or with other treatments such as enzalutamide at this time point. (n=3, 
*p<0.05, **p<0.01, ***p<0.001, One-way ANOVA, ± SEM) 
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Figure 5.5 
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Figure 5.5:  Insulin increases EMT and NE transcriptional profile in 22RV1 and 
DUCaP cells. 22RV1 and DUCaP cells were cultured under androgen deprived 
conditions and treated with insulin (10nM), DHT (10nM) and enzalutamide (10μM) 
in a similar fashion (48hr) to LNCaP cells in Figure 4. qRT-PCR shows that levels of 
both (A) EMT and NE transcription factors such as FOXC2, ZEB1 and SOX8 
significantly increase in 22RV1 cells with insulin treatment, however (B) muted rise 
in the mesenchymal transcripts tested was seen, with VTN showing significant rise in 
22RV1s and no significant change with insulin for VIM and MMP9. (C) NE markers 
CHGA, NCAM and SST showed significant rise with insulin treatment. DUCAP 
cells replicated LNCaP transcriptional profile more faithfully, with significant rise in 
transcription observed with insulin and AR inhibitor enzalutamide for both (D) EMT 
and NE transcriptional factors, (E) mesenchymal markers and (F) NE markers (n=3, 
*p<0.05, ***p<0.001, One-way ANOVA, ± SEM).   
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Figure 5.6 
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Figure 5.6: No change in protein levels of epithelial markers across different cell 
lines. (A) No change was observed in transcription of epithelial markers in LNCaPs 
treated with insulin (10nM, DHT (10nM) and enzalutamide (10μM) for 20hr. (B) 
After 48h of treatment of androgen deprived cells, insulin (10nM) induced 
transcriptional downregulation of epithelial markers EPCAM, E-cad and DSP in 
LNCaP cells, which were up-regulated by addition of DHT (10nM). AR inhibition by 
enzalutamide (10μM) reversed the effects of DHT and mirrored those of insulin. 
However, protein levels of both E-cad (C) and EPCAM (D) remained stable across 
the treatments. (E) Insulin increased transcripts of epithelial markers in 22RV1 cells, 
but did not affect protein levels (F). DUCaP data replicates LNCaP results, where 
EPCAM and E-cad transcripts are increased in response to DHT (G), but protein 
levels remain stable across different cell lines (H) (n=3, *p<0.05, **p<0.01, 
***p<0.001, One-way ANOVA, ± SEM) 
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5.2.2 FOXC2 drives insulin-induced migration  
LNCaP cells expressing shRNA against FOXC2 and ZEB1 were engineered to 
determine the effect on insulin action in PCa cells.  LNCaP cells with constitutive 
FOXC2 knockdown (shFOXC2) did not display insulin-enhanced migration in 
transwell assays, in contrast to the control cells (shFF3; Figure 5.7A). Additionally, 
there was no increase in EMT and NE transcripts by insulin in FOXC2 knockdown 
(Figure 5.7B). The increase in nuclear translocation of FOXC2 and Zeb1 proteins by 
insulin were diminished in FOXC2 knockdown cells, compared to the control cells, 
as was the rise in total and phosphorylated ERK1/2 (Figure 5.7C). In contrast, dox-
induced knockdown of ZEB1 in LNCaP cells dramatically reduced migration in 
vehicle conditions (androgen-free) making any additional effect of insulin difficult to 
delineate (Figure 5.8A).  QRT-PCR showed that knockdown of Zeb1 with two 
different vectors in LNCaP cells failed to block subsequent insulin driven induction 
of transcription of FOXC2, VTN and MMP9, indicating that inhibiting Zeb1 did not 
prevent insulin induced transcription of mesenchymal genes (Figure 5.8B). Together, 
these data suggest that FOXC2, rather than Zeb1 drives the insulin induced 
functional changes observed in this study. 
5.2.3 PI3K and MAPK pathways signal insulin driven plasticity  
Genetic knockdown of IR reduced insulin driven transcription of EMT markers 
FOXC2, MMP9, VTN, indicating signalling though the IR drives insulin activated 
plasticity programs such as EMT (Figure 5.9). However, targeting IR clinically is not 
viable (Philippou, Christopoulos, & Koutsilieris). Thus, effect of inhibitors to 
signalling downstream of IR was tested. The addition of MEK1/2 inhibitors U0126 
and PD98059 prevented insulin induced gain of invasion and migration (Figure 5.9B 
and C) in LNCaP cells, and prevented insulin induced increase in FOXC2, Zeb1 and 
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phosphorylated ERK1/2 proteins in LNCaP (Figure 5.9D) and DU145 cells (Figure 
5.9E). The PI3K inhibitor LY294002 also achieved dramatic reduction in insulin 
induced invasion and migration, and reduced insulin induced upregulation of FOXC2 
and ZEB1 (Figure 5.9B-E, Supplementary Figure 5.3). The crosstalk between 
PI3K/AKT/mTOR and RAS/RAF/MEK pathways is well-described in PCa, 
suggesting combination therapy inhibitors targeting both pathways may be required 
to prevent disease progression (Gioeli et al., 2011; Lodi, Woods, & Ronen, 2014; 
Park et al., 2015). Thus, these results indicate that PI3K and MEK inhibitors may be 
useful to counter the effects of insulin in PCa. Together, the data suggests insulin 
signals through a combination of the PI3K and MEK pathways downstream of IR or 
hybrid IR:IGF1R to promote cellular invasion and migration.  
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Figure 5.7:  Knockdown of FOXC2 prevents insulin induced migration and 
plasticity transcriptional profile. (A) LNCaP cells with constitutive FOXC2 
knockdown were unable to migrate through a transwell in response to 40hr insulin 
treatment, unlike their control counterparts with scramble knockdown (Scale bars = 
100μm). (B) LNCaP cells with constitutive FOXC2 knockdown were also unable to 
Figure 5.7 
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up-regulate several EMT and NE markers in response to 48h insulin (Ins) treatment 
compared to vehicle (Veh), unlike their control counterparts with scramble 
knockdown. Knockdown of FOXC2 prevents insulin induced rise in Zeb1, indicating 
that Zeb1 may be upregulated downstream of FOXC2 upon insulin stimulation. (C) 
Knockdown of FOXC2 also reduced nuclear translocation of FOXC2 and Zeb1, and 
reduced total and phosphorylated MAPK.  
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Figure 5.8: Knockdown of Zeb1 prevents migration. (A) LNCaP cells with  
inducible Zeb1 knockdown (shZeb1) were unable to migrate through a transwell in 
response to 40h insulin treatment following 3 days doxycycline induction 
(250ng/ml), unlike their control counterparts (shNT) (scale bars = 100μm). (B) 
Reduction in Zeb1 transcripts were observed for the two LNCaP knockdown cells 
lines, that was not observed in LNCaP shNT, including with insulin treatment. 
However, insulin treatment did not significantly increase FOXC2 in response to 
Figure 5.8 
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insulin treatment in the Zeb1 knockdown cells. (n=3, *p<0.05, **p<0.01, 
***p<0.001, One-way ANOVA, ± SEM) 
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Figure 5.9: Insulin induced EMT blocked by IR knockdown and PI3K and 
MEK inhibitors. (A) Expression of FOXC2 and other mesenchymal markers 
following insulin (10nM) +/- DHT (10nM) treatment using 5-day doxycycline 
Figure 5.9 
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(250ng/mL/day) induced shINSR3 cells. Insulin-induced increases are muted with 
shINSR induction. DHT inhibits insulin-induction. PSA control for DHT response. 
(n=3, *p<0.05, **p<0.01, ***p<0.001, One-way ANOVA, ± SEM). Inhibitors to 
PI3K and ERK1/2 reduced both insulin induced transwell invasion (B) and wound-
scratch migration (C) in LNCaP cells, and prevented insulin induced rise in FOXC2, 
Zeb1 and phosphorylated MAPK in LNCaP cells (D) and DU145 (E) cells. (n=3, 
*p<0.05, ***p<0.001, One-way ANOVA, ± SEM). 
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5.2.4 FOXC2 expression in clinical samples correlates with INSR clinically   
Finally, insulin receptor and FOXC2 expression in publicly available transcriptional 
databases of clinical tissue accessed through the OncomineTM was analysed. 
Expression of INSR correlated significantly with FOXC2 in both localized and 
metastatic tumours, but not in benign prostate tissue in the Grasso (Grasso et al., 
2012) and Yu (Yu et al., 2004) clinical datasets (Figure 5.10A and B). No correlation 
between INSR and ZEB1 was observed (data not shown). This reflects the in vitro 
results where a more striking relationship between insulin signalling and FOXC2 is 
apparent with insulin driving functional and transcriptional changes through FOXC2 
rather than Zeb1. Additionally, among patients with metastatic tumours that have 
wild type AR amplification, increased FOXC2 mRNA in tumours correlated with 
significantly reduced median overall survival (Figure 5.10C). These data highlight 
the potential clinical significance of the relationship between insulin signalling and 
FOXC2 in PCa. 
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Figure 5.10: FOXC2 expression significantly correlates with insulin receptor 
expression in PCa patient samples. Linear regression shows significant positive 
association between FOXC2 and INSR in PCa patients with localized and mCRPC 
tumours in both (A) Grasso and (B) Yu datasets, accessed using OncomineTM. (C) 
Kaplan-Meier survival curve shows FOXC2 expression is significantly associated 
with overall survival in mCRPC patients with wild type AR amplification mutation 
in Grasso. Median overall survival is significantly reduced by 62% in patients with 
metastatic tumours expressing high levels of FOXC2 compared with patients with 
low level of FOXC2 expression.  
 
 
 
 
Figure 5.10 
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5.3 Discussion 
Previous reports show androgen deprivation can induce migration and 
invasion in prostate cancer cells by induction of EMT-like genetic changes (Sun et 
al., 2012; Zhu & Kyprianou, 2010). siRNA mediated knockdown of AR also results 
in EMT activation and increased metastasis (Izumi et al., 2013). Androgen 
deprivation has been also reported to induce NEtD in LNCaP cells and leads to up-
regulation of various NE markers and neuropeptides (Burchardt, et al., 1999; Li, et 
al., 2013; Yuan, et al., 2007; Zelivianski et al., 2001). The results in this chapter 
indicate that insulin can accelerate both of these processes in LNCaP cells, with 
insulin induced markers of both NE and EMT appearing as early as 20h post-
treatment. These mechanisms provide the molecular profile of insulin driven 
invasion and migration properties in PCa cells. Recently, insulin has been shown to 
increase invasion in endometrial and pancreatic cancer cells (Wang, et al., 2010; 
Wang, et al., 2012), but the studies did not explore molecular mechanisms. This 
study is the first of its kind to show insulin augments adaptive plasticity via an 
induction of EMT and NE markers, without further changing levels of epithelial 
proteins. The results suggest this occurs through PI3K/Akt and Ras/Raf/MAPK 
signalling and FOXC2 upregulation (Figure 5.11). Previous studies also support that 
Ras/Raf/MAPK (Kim, Adam, & Freeman, 2002) and PI3K/Akt/mTOR (Wu & 
Huang, 2007) pathways can regulate NE phenotype in PCa. 
Insulin has been shown to regulate FOXC2 in human endothelial cells (Fujita 
et al., 2006) and mouse adipocytes (Gan, Liu, Jin, Zhou, & Sun, 2015; Gronning, 
Cederberg, Miura, Enerback, & Tasken, 2002) but this is the first time that insulin 
regulation of FOXC2 has been demonstrated in PCa cells. FOXC2 is also known to 
regulate both EMT and NE plasticity mechanisms in PCa (Paranjape, et al., 2016), 
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with downstream activation of Zeb1, which is reflected in our study (Figure 4, 5, 6 
and Supplementary Fig S5). The observation that FOXC2 activation drives 
mesenchymal phenotype without changing epithelial markers is also consistent with 
previous studies in breast and PCa (Hollier et al., 2013; Paranjape, et al., 2016). It is 
interesting to observe that retention of epithelial characteristics was greatest in the 
22RV1 cells, compared to LNCaP and DUCaP. A partial EMT (Christiansen & 
Rajasekaran, 2006; Gavert, et al., 2011; Paez-Ribes, et al., 2009; Wicki, et al., 2006), 
where cells retain epithelial characteristics, while gaining mesenchymal 
characteristics such as MMP protease expression (Nabeshima et al., 2000; Wolf et 
al., 2007), as observed in the data here with MMP9, has been reported to result in 
cell migration as groups, in either sheet, clusters or chains, known as collective 
migration. Thus, insulin may increase collective migration in PCa cells, especially in 
those with mutated AR,  like the 22RV1s. Studies in lung (Kusters et al., 2007; 
Liotta, Kleinerman, & Saidel, 1974) and breast cancer (Le et al., 2005; Radunsky & 
van Golen, 2005) have shown that circulating tumours cells (CTCs) that leave the 
primary tumour to travel through the blood or lymphatic system in patients are more 
likely to survive as groups or clumps rather than single cells and are also better at 
seeding metastatic tumours. This concept is supported by histological observations of 
groups of cancer cells captured together in blood or lymphatic vessels (Wang, 
Enomoto, Asai, Kato, & Takahashi, 2016). Cancer cells in collective migration are 
also better at survival and metastasis (Calbo et al., 2011; Cleary, Leonard, Gestl, & 
Gunther, 2014; Marusyk et al., 2014; Tabassum & Polyak, 2015). Seeding of PCa 
metastases by cells in circulation as a collective has also been shown clinically 
(Gundem et al., 2015). Collective migration can occur for both moderately 
differentiated tumour, as well as poorly differentiated tumours (Wang, et al., 2016). 
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Our results suggest that ADT in combination with hyperinsulinemia activates 
molecular changes consistent with collective migration. 
The most prominent EMT and NE transcriptional profile was occurred in 
LNCaP cells. The PTEN status of PCa cells may contribute to this difference across 
the cell lines in cell plasticity response. PTEN mutations prime cells for EMT and 
invasion through additional activation of RAS/RAF/MEK pathway, without which 
significant metastatic burden is not achieved (Mulholland et al., 2012).  Unlike both 
LNCaP cells, DUCaP and 22RV1 cells are PTEN positive, which may alter 
signalling networks downstream of IR, resulting in a muted more EMT response. 
Consistent with the data from Chapter 4, 22RV1 cells did not respond to CP751871 
inhibition.  
Recent studies have suggested that crosstalk might exist between NE and 
EMT mechanisms where SNAI1, crucial for EMT, has been shown to regulate 
LNCaP NE phenotype (McKeithen, et al., 2010). Importantly, recent papers support 
the data here that FOXC2 can regulate both EMT and NE processes simultaneously 
in PCa cells (Paranjape, et al., 2016). Activation of both EMT and NE processes can 
lead to increased stemness in PCa cells (Nouri, et al., 2017). Moreover, in LNCaP 
and PC3 cells, treatment with neuropeptides showed increased migration and 
invasion (Hoosein, Logothetis, & Chung, 1993) and increased activity of 
mesenchymal markers such as MMPs (Festuccia et al., 1998; Nagakawa et al., 2000; 
Sehgal & Thompson, 1999). Thus, literature, along with the data in this Chapter, may 
suggest EMT and NE markers are being expressed in the same cells. 
Immunofluorescence imaging of insulin treated LNCaP cells co-staining for markers 
of both EMT and NE will illuminate whether insulin is driving EMT and NE 
phenotype in the same cells or creating a heterogeneous population. Additionally, 
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immunofluorescent imaging with both mesenchymal and epithelial markers can help 
better delineate co-expression of mesenchymal and epithelial markers within the cell 
populations.   
FOXC2 and insulin display positive feedback mechanisms in adipose tissue 
where FOXC2 is increased downstream of insulin signalling and in turn further 
increases the sensitivity of the tissue to insulin (Dahle et al., 2002; Datta, Lindfors, 
Miura, Saleem, & Lehtonen, 2016; Di Gregorio, Westergren, Enerback, Lu, & Kern, 
2004; Zhang, Zhang, et al., 2013). Whether FOXC2 mediates insulin sensitivity in 
PCa tumours requires further investigation. A recent study showed that in vivo 
inhibition of p38MAPK reduced the effects of FOXC2 in PCa (Paranjape, et al., 
2016). We did not investigate p38MAPK inhibitors, but report that inhibition of 
ERK1/2 (p42MAPK) by MEK inhibitors leads to reduction in FOXC2 as well as 
insulin driven invasion and migration. FOXC2 is a phosphoprotein (Golden & 
Cantley, 2015) and is phosphorylated by both p38MAPK (Paranjape, et al., 2016) 
and ERK1/2 (Ivanov et al., 2013). Knockdown of FOXC2 reduced ERK1/2 levels, 
indicating FOXC2 may directly regulate the RAS/MAPK/ERK1/2 pathway, as 
previously described (Cui et al., 2014; Cui et al., 2015; Sun, Xie, Li, & Kong, 2015; 
Yang, Cui, Dai, & Liao, 2016). Further studies are needed to unveil genomic and 
non-genomic targets of FOXC2 as well as its regulation of and by the 
RAS/MAPK/ERK pathway. Importantly, ERK1/2 inhibitors may be effective at 
inhibiting FOXC2 action in PCa similarly to p38MAPK inhibitors (Paranjape, et al., 
2016).   
These in vitro results suggest ADT-induced hyperinsulinemia can impact on 
cancer progression and potentially aide in metastasis related processes. 
Hyperinsulinemia has been specifically reported to promote breast cancer metastasis 
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to the lung in an elegant mouse model of non-obese insulin resistance (Ferguson, et 
al., 2013). Our findings highlight the need for monitoring insulin levels in PCa 
patients receiving ADT, who predictably develop hyperinsulinaemia, and build a 
strong case for targeting insulin and downstream activated pathways.  
IR inhibitors are not clinically useful, due to potential to cause 
hyperglycaemia. Inhibitors to IGF1R, which target hybrid receptors, also have 
undesirable metabolic effects (Philippou, et al.), as well as resistance mechanisms by 
the tumour by up-regulation of IR (Weinstein, et al., 2014). Our results indicate that 
PI3K and MAPK inhibitors may be useful in PCa patients who present with or 
develop ADT induced hyperinsulinemia, with recent studies advocating the use of 
inhibitors combinations to target multiple pathways  (Bitting & Armstrong, 2013; 
Gioeli, et al., 2011; Lodi, et al., 2014; Mulholland, et al., 2012; Park, et al., 2015) 
(Figure 5.11). Hyperinsulinemia may alternatively be targeted via re-positioning 
diabetes drugs such as the insulin-sensitising drug, metformin as adjuvant ADT 
therapy, to reduce circulating ligand levels (Gunter, Sarkar, Lubik, & Nelson, 2013) 
(Figure 5.11). Recent literature suggests metformin may also improve both quality of 
life and overall survival by reducing insulin resistance and hyperinsulinemia and 
associated negative impacts on PCa progression, but may also have direct beneficial 
effects on PCa proliferation (Gunter, et al., 2013). Thus further studies to understand 
the molecular mechanisms of insulin-lowering drugs in PCa are needed.  
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Figure 5.11: Strategies to inhibit insulin induced PCa invasion and plasticity. 
This study shows that insulin receptors in PCa cells can signal through a combination 
of PI3K/Akt and RAS/RAF/MAPK pathways to up-regulate FOXC2 transcription 
factor, which then activates transcription of a series of EMT and NE markers, to 
promote gain of cell invasion and migration. Insulin can also activate proliferation 
through these pathways. Androgens activate proliferation, but block migration and 
invasion. These insulin induced pathways can be blocked top-down by reducing 
ADT-induced systemic hyperinsulinaemia in PCa patients through use of anti-
diabetic drug metformin, which would reduce circulating insulin levels and lower 
ligand availability for insulin receptors in PCa cells. Alternatively, signalling may 
Figure 5.11 
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also be targeted downstream of the insulin receptors by targeting PI3K and MAPK 
pathways with small molecule inhibitors. Direct inhibition of insulin receptors, either 
IR or IGF1R, leads to worsening of insulin resistance and hyperinsulinaemia in 
patients and are not viable for clinical use in PCa (Philippou, et al.).  
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6.1 Overall hypothesis of work in the thesis 
The growth and survival of PCa tumours in the post-ADT environment remains, in 
most cases, dependent on the AR axis. This means that treatments for CRPC will 
continue to target androgen signalling leading to prolonged duration of androgen 
deprivation and exacerbated side effects (Conteduca, et al., 2015; Karzai, et al., 
2016; Smith, et al., 2008). New androgen suppressing and AR targeting drugs 
continue to be developed for advanced PCa, including ARN509, TAK-700, Lupron, 
VPC13566, VPC14228, VPC14449 (Dalal et al., 2014; Munuganti et al., 2014) 
(Ahmed, et al., 2014). Results from this study show that AR antagonists promoted 
invasion. This was associated with inhibition of cellular proliferation and PSA 
secretion. Thus, if patients are going through antiandrogen treatment, the cancer may 
regress, however, there is a high possibility that metastasis might be augmented. 
Additionally, the metabolic side effects of ADT include rapid development of insulin 
resistance and hyperinsulinemia, along with development of dyslipidaemia and 
increased abdominal obesity (Karzai, et al., 2016; Redig & Munshi, 2010; Smith, et 
al., 2008). Far from being a minor inconvenience of ADT, the deterioration of 
metabolic health and the increased risk of metabolic syndrome and cardiovascular 
disease, put men on long-term ADT at risk of other serious conditions such as 
cardiovascular disease (Karzai, et al., 2016; Redig & Munshi, 2010; Smith, et al., 
2008). As discussed in the thesis, although development of hyperinsulinemia is also 
specifically associated with more rapid PCa progression, treatment failure and more 
aggressive disease (Faris & Smith, 2010; Flanagan, et al., 2010; Hammarsten & 
Hogstedt, 2005; Ma, et al., 2008), it is not clinically addressed. The effects of insulin 
on androgen deprived PCa cells have not been thoroughly examined. The 
overarching hypothesis of the work presented in this thesis was that elevated insulin 
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levels, resulting from ADT may lead to prolonged insulin signalling in prostate 
tumour cells to promote pathways of disease progression. 
6.2 Key findings and translational impact 
Data from this thesis filled several knowledge gaps of insulin action in PCa. 
Preceding these studies, the dogma in PCa was that IGF1 and IGF1R signalling were 
important drivers of PCa progression, which led to the development and clinical 
assessment of several IGF1R inhibitors (Philippou, et al.). Although IGF1R 
continues to play an important role in PCa tumorigenesis and in primary PCa, work 
in Chapter 3 of this thesis showed, that contrary to expectation, IGF1R expression in 
PCa clinical cohorts was reduced in metastatic tissue compared to primary tissue, 
while INSR was increased. This is consistent with a recent study reporting reduction 
in IGF1R protein levels in PCa metastases (n=12) compared to primary (n=12) tissue 
(Hellawell, et al., 2002); however another study showed upregulation of IGF1R 
transcripts in metastatic (n=25) verses primary (n=65) PCa tumours (Chen et al., 
2013). The relative prominence of the INSR transcript in PCa compared to IGF1R, 
was identified and showed that INSR-A transcripts are higher than IGF1R transcripts 
in patient derived samples (Figure 3.2). Additionally, while androgen regulation of 
IGF1R had been extensively characterized, androgen regulation of IR was unknown. 
The regulation of IR by androgen and AR inhibitors was characterized for the first 
time. INSR-A levels negatively correlated with AR transcript levels, while INSR-B 
and IGF1R positively correlated with AR. IR protein levels also negatively 
correlated with AR protein levels across PCa cell lines. It was seen that androgen 
deprivation can alter IR to IGF1R stoichiometry by reducing IGF1R protein and 
transcript levels.  Short-term treatment with AR inhibitors also showed a trend 
towards increased IR expression. However, the most potent response was observed 
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after AR knockdown in the LNCaP shAR cells, which showed increased IR 
transcript and protein levels in vitro and in vivo (Figure 3.6). Whether this is an 
adaptive response of the cells to reduced IGF1R levels or a release of IR from 
transcriptional repression by AR was not explored. 
AR inhibition also increased nuclear IR levels (Figure 3.8). The role of IR as a 
transcriptional regulator has been described (Nelson, et al., 2011); however, its 
targets in PCa are unknown. Paradoxically, when DHT was added back to cells, this 
treatment also increased nuclear IR levels (Figure 3.7 and 3.8). However, there was a 
clear morphological difference between cells with DHT stimulated co-translocation 
of both AR and IR to the nucleus compared to translocation of IR to the nucleus 
following AR inhibition (Supplementary Figures 3.3 and 3.4). This novel and 
provocative data requires further studies to determine whether IR nuclear 
translocation occurs in a coordinated manner with the AR transcriptional complex, 
and whether it is recruited to DNA at different sites under AR activated or repressed 
conditions. Alternatively, IR could attend to some shared sites as AR, but have 
opposing transcriptional effects depending on AR nuclear presence. Most 
importantly, insulin treatment further increased INSR-A and IR levels in androgen 
deprived LNCaP cells, in vitro. Although there was an increase in tumour INSR 
expression with Gleason Grade (Cox, et al., 2009) and metastatic progression 
(Oncomine, Figure 3.2), it is difficult to explore this transcriptional regulation in 
clinical samples due to confounding hormonal changes in men with advanced PCa. 
Nevertheless, this data suggests that cells potentially increase their capacity to signal 
through the IR following ADT, whereupon there is a simultaneous increase in 
circulating ligand. Thus, the work in Chapter 3 of this thesis supported the 
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overarching hypothesis that elevated insulin levels in androgen deprived contexts 
prolongs insulin signalling in PCa cells.  
The thesis went on to question the consequences of increased insulin signalling in 
androgen-deprived PCa cells. As supported by the microarray data in Chapter 3 
(Figure 3.10A), it was seen that androgens and insulin could have unique and similar 
effects in PCa cells. Both androgens and insulin stimulated cell proliferation, but 
migration and invasion was blocked by androgens, while insulin stimulated these 
processes. Androgens maintain the epithelial differentiation of prostate and PCa cells 
(Bishop, et al., 2015), and thus it was unsurprising that androgens blocked migration 
and invasion processes, while stimulating proliferation. The absence of androgens 
removes the differentiation signal in PCa cells and can stimulate cell migration and 
invasion (Bishop, et al., 2015; Li, et al., 2014; Nouri, et al., 2014). Insulin, under 
these conditions, was shown to accelerate gain of cell migration and invasion in PCa. 
Previously, suggestive evidence existed showing serum from obese mice and obese 
men, which would have high levels of insulin, increased migration of PCa cells 
(Kushiro & Nunez, 2011b; Price, et al., 2012a). A more recent study also showed 
that serum from obese PCa patients also significantly increased PC3 cell migration, 
but reduced invasion and LNCaP proliferation (Mora, Fleshner, Klotz, & 
Venkateswaran, 2015). The complex cocktail of humoral factors in human serum 
makes it difficult to delineate the contribution of insulin to these processes. Evidence 
in Chapter 4, thus, for the first time show that insulin could directly activate all three 
processes in androgen deprived PCa cells, as inhibition of IR blocked the insulin 
induced effects. Action of insulin for proliferation, migration and invasion was most 
potent in PCa cells with functional PTEN suggesting that insulin is acting, at least 
partially, by PI3K/Akt pathway. In vivo experiments are needed to confirm whether 
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this is primarily an in vitro observation and might identify PTEN status as a 
biomarker of tumours that will most benefit from therapies targeting insulin action in 
PCa. The results also support the overarching hypothesis that insulin action in PCa 
cells activates mechanisms of disease progression, namely proliferation, migration 
and invasion.  
Insulin treatment increases expression of IGF2 which can then signal through the IR 
(Chao & D'Amore, 2008). Our team had recently shown that IGF2 can promote de 
novo steroidogenesis in androgen deprived PCa cells (Lubik, Gunter, Hollier, 
Ettinger, et al., 2013), like insulin (Lubik, et al., 2011), yet again this could suggest 
that the de novo steroidogenesis induced by insulin could have been partially effected 
by IGF2. IGF2 caused a dramatic increase in cell migration and invasion. To attempt 
to delineate the effects of insulin from the effects of IGF2, further experiments are 
needed to test insulin-induced migration in the presence of an IGF2 neutralising 
monoclonal antibody. These experiments would clarify the extent to which IGF2 
may have contributed to insulin-induced migration. Nevertheless, IGF2 was 
increased significantly in clinical metastatic PCa samples and in androgen 
deprivation, while its inhibitory receptor IGF2R was reduced. A recent study of 38 
CTCs isolated from 5 CRPC patients and 3 hormone sensitive PCa patients showed 
common up-regulation of IGF1 and IGF2 transcripts, again highlighting the role of 
these molecules in advanced PCa. In this study, IGF1R expression did not commonly 
increase across the CTCs studied, and INSR-A or INSR-B levels were not measured 
(Chen, et al., 2013). These results warrant further research into IGF2 action in PCa 
including the exploration of the potential of IGF2 as a biomarker for at risk patient 
populations as it could also be targeted in advanced PCa.  
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While previous studies have identified insulin induced cell migration and invasion in 
endometrial (Wang, et al., 2012) and pancreatic (Zhao, et al., 2012) cancers, the 
molecular mechanisms underlying these effects have remained uncharacterized. 
Drawing from the leads provided by microarray analysis, Chapter 5 of this thesis 
defined, for the first time, the molecular profile of insulin induced cell migration and 
invasion. Insulin induced transcription of several mesenchymal and neuroendocrine 
(NE) markers such as vimentin, MMP9, chromogranin A and NCAM, however 
epithelial genes and proteins remained unchanged. Maintenance of epithelial features 
could be indicative of collective cell migration, although more detailed studies are 
required. Immunofluorescent imaging with co-staining for mesenchymal and 
epithelial markers could identify the extent to which the population of cells are co-
expressing markers of both epithelial and mesenchymal states, as is defined by the 
features of collective cell migration (Christiansen & Rajasekaran, 2006; Gavert, et 
al., 2011; Paez-Ribes, et al., 2009; Wicki, et al., 2006). Recently it has been 
hypothesized that aberrant mutations in cancer are unlikely to achieve the co-
ordinated and sequential molecular changes that produce a defined and complete 
EMT in development to transform epithelial cell to mesenchymal ones, and thus 
EMT in cancer is likely to be partial. This is supported by the lack of histological 
evidence of complete EMT in cancer and a lack of consensus on the molecular 
definitions of EMT in cancer (Wang, et al., 2016). The data in Chapter 5 also 
supports this growing perspective. Also, most PCa metastases (Haider et al., 2016) 
display partial EMT, with retention of epithelial features. Additionally, recent studies 
of circulating tumour cells (CTCs) from CRPC patients also show co-expression of 
epithelial markers EPCaM and E-cadherin, along with mesenchymal proteins 
vimentin, N-cadherin and O-cadherin in greater than 80% of the samples  
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(Armstrong et al., 2011), again supporting Chapter 5 data that migratory cells (like 
CTCs) could have co-expression of both types of markers. Recent studies have also 
begun to define the clinical NE phenotype in metastatic CRPC. Small cell 
neuroendocrine prostate cancer (NEPC) are AR independent, lack AR expression, 
and occur more frequently after androgen targeting agents (Zhang et al., 2015). 
NEPC is resistant to AR blockage (Beltran et al., 2014) and overexpress 
synaptophysin (SYP) and chromogranin A (ChgA) (Beltran et al., 2011). They also 
lack REST expression (Chang et al., 2017; Zhang, et al., 2015), but have up-
regulated AURKA and n-MYC (Beltran, et al., 2011; Epstein et al., 2014; Mosquera 
et al., 2013).  Loss of RB1, a protein phosphorylated by cyclin dependent kinases 4/6 
to regulate cell cycle progression from G1 to S phase, is also more prevalent in 
NEPC (70%) compared to adenocarcinoma CRPC (32%) (Tan et al., 2014). While 
insulin showed up-regulation of ChgA transcripts in PCa cells in Chapter 5, insulin’s 
regulation of REST, RB1, AURKA or n-Myc need to be defined.  
Although clear clinical definitions of EMT and NE are emerging, recent studies have 
shown that several of these molecules could be useful as biomarkers in PCa. 
TWIST1, N-cadherin and vimentin expression in localized PCa samples can predict 
biochemical recurrence (BR) in patients (Behnsawy, Miyake, Harada, & Fujisawa, 
2013) (Gravdal, Halvorsen, Haukaas, & Akslen, 2007) and nuclear TWIST is 
associated with increasing aggressiveness in localized PCa (Yuen et al., 2007) and 
metastatic CRPC (Haider, et al., 2016). Elevated 80kDa E-cadherin fragment in 
serum, due to MMP cleavage, may also be a predictor of metastatic CRPC (Kuefer et 
al., 2003). Also, combining serum vitronectin levels with PSA is a more accurate 
biomarker for PCa metastasis than PSA alone (Niu, Zhang, Bi, Yuan, & Chen, 2016). 
Lindsay et al. also show that detection of vimentin positive CTCs can be used to 
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predict PCa patients with reduced overall survival (OS), even when their PSA levels 
are no different from patients with higher OS (Lindsay et al., 2016). Additionally, 
patients with increased serum levels of ChgA and/or NSE could predict reduced 
responsiveness to abiraterone acetate treatment (Fan et al., 2017).  
It was identified that insulin induced mesenchymal and NE transcriptional profile 
was driven by a rise in FOXC2 transcription factor. Clinical data showed that 
FOXC2 was a predictor of overall survival in metastatic PCa patients and its levels 
correlated positively with IR levels in PCa metastasis. Again, these novel results 
suggest that FOXC2 and IR could be biomarkers for PCa patients at risk of cancer-
specific mortality. Targeting FOXC2 and IR directly is problematic for both proteins. 
As with most EMT markers, expression of FOXC2 may be too transient in nature to 
allow easy targeting through inhibitors. And inhibiting IR protein in patients may 
result in potentially lethal hyperglycaemia. Signalling through the IR and 
downstream activation of PI3K/Akt and Ras/MEK pathways were required to 
produce insulin driven migration and invasion responses, as well as FOXC2 
expression. These results thus make the case for clinically using inhibitors to PI3K 
and MEK pathways to inhibit IR action and FOXC2 in PCa, rather than direct 
inhibitors to FOXC2 and IR protein. This has also been suggested for FOXC2 by 
another recent study (Paranjape, et al., 2016). Of note, Mulholland et al. showed in a 
mouse model of CRPC that PI3K activation through PTEN deletion was sufficient 
for PCa development, but PCa metastases could only occur when both PI3K and 
MAPK pathways were activated. Additionally, activation of both PI3K and MAPK 
pathways lead to development of primary tumours with EMT and stem cell like 
features, which was not observed with PI3K pathway activation alone. Further, 
inhibitors to PI3K pathway did not relieve metastatic burden. Single inhibitors to 
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MAPK pathway also relieved PCa metastases, but did not reduce primary tumour 
volume. Combination inhibitors to PI3K and MAPK pathways reduced both primary 
tumour volume and prevented metastases. These data thus indicate that PI3K 
pathway may be involved more in PCa proliferation and tumorigenesis, while MAPK 
pathway in PCa is important for de-differentiation, EMT and metastases 
(Mulholland, et al., 2012). This is consistent with the work in this thesis, showing 
insulin failed to produce significant proliferation in PTEN negative cell lines, but 
produced migration, invasion and EMT across both PTEN positive and negative cell 
lines (Mulholland, et al., 2012).  
Thus, Chapter 5 defines insulin induced migration in cancer for the first time, and 
provides novel data that stresses the importance of IR and FOXC2 proteins in PCa 
metastasis.  This chapter identified further mechanisms of PCa progression, namely 
activation of cell plasticity processes of EMT and enhanced adoption of NE 
phenotype, both of which processes are involved in PCa metastasis (Nouri, et al., 
2014). Thus, these results again support the overarching hypothesis that insulin 
action in PCa cells activates mechanisms of disease progression, namely EMT and 
NE processes.  
Overall, data in this thesis provide mechanistic explanation for the epidemiological 
studies showing hyperinsulinemia associated with PCa aggression and mortality. 
Similar studies in breast cancer also show that hyperinsulinemia associates with 
cancer-specific mortality and metastatic progression, rather than initiation (Barone, et 
al., 2008; Bianchini, et al., 2002; Calle, et al., 2003; Renehan, et al., 2008; Xue & 
Michels, 2007). In vivo studies in breast cancer also show that hyperinsulinaemia 
increased metastasis to the lung (Ferguson, et al., 2012) (Ferguson, et al., 2013) and 
that IR knockdown prevented metastases and EMT in the xenografts (Zelenko, et al., 
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2016). Diet induced hyperinsulinaemia also increased LNCaP tumour growth 
(Venkateswaran, et al., 2007). The functional processes driven by insulin in androgen 
deprived PCa cells are required for cancer progression. Insulin induced proliferation 
in the presence of AR inhibitors in PTEN positive cell lines could explain recurrent 
PCa tumours post-ATT treatments. On average PCa patients experience recurrence 
post enzalutamide and abiraterone within 4 to 5 months. Monitoring and controlling 
hyperinsulinemia in these patients is not currently done and might be beneficial. 
Additionally, activation of cell migration and invasion through adoption of EMT and 
NE processes could explain rise in PCa metastasis and NE tumours post ADT. 
Again, monitoring and controlling hyperinsulinemia in these patients might be 
beneficial.  
6.2.1 Summary of clinically relevant findings in thesis: 
1. Insulin can directly activate disease progression mechanisms in PCa cells, and 
thus ADT induced insulin resistance and hyperinsulinaemia need to monitored 
and targeted in advanced PCa patients. 
2. PTEN status could be used to stratify patients that would benefit most from 
therapies targeting insulin action in PCa (described in section 6.3) 
3. FOXC2 and IR may play important roles in metastatic PCa and elevated FOXC2 
can predict overall survival (OS) in metastatic CRPC patients. 
4. Increased IGF2 secretion by PCa tumours can also progress PCa and tumour 
IGF2 expression may be a biomarker for PCa progression. 
6.3 Therapeutic options for targeting pathways identified in thesis    
The results in this thesis support the overarching hypothesis that androgen 
deprivation primes PCa cells to upregulate their capacity for insulin signalling, which 
may drive tumour proliferation and plasticity to contribute to disease progression. 
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Further studies in a suitable in vivo model are required (described in section 6.4, 
Future directions). Nevertheless, the results of this thesis provide rationale that 
compels better targeting and monitoring of ADT induced hyperinsulinemia in 
patients. Several strategies for therapeutically targeting the pathways of insulin 
driven PCa progression as identified in this thesis could be implemented.  
6.3.1 Targeting ligand availability 
Lowered testosterone by ADT in PCa patients results in hyperinsulinemia and 
elevated circulating insulin levels, which associates with increased PCa specific 
mortality and more aggressive forms of the disease (Faris & Smith, 2010; Flanagan, 
et al., 2010; Hammarsten & Hogstedt, 2005; Ma, et al., 2008). Elevated circulating 
insulin levels means greater ligand availability for cells of PCa tumours in patients, 
which suggests increased insulin signalling in the tumours. Thus, the disease 
progressive pathways activated by insulin signalling in PCa may also be targeted by 
reducing ligand availability through improved whole body insulin sensitization and 
treating underlying hyperinsulinemia. This can be achieved by use of existing anti-
diabetic drugs as well as with lifestyle changes.  
 
Repurposing biguanides as treatments for PCa.  
 
Biguanides such as metformin used in diabetes to treat insulin resistance may be 
repurposed as adjuvant therapy to ADT in PCa to reduce hyperinsulinemia. 
Metformin works by inhibiting hepatic gluconeogenesis, promoting increased 
glycolysis instead in the liver, and to some extent in other metabolic tissues such as 
skeleton muscles and adipose tissues. Increased glycolysis by metformin is also 
paired with inhibition of oxidative phosphorylation as metformin is a mitochondrial 
complex I inhibitors. However, metformin, unlike its more potent fellow biguanide, 
phenformin, is less likely to produce lactic acidosis in patients, making it safe and 
  
Chapter 6: Discussion 189 
widely used. By reducing hyperglycaemia, metformin also results in hepatic insulin 
sensitization and lowers circulating insulin levels (Gunter, et al., 2013). Thus, 
metformin is routinely prescribed for managing diet induced insulin resistance, as 
with diabetes and obesity. However, whether metformin can reduce ADT induced 
hyperinsulinemia is currently under investigation. Our lab had undertaken a pilot 
clinical study, named ADMET (ACTRN12614001054606), to examine the efficacy 
of metformin to reduce ADT induced hyperinsulinemia in PCa (unpublished work). 
Forty-five hormone therapy naïve PCa patients commenced ADT for 12 weeks prior 
to randomisation to metformin or placebo groups, and effect of metformin in 
combination with ADT was studied. 50% of patients already had metabolic 
syndrome at the start of trial in both arms of the study. Patients were given daily oral 
doses of metformin for 54 weeks. Patients on ADT alone developed significant 
insulin resistance, with increased circulating insulin and leptin levels. 30 weeks post 
randomization, metformin co-treatment significantly lowered insulin resistance, 
measured through glucose tolerance tests (GTT) and HOMA scores, as well as 
reduced circulating leptin levels. Thus, preliminary data from this randomized 
prospective study suggests that metformin may be beneficial in improving PCa 
outcomes by lowering insulin resistance (unpublished). Another recent randomized 
prospective study of ADT naïve patients in a Chinese cohort (n=31 in each arm) also 
showed that metformin in combination with ADT reduced fasting glucose and waist 
circumference in patients, but did not change insulin, C-peptide or BMI significantly 
at the end of trial at 24 weeks post randomization (Zhu et al., 2017). Early start of 
PCa patients on metformin might be useful, as evidence suggests that use of 
metformin prior to ADT start may prevent the metabolic side effects of androgen 
deprivation from ever developing (Cohen, 2009). While these small prospective 
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clinical studies have shown metformin to be beneficial with ADT to reduce 
metabolic side effects, a recent retrospective cohort study has shown that metformin 
combined with docetaxel chemotherapy does not increase PCa specific, or overall 
survival in metastatic CRPC patients with diabetes (Mayer, Klotz, & 
Venkateswaran).  
Although metformin can benefit PCa patients by reducing circulating insulin levels, 
recent studies have also investigated its effects directly on PCa cells. However, these 
studies treat PCa cells at high doses in the mM range. Metformin is a positively 
charged compound, and thus it is not absorbed by cells unless expressing cation 
transporters. The highest concentrations of metformin are found in the 
gastrointestinal tract and the liver, possibly explaining why metformin has such an 
excellent safety profile and exerts its primary effects on hepatocytes.  Physiological 
levels of metformin at PCa tumours are likely to be extremely low due to its levels 
being extremely low in general circulation.  
In the work of Appendix A of this thesis, I explored the direct effects of 
physiological levels of metformin on PCa cells. While high dose metformin inhibited 
invasion in PCa cells, low dose metformin did not affect EMT related processes. 
Low dose metformin also did not affect INSR-A receptor expression in PCa cells. 
However, low dose metformin reduced androgen action in LNCaP cells, by reducing 
DHT driven PSA and IGF1R transcription. Other studies support this observation at 
much higher doses of metformin (Kato et al., 2015; Lee et al., 2014; Malaguarnera et 
al., 2014; Wang et al., 2015), but this is the first time this direct action of metformin 
on androgen axis has been shown at the physiological dose of metformin. 
Importantly for clinical translation, plasma membrane monoamine transporter 
(PMAT) was identified for the first time as the cation transporter involved in 
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metformin uptake by PCa cells. Thus mutations in PMAT in PCa tumours may 
predict metformin uptake and its ability to confer direct effects on androgen action in 
PCa cells.  
Although the direct effects of metformin observed in the work of Appendix A of this 
thesis did not affect INSR-A expression or EMT induction, it is possible that 
metformin levels accumulate in PCa cells over time, producing a wider range of 
direct functions. More in vitro studies are needed that investigate low dose 
metformin action over chronic treatment periods, rather than high dose metformin 
action over short treatment times. Unfortunately, most in vitro work on metformin 
action in PCa cells are done at doses in the mM rather than µM range. 
Diet and exercise changes  
Insulin resistance and hyperinsulinemia may also be targeted in PCa patients by early 
interventions aiming to improve diet and exercise routines. Exercise has been shown 
to reduce metabolic syndrome associated with ADT (Galvao, Newton, Taaffe, & 
Spry, 2008). However, another study showed that while a three-month exercise 
routine reduced fat mass in 63 PCa patients when combined with ADT, no 
significant changes in triglycerides, insulin and glucose levels were observed 
(Cormie et al., 2015), which is in keeping with the primary effects of ADT relating to 
insulin and lipids and not fat mass. Similarly, a 6-month randomized trial of PCa 
patients on ADT in combination with all three of metformin, low glycaemic diet and 
exercise showed reduced waist circumference, BMI and blood pressure, but no 
significant change in biochemical markers of insulin resistance (Nobes, Langley, 
Klopper, Russell-Jones, & Laing, 2012). The ADMET clinical trial of metformin 
with ADT performed by our lab had shown that significant reduction in insulin 
resistance acquired over the first 12 weeks, required prolonged treatment of at least 
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42 weeks. Thus, three- and six-month interventions might not have been long enough 
for the insulin sensitizing effects of exercise to manifest.   
6.3.2 Targeting the insulin receptors 
It was seen that both AR inhibition and insulin treatment resulted in increased 
expression of IR and hybrid IR:IGF1R receptors by the PCa cells. Inhibiting these 
receptors is thus a natural option to preventing insulin action in PCa. Curbing insulin 
signalling at the receptor level is possible through tyrosine kinase inhibitors, such as 
BMS745807-04, which blocks action through both IR and hybrid receptors (Carboni 
et al., 2009). Clinically, this drug has not been tested in PCa patients. Another 
tyrosine kinase inhibitor of IGF1R/IR with additional cross over inhibition of HER2 
receptor (Youngren et al., 2005), nordihydroguareacetic acid (NDGA), has been 
tested in two very small PCa clinical trials, with significant reduction in PSA in only 
a subset of patients (Ryan et al., 2008) (Friedlander et al., 2012). Similarly, CP 
758171, which can downregulate hybrid IR:IGF1R receptors (Cohen et al., 2005; 
Pandini et al., 2007), in combination with docetaxel in CRPC patients  did not show 
PSA decline or improvement in PFS, but showed a trend towards lower number of 
circulating tumour cells (CTCs, n= 46), especially IGF1R positive CTCs (n=22) 
(NCT00313781). Thus, clinical utility of direct inhibitors to insulin receptors appear 
to be limited, and may be due to development of resistance through other pathways 
(detailed in section 6.3.4). Moreover, use of inhibitors to insulin receptors carries the 
risk of development of hyperglycemia (Gualberto & Pollak, 2009), IGF1R mAb 
induced hyperglycaemia is mild (grade 1-2), and easily controlled with oral diabetic 
medications such as metformin during treatment period (Chen & Sharon, 2013). 
Specifically, CP 751871, whose effects were studied in vitro in this thesis, show only 
variable rise in insulin levels clinically (Haluska et al., 2010; Lacy et al., 2008).  
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6.3.3 Targeting downstream pathways to insulin receptors 
Work in this thesis showed that the PI3K and MAPK pathways were activated 
downstream of the insulin receptors to promote proliferation, migration and invasion 
responses in androgen deprived PCa cells. Thus, clinically targeting these pathways 
may also be useful in curbing the disease progressing actions of insulin in PCa. 
Mutation that lead to constitutive activation in both the PI3K and MAPK pathways 
were identified to be significantly increased in CRPC metastasis (100% and 90% 
respectively) compared to primary tumour tissue (42% and 43% respectively), 
underscoring their prominent role in PCa progression (Mulholland, et al., 2012; 
Taylor et al., 2010). Several inhibitors to both these pathways were developed. The 
MAPK pathway can be targeted with MEK inhibitor (PD325901, GDC-0941, GSK-
1120212), but these have not yet been tested clinically in PCa. Inhibition of the PI3K 
pathway has been clinically assessed with mTOR inhibitors (rapamycin, everolimus, 
temsirolimus, ridaforolimus) and Akt inhibitors (perifosine), however their clinical 
utility has been low, with no significant pathological or clinical benefits (Bitting & 
Armstrong, 2013). 
6.3.4 Combination therapies  
A consistent feature of the tested targeted therapies in CRPC is their inability to 
produce lasting disease remission. The latest ATT drugs abiraterone acetate and 
enzalutamide increase OS by 4-5 months on average (Scher et al., 2012b), before 
disease becomes resistant. Similarly, the latest clinical trials with PI3K inhibitors fail 
to show significant gains in PFS (Bitting & Armstrong, 2013). Negative regulation 
between these pathways has been identified as mechanisms of gain of resistance to 
single agents (Figure 6.1). Inhibiting AR can activate the PI3K pathway (Carver et 
al., 2011). Similarly, inhibiting MAPK can also activate the PI3K pathway (Gioeli, et 
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al., 2011).  While inhibiting PI3K alone can activate AR (Kaarbo et al., 2010) 
(Carver, et al., 2011), the MAPK pathway (Bitting & Armstrong, 2013) (Axelrod et 
al., 2013) and lead to constitutive activation of insulin receptors (Chandarlapaty et 
al., 2011; Rodrik-Outmezguine et al., 2011).   
Given these complex negative regulations between the pathways stimulated 
downstream of insulin and AR, combination therapy may be more useful than single 
agents in targeting insulin action in PCa. Preclinical studies show that combination of 
PI3K and MAPK pathway inhibitors produces synergistic inhibition of proliferation 
in vitro (Axelrod, et al., 2013; Gioeli, et al., 2011; Steelman et al., 2010) and in vivo 
(Kinkade et al., 2008; Park, et al., 2015) and inhibition of tumour metastases 
(Mulholland, et al., 2012), compared to single agents alone. Similarly, combination 
of PI3K/mTOR and AR inhibitors bicalutamide and enzalutamide are more effective 
inhibitors of proliferation than single agent inhibitors of either pathway in preclinical 
studies (Carver, et al., 2011; Schayowitz, Sabnis, Goloubeva, Njar, & Brodie, 2010; 
Wang et al., 2008; Zhang et al., 2009). Several clinical studies are now thus 
underway to test combinations of PI3K inhibitors with AR inhibitors and IGF1R 
inhibitors (Table 6.1). However, given the crosstalk between these pathways, gain of 
resistance to even the combinations being tested is likely. Not surprisingly, mTOR 
inhibitor everolimus in combination with bicalutamide (Table 6.1) showed 
development of resistance through p38MAPK pathway (D'Abronzo, Beggs, Bose, & 
Ghosh, 2014). Other studies are yet to report, though, early results of mTOR 
inhibitor temsirolimus with IGF1R monoclonal antibody cixutumumab reported in 
2011 showed median time to progression as 32 weeks, for seven recruited patients 
(Bitting & Armstrong, 2013). It needs to be tested whether maximal therapeutic 
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benefit would be obtained through a cocktail of inhibitors to IR/IGF1R, PI3K, 
MAPK, AR, along with metformin and recommended lifestyle changes.  
 
Figure 6.1 Negative regulations between the PI3K pathway and the MAPK and 
AR pathways. Significant negative relation exists between the PI3K and AR 
pathways, with AR blocking Akt phosphorylation, and both PI3K and Akt reducing 
AR levels. PTEN also increases AR levels, and loss of PTEN suppresses AR 
expression. The PI3K and MAPK pathways also negatively regulate each other, with 
MEK suppressing PI3K phosphorylation and Erk suppressing mTOR activation. 
Inversely, Akt can suppress Raf activation, and S6K, downstream of mTOR can 
suppress Erk activation. S6K also provides negative feedback to the IR-A and 
IGF1R:IR hybrid receptors, downregulating their expressing with PI3K pathway 
activation. Reviewed in (Bitting & Armstrong, 2013).   
Figure 6.1 
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Table 6.1 Combination treatments of small molecule inhibitors currently in 
clinical trial in PCa.  
Target 
Pathways Study agents 
Patient 
population Registry Therapeutic efficacy 
PI3K and 
AR 
Bicalutamide and 
everolimus 
CRPC that has 
progressed after 
abiraterone 
acetate NCT00630344
Failure to show 
increase in time to 
progression 
Bicalutamide and 
everolimus 
Recurrent or 
metastatic CRPC 
after first-line ADT NCT00814788
Some patients 
responded strongly; 
others were resistant 
due to upregulation 
of p38MAPK pathway 
Abiraterone 
acetate and 
BEZ235 
mCRPC patients 
progressed after 
abiraterone 
acetate NCT01717898
Study terminated due 
dose limiting toxicities 
on lowest dose level 
Abiraterone 
acetate and 
BKM120 metastatic CRPC NCT01741753
Study terminated due 
to financial problems 
Abiraterone 
acetate and 
BEZ235 or 
BKM120 
mCRPC patients 
progressed after 
abiraterone 
acetate NCT01634061
Study completed July 
2015; no results yet 
available 
Abiraterone 
acetate and GDC-
0980 or CDC-0068 
CRPC post 
docetaxel NCT01485861 Study ongoing 
Bicalutamide and 
MK2206 
Patients with 
rising PSA at high 
risk of progression 
after primary 
therapy NCT01251861 Study ongoing 
PI3K and 
IGF1R Temsirolimus and 
cixutumumab 
Chemotherapy 
naïve metastatic 
CRPC NCT01026623
Study completed 
February 2013 with 
16 patients enrolled; 
no results yet 
available 
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6.3.5 Clinically targeting EMT and NE phenotypes in PCa 
Insulin induced an EMT and NE transcriptional profile in PCa cells to bring about 
cell migration and invasion. Thus, these post-transcriptional processes may also be 
directly targeted to curb the action of insulin in PCa.  
The transitory nature of EMT program and many of the EMT markers, especially 
transcription factors are intracellular and/or nuclear, make it hard for drugs to inhibit 
them. However, some preclinical studies have identified EMT inhibitors in PCa. 
Proteasome inhibitor NPI-0052 reversed EMT in PCa cells (Baritaki et al., 2009) and 
two monoclonal antibodies targeting N-cadherin could reduce PCa PC3 and LNCaP 
xenograft growth and metastases (Tanaka et al., 2010). Additionally, several small 
molecule inhibitors, especially of TGFβ and its receptors, are in clinical trials 
currently for other cancers (Kothari, Mi, Zapf, & Kuo, 2014).  
NE phenotype in PCa is primarily being targeted with Aurora A inhibitors. Aurora A 
inhibitor alisertib (MLN8237) has shown dramatic reduction in in vitro and in vivo 
proliferation of NCI-H660 NE PCa cell line, with complete loss of synaptophysin 
protein in NCI-H660 tumours post treatment (Beltran, et al., 2011). It is being tested 
in metastatic and NEPC (NCT01799278). Early results show that Aurora A inhibitor 
alisertib after lead to complete resolution of liver metastases in two metastatic CRPC 
patients (Beltran et al., 2016). Other recent pre-clinical studies of this drug, however 
fail to show reduction in tumour burdens of pre-clinical models driven by n-MYC 
overexpression (Lee et al., 2016). Regardless, a different Aurora A inhibitor, CD532, 
showed reduction in both n-MYC protein levels and tumour burden in vivo (Lee, et 
al., 2016).  
However, other methods of targeting NE phenotype in PCa may also exist. As 
discussed in section 6.2, clinically NE PCa cells also show loss of RB1 and n-MYC 
over expression. As RB1 loss characterizes NEPC, taxane treatment may be useful. 
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In vitro models have shown that RB1 negative PCa are hypersensitive to taxanes (de 
Leeuw et al., 2015). Inhibition of n-MYC action in may also targeted by suppressing 
enhancer of zeste homolog 2 (EZH2) which is upregulated downstream of n-MYC 
(Dardenne et al., 2016; Pellakuru et al., 2012). EZH2 inhibitors are in clinical trials 
to treat other cancers (Kim & Roberts, 2016).  Inhibitors to RNA polymerase I have 
also shown promise in lung tumours to prevent n-MYC action (Kim et al., 2016), and 
may thus also prevent n-MYC driven action in NE PCa cells.  
6.4 Future directions 
6.4.1 Clinical studies 
Trials are currently ongoing with combinations of inhibitors to PI3K and AR 
pathways, as well as one trail with PI3K and IGF1R inhibitor combination (Table 
6.1). However, although there is extensive pre-clinical evidence that PI3K inhibition 
alone can lead to compensation by MAPK pathway, there are no current clinical 
studies investigating the effect of combining PI3K and MAPK pathway inhibitors on 
outcomes for metastatic CRPC patients. These trials might produce greater clinical 
efficacy.  
6.4.2 In vivo studies 
Current clinical trials of single agent inhibitors of PI3K pathway, AR pathway, or 
IGF1R/IR pathway has shown limited benefit in patients, with rapid development of 
resistance through compensatory pathways. Thus, better pre-clinical studies are 
required to develop inhibitor cocktails that can lead to maximum suppression of 
insulin signalling in PCa. This can include inhibitors to IR/IGF1R, PI3K/Akt/mTOR, 
MEK and AR. Such combination treatments in PDX xenografts and in vitro can 
provide much needed insight into therapeutic benefit and development of drug 
resistance.  
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Diet-induced hyperinsulinemia in mouse models is known to increase insulin 
receptor expression, AKT activation and proliferation in LNCaP xenografts 
(Venkateswaran, et al., 2007). However, the aetiology of castration-induced 
metabolic changes differs fundamentally from diet-induced metabolic changes. For 
example, LDL and HDL levels in response to ADT differ with obesity-related 
cholesterol dysregulation, and the development of insulin resistance in ADT is not 
due to increased fat mass (Smith, et al., 2008). Thus, castration-induced metabolic 
dysfunctions need to be studied independently to diet-induced metabolic changes.  
Unlike men, mice do not develop insulin resistance upon castration (Inoue et al., 
2010), even in conjunction with a high-energy diet, and this is a major caveat in their 
suitability as a model for studying the effect of castration-induced metabolic 
dysfunction in PCa. However, castrated rats are an accepted model for studying the 
androgen deficiency in men (Christoffersen, Raun, Svendsen, Fledelius, & 
Golozoubova, 2006; Holmang & Bjorntorp, 1992; Vanderschueren et al., 1994; Xia 
et al., 2013).  
Castration in rats leads to reduced food intake, reduced body weight gain, a reduced 
percentage of lean body mass and an increased fat percentage (Gentry & Wade, 
1976; Krotkiewski, Kral, & Karlsson, 1980; Woodward, 1993). Much is known 
about the development of castration-induced metabolic dysfunctions in rats, 
indicating a complex interaction between insulin sensitivity and dyslipidemia. 
Testosterone directly favors insulin gene expression and release by pancreatic islets 
in rats (Morimoto, Fernandez-Mejia, Romero-Navarro, Morales-Peza, & Diaz-
Sanchez, 2001). At 10-week post-castration, rats show increased total cholesterol 
(Christoffersen, et al., 2006; Haug, Hostmark, Spydevold, & Eilertsen, 1986) and 
increased fasting glucose and insulin serum levels, indicating some hepatic insulin 
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resistance(Christoffersen, et al., 2006; Xia, et al., 2013). However, this hepatic 
insulin resistance is compensated by increased insulin sensitivity in rat muscles, 
which accounts for 70% of the whole body’s insulin sensitivity(Ferrannini et al., 
1988). Thus, at 10-week post-castration male rats do not show whole body insulin 
resistance in glucose tolerance tests or insulin tolerance tests (Christoffersen, et al., 
2006; Xia, et al., 2013). However, testosterone deficiency eventually leads to muscle 
wasting (Vermeulen, 1996) and visceral fat aggregation in rats, with HE staining 
showing liver tissues steatotic and intracellular fat in muscle cells (Xia, et al., 2013). 
By 30-week post-castration (Xia, et al., 2013), rats show whole body insulin 
resistance as well as severe dyslipidemia, with increased glycerol, which is a marker 
of lipolysis and a precursor for hepatic gluconeogenesis, reflected in increased serum 
glycerol as a marker of lipolysis. Thus castration-induced testosterone deficiency in 
rats induces significant hepatic and extra hepatic insulin resistance, reduces lean 
body mass and increases percentage fat mass resulting in severe dyslipidemia with 
increase in total cholesterol and lipolysis, creating a similar metabolic response to 
men undergoing ADT (Smith, 2004; Xu et al., 2002).  
Thus, castrated rat models could be used to study whether castration induced 
hyperinsulinemia affects PCa metastasis. We have also developed LNCaP cells with 
inducible knockdown of INSR. Xenografts of these LNCaP shINSR cells in these rat 
models could also show whether the effects of castration induced hyperinsulinemia 
on PCa is specific to IR signaling. Whether the adaptive response to ADT observed 
in vitro in this thesis, where androgen deprivation and AR suppression increased IR 
and decreased IGF1R, is reflected in vivo could also be studied. Further, whether 
IGF1R is reduced in PCa metastases that result from castration induced 
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hyperinsulinemia would also be illuminating and would build on the in vitro work in 
this thesis.  
6.4.3 In vitro studies 
The work in this thesis raises opportunities for further molecular studies. Work in 
chapter 3 shows rise in nuclear IR, which is has been shown to regulate transcription 
in hepatocytes (Nelson, et al., 2011). The transcriptional targets of nuclear IR are 
unknown in PCa, yet work in chapter 3 and 5 identify several genes that are 
transcriptionally regulated by insulin in PCa, such as up-regulation of INSR-A, 
FOXC2, CHGA, SOX8. Work in chapter 3 also implies that nuclear IR may have 
different effects on transcription based on whether it co-localizes to the nucleus with 
AR by DHT. As INSR-A, EMT and NE genes get downregulated by androgens, 
these genes are ideal targets for further understanding the transcriptional effect of 
nuclear IR in PCa in the presence and absence of AR. It could be that IR in the 
presence of AR at the FOXC2 promoter region inhibit transcription rather than 
activate it. Nelson et al found that IR can prevent transcription at promoter of genes 
by recruiting a host of IR signalling molecules, including Raf, MEK and Erk to the 
promoter site to crowd out DNA polymerase II and cause its disassociation from 
promoter region (Nelson, et al., 2011). 
A recent study has also shown that EMT is required for resistance to chemotherapy 
rather than metastasis (Zheng et al., 2015). Chapter 5 of this thesis shows insulin 
induces an EMT transcriptional profile in PCa cells. It is possible that EMT pathway 
activation could also play a role in insulin driven resistance to AR inhibitors, as 
depicted by the proliferation data of chapter 4 of this thesis. This hypothesis could be 
tested by specifically inhibiting EMT pathway in PCa cells, as is the case with the 
FOXC2 knockdown LNCaP cell models used in chapter 5 of this thesis. If EMT is 
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involved in causing insulin driven resistance to AR inhibitors, insulin induced 
proliferation in the presence of AR inhibitors will be lower in the LNCaP shFOXC2 
cells compared to control cells.  
Insulin induced proliferation in the data here by activating PI3K/Akt/mTOR 
pathway. This pathway also prevents cell apoptosis by inhibiting Bcl-2 family of 
molecules. Apoptosis was not measured in this thesis. As insulin, induced 
proliferation even with AR inhibitors it could be reasonable assumed that apoptosis 
would be reduce din this context. However, cellular apoptosis could be measured by 
FACS analysis of Annexin 5 expression in insulin treated cells with and without AR 
inhibitors, as well as investigating regulation of Bcl-2 family of molecules by insulin 
with qRT-PCR and western blotting.  
Hybrid receptor expression could be quantitated by immunoprecipitation by IGF1R 
and then immunoblotting for IR. To complement the immunofluorescent and 
subcellular fractionation data of IR and IGF1R, FACS analysis of live PCa cells for 
IR and IGF1R could be performed to quantitate cell surface expression of these 
receptors across PCa cell lines and with different treatment combinations of DHT, 
insulin and inhibitors to AR and IR.  
AR are shown to decrease IR expression in PCa cells, however androgens increase 
insulin sensitivity in classically metabolic tissues such as liver, skeletal muscles and 
adipose. Thus, AR is expected to increase IR expression and function in cells of 
these tissues. This converse regulation of IR by androgens in classically metabolic 
tissues verses PCa tissues could be due to differences in expression of IR isoform. 
PCa cells expression IR-A, while hepatocytes, myocytes and adipocytes express IR-
B. In the Chapter 3 data of this thesis, INSR-B levels are positively associated to AR 
transcript levels, unlike INSR-A, across PCa cell lines. Androgens also up-regulated 
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INSR-B levels compared to INSR-A levels. A recent study also showed that DHT, 
acting through the AR, increased activity at the INSR promoter (Weinstein, et al., 
2014), which appears contrary to the data of chapter 3 of this thesis, showing AR 
downregulates IR. It could be that in this study DHT was up-regulating INSR-B 
expression through its increased activity at the INSR promoter rather than INSR-A. 
mRNA expression of the two isoforms of IR were not reported in this study. This 
analysis generates the hypothesis that DHT would downregulate INSR-A in 
hepatocytes, myocytes and adipocytes, and warrants investigation of DHT regulation 
of IR in classically metabolic tissues as a comparison to PCa tissues. This could 
include investigation of whether DHT causes IR-B nuclear translocation like IR-A. 
This could be studied by staining for IR in androgen treated hepatocytes, myocytes 
or adipocytes as they express IR-B. IR-B has been reported to translocate to the 
nucleus of insulin treated hepatocytes to regulate metabolism related genes 
glucokinase (Gck) and early growth response 1 (egr-1) (Nelson, et al., 2011). IR-A 
would probably regulate different genes, such as those involved in mitosis, apoptosis, 
invasion and migration.  
6.5 Concluding remarks 
This thesis provides evidence for the first time that insulin in an androgen deprived 
context can directly activate cell plasticity pathways of EMT and NE differentiation 
to promote migration and invasion. These effects were brought about by the 
PI3K/Akt and MAPK pathways and upregulation of the FOXC2 transcription factor. 
This work thus compels better monitoring and targeting insulin resistance in PCa 
patients. While inhibitors to the insulin receptors, PI3K pathway and MAPK pathway 
are available and their combined use with androgen/AR targeted therapies in PCa, 
especially metastatic CRPC, need to be further studied. Emerging evidence however 
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shows that early metformin prescription, along with lifestyle changes may be 
beneficial.  
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Appendices 
Appendix A 
Exploring the efficacy of targeting insulin signalling in PCa with biguanides as 
an adjuvant to ADT 
A1.1 Introduction 
The work presented in this thesis, along with recent publications(Bishop, et al., 2015; 
Burchardt, et al., 1999; Li, et al., 2014; Nouri, et al., 2014; Yang, et al., 2005) has 
identified that an androgen free environment releases PCa cells of an important 
differentiation pressure, which results in the emergence of cell sub-populations 
expressing characteristic mesenchymal and neuroendocrine molecules.  
The findings from this thesis have established that in this milieu, insulin can further 
promote invasion and migration. This was characterised by the expression of 
molecules associated with EMT and NEtD which confer increased invasive potential 
and could contribute to a more aggressive tumour phenotype, thus, providing 
rationale for targeting iatrogenic hyperinsulinaemia as a result of ADT. 
The critical role of this hormone in glucose homeostasis, and the serious 
consequences of hyperglycaemia have made targeting the insulin receptor 
challenging. Moreover, early clinical trials of NDGA (Ryan, et al., 2008) 
(Friedlander, et al., 2012) and CP758171 (NCT00313781), inhibitors that target both 
IR and IGF1R, have shown limited benefit, with drop in PSA and CTC numbers only 
in a small subset of metastatic CRPC patients, and no change in PFS or OS. Instead, 
approaches which target ligand availability by normalising insulin sensitivity and 
reducing circulating insulin levels may be a preferable option.  
Targeting hyperinsulinaemia with biguanides 
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This thesis has contributed to mounting evidence that hyperinsulinaemia resulting 
from ADT should be clinically addressed. Insulin resistance is a clinical scenario that 
has long been treated in conditions such as type 2 diabetes and obesity using 
hypoglycaemic drugs such as metformin and phenformin, which logically prompts 
the question of their utility in combating ADT-induced hyperinsulinaemia. 
Metformin and phenformin both belong to the biguanide class of compounds and 
have both been used to improve insulin sensitivity in diabetes, however, phenformin 
was rapidly withdrawn from use due to development of lethal lactic acidosis in 
patients.  Metformin, however, has a much safer profile and is one of the most 
widely used drugs in diabetes. It acts to reduce systemic hyperinsulinaemia by 
inhibiting hepatic gluconeogenesis (Natali & Ferrannini, 2006), reducing intestinal 
glucose absorption (Natali & Ferrannini, 2006), increasing glucose utilization by 
peripheral tissues (Natali & Ferrannini, 2006), and counteracts the conversion of 
glycogen to glucose by glucagon (Miller et al., 2013). It may also lower plasma 
triglycerides by improving fatty acid oxidation (Geerling et al., 2014). However, it 
does not improve peripheral insulin sensitivity (Natali & Ferrannini, 2006). Rather, 
reduction in hyperinsulinaemia occurs as a result of reduced pancreatic insulin 
secretion in response to reduced glucose levels.  Along with its use in type 2 diabetes 
mellitus (T2DM), metformin is also routinely used to treat hyperinsulinaemia and 
hyperlipidaemia in polycystic ovarian syndrome (Diamanti-Kandarakis, Economou, 
Palimeri, & Christakou, 2010) and weight gain induced by antipsychotic medicine 
(Wu et al., 2008). 
Metformin and phenformin are both positively charged hydrophilic molecules that 
are unable to enter cells without the help of cation transporters (Graham et al., 2011). 
Several recent studies have uncovered the main transporters involved in metformin 
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uptake, including plasma membrane monoamine transporter (PMAT, SCL29A4 
gene), organic cation transporter (OCT1, SCL22A1 gene and OCTN1 SCL22A4 gene) 
and thiamine transporter (THTR2, SCL19A3 gene) which mediate intestinal 
absorption (Gong, Goswami, Giacomini, Altman, & Klein, 2012; Liang et al., 2015; 
Nakamichi et al., 2013); OCT1 and OCT3 (SCL22A3 gene) which mediate uptake by 
liver (Gong, et al., 2012); and OCT2 (SCL22A2 gene) and multidrug and toxin 
extrusion 1 and 2 (MATE1, SCL47A1 gene and MATE2 SCL47A2 gene), which 
mediate metformin excretion into the liver by the kidneys (Gong, et al., 2012). OCT3 
may also be involved in metformin uptake by peripheral tissue such as skeletal 
muscle, fat and brain (Chen et al., 2015). Loss of function mutations in OCT1 
hinders anti-hyperglycaemic effects of metformin (Shu et al., 2007), while loss of 
function mutations in MATE1 enhances them (Becker et al., 2009), due to reduced 
uptake by liver and reduced excretion in urine respectively.   
Once inside the cell, the most well characterised mode of action of metformin is its 
inhibition of complex I of the electron transport chain (ETC), which decreases ATP 
production, increases relative AMP levels within cells and activates AMP kinase 
(AMPK), causing the cell to go into an energy saving state. Rise in AMP and 
activation of AMPK pathway inhibits biosynthetic/ATP consuming pathways such as 
gluconeogenesis, lipogenesis, protein synthesis and transcription (Foretz, Guigas, 
Bertrand, Pollak, & Viollet, 2014) (Figure A1.1).    
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Figure A1.1 Pathways for cellular actions of metformin in the liver. Metformin 
can be taken up by hepatocytes by OCT1 cation transporter, where it inhibits actions 
of complex 1 of ETC, decreasing ATP and increasing AMP and ADP, which can 
directly inhibit various steps of gluconeogenesis as well as antagonize the actions of 
glucagon. Increased AMP levels also activate AMPK pathway which can block other 
ATP consuming pathways such as lipogenesis, while activating ATP generating 
pathways such as fatty acid oxidation. Figure adapted from (Foretz, et al., 2014) 
 
Metformin and PCa progression 
Several epidemiological studies have retrospectively attempted to delineate the 
relationship between PCa risk and metformin intake among men, with mixed results. 
While some studies show metformin intake is associated with reduced risk of PCa 
(Preston et al., 2014; Tseng, 2014), several others found no associated between 
metformin use and risk of PCa, either exclusively among diabetic patients (Azoulay, 
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Dell'Aniello, Gagnon, Pollak, & Suissa, 2011; Kowall, Stang, Rathmann, & Kostev, 
2015; Nordstrom, Clements, Karlsson, Adolfsson, & Gronberg, 2015), or among the 
general population (Feng et al., 2015; Franciosi et al., 2013; Zhang, Li, Tan, Chen, & 
Wang, 2013).  Overwhelmingly though, most recent research into associations 
between metformin use and progression of PCa show a negative correlation. While 
Rieken et al found that for T2DM patients with PCa, metformin use did not associate 
with reduced risk of biochemical PCa occurrence after radical prostatectomy (Rieken 
et al., 2014), several subsequent studies reported reduction of risk of biochemical 
failure after treatment of localized disease with metformin use (Hwang et al., 2015; 
Raval et al., 2015; Spratt et al., 2013; Winters et al., 2015) as well as decreased PCa 
specific mortality (Margel et al., 2013; Stopsack, Ziehr, Rider, & Giovannucci, 2016; 
Xu et al., 2015).  
Numerous reviews have highlighted the potential for metformin to be used clinically 
to counteract PCa progression (Hankinson, Fam, & Patel, 2017). Metformin may 
confer anti-PCa effects by either an “indirect mechanism” where it reduces 
hyperglycaemia or hyperinsulinaemia, both of which are associated with PCa or by 
“direct mechanisms” where it acts on PCa cells to have anti-neoplastic and tumour 
suppressive effects. It is unclear whether metformin use can reduce ADT induced 
hyperinsulinaemia and further, if in systematic hyperinsulinaemia will reduce tumour 
insulin signalling. A recent randomized prospective study of metformin in 
combination with ADT in a Chinese cohort of hormone naïve PCa patients (n=31 in 
each arm) showed decrease in fasting glucose, but not insulin or C-peptide levels 
after 24 weeks of treatment (Zhu, et al., 2017). However, a similar randomized 
prospective trail of ADT and metformin in hormone naïve PCa patients (n=45 total) 
by our group here at the Princess Alexandra Hospital, (ADMET, 
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ACTRN12614001054606), has shown significant reduction in insulin resistance and 
hyperinsulinaemia after 30 weeks of treatment (results unpublished). Although these 
studies show promise for metformin use early in PCa, its combination with docetaxel 
for advanced patients suffering from metastatic CRPC does not increase cancer 
specific or overall survival (Mayer, et al.). Thus, it is possible that metformin needs 
to be administered to patients early in their treatment regime to be effective.  
Whilst the jury is out on the efficacy of metformin use, the direct effects of 
metformin and phenformin in PCa cells was examined in the work of this Appendix. 
Much controversy also exists regarding the clinical relevance of the numerous in 
vitro and in vivo studies depicting anti-neoplastic ‘direct’ effects of metformin in 
PCa. The plasma concentration of metformin in patients is in the 10-20μM range 
(Frid et al., 2010); however existing studies showing direct effects of metformin use 
much higher concentrations of 0.625μM - 20μM (detailed in section A.13). It is 
unknown whether biguadines can produce direct cellular effects in PCa at 
concentrations closer to that of plasma in patients, which may be more clinically 
translatable. Thus the direct effects of metformin and phenformin in PCa cells at low 
concentrations were examined.  
A1.2 Results 
 
Proliferation of LNCaP cells in response to various doses of metformin and 
phenformin was studied using the IncucyteTM to measure change in cell confluency 
over 48h. These dose curves were established to determine non-toxic concentrations 
of drug for further analyses. No toxicity was observed for metformin with doses 
equal to or below 1mM (Figure A1.2A). Phenformin, which is known to be more 
toxic to cells, demonstrated cytostatic effects from 50 μM, reduced growth with 5-10 
μM and no effect below 5μM (Figure A1.2B). These results were confirmed using 
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Alamar Blue cell viability assessment (not shown). Metformin and phenformin are 
also known activators of AMPK. As plasma concentrations of metformin do not 
normally rise above 20μM (Frid, et al., 2010), the effect on AMP activation at the 
very low and more clinically relevant dose of 30μM metformin was tested. A slight 
increase in AMPK phosphorylation was observed with both metformin (30μM) and 
phenformin (30μM) treatments, which was abolished with the addition of insulin 
(10nM) (Figure A1.2C). Together these results show that the 30μM low dose of 
metformin and phenformin is non-toxic to LNCaP cells and may elicit some direct 
cellular effects in PCa by activation of AMPK.  
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Figure A1.2 Biguanides regulate PCa growth in a dose dependent manner in 
vitro. LNCaP cell confluency was measured using Incucyte at doses of (A) 
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metformin from 500μM to 30mM and (B) phenformin doses between 500nM to 
500μM. Metformin doses at and above 5mM lead to significant reduction in growth 
of LNCaP cells over 48h. (n=3) Phenformin doses above 50μM lead to significant 
reduction in LNCaP growth. (n=3) (C) AMPK activation by metformin (30μM) and 
phenformin (30μM) in DUCAP cells was measured by western blot. Quantification 
of bands (in blue bars) show increase in the ratio of phosphorylated AMPK 
(pAMPK) over total AMPK (tAMPK) after 30 minutes of treatment with metformin 
and phenformin.  
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Transwell assays of LNCaP cells showed invasion through Matrigel was completely 
blocked with the non-toxic dose of 1mM metformin (Figure A1.3A). Cells were 
androgen deprived in charcoal stripped-media for 24h and serum starved for another 
24 hours, with treatments, before being seeded into transwells. The assay was 
terminated after 16 hours.  
This thesis identified FOXC2 as an important inducer of cell migration and EMT in 
PCa. Additionally, insulin upregulated of vimentin which may contribute to the 
mesenchymal phenotype and increased migration. Changes to the expression of these 
EMT molecules were investigated in DuCaP cells after 48 hours of treatment with 
30μM metformin or phenformin. Metformin alone did not reduce expression of 
FOXC2 or vimentin with insulin or insulin and enzalutamide. It also did not affect 
DHT driven suppression of FOXC2 and vimentin (Figure A1.3B).  Compared to 
vehicle treatment, phenformin however significantly reduced insulin driven rise of 
both FOXC2 and vimentin protein levels in DUCAPs (Figure A1.3B). Similarly, 
transcript levels of both FOXC2 and vimentin were not altered with metformin 
(30μM) in both LNCaPs and 22RV1s, however phenformin significantly reduced 
vimentin transcription in both LNCaPs and 22RV1s (Figure 1.4C and D). 
Interestingly, phenformin increased FOXC2 transcripts in LNCaPs and did not 
suppress its levels in 22RV1s (Figure 1.3C and D). Together these results show that 
metformin does not directly affect EMT changes at the low dose of 30μM in PCa 
cells, but the more potent phenformin can suppress some mesenchymal molecules 
such as vimentin.   
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Figure A1.3 Low dose of metformin does not directly regulate EMT in PCa 
cells. (A) LNCaP cell invasion through MatrigelTM was measured in transwell assays. 
Insulin treatment significantly increased invasion of LNCaP cells, which was 
inhibited with 1mM metformin treatment. (n=3) (B) At 30μM phenformin 
significantly reduced insulin induced rise in FOXC2 and vimentin protein levels in 
DUCAP cells after 48h of treatment, whereas, metformin treatment did not lead to 
any significant alterations. (n=3) (C and D) Transcription of FOXC2 and vimentin 
levels in LNCaP (C) and 22RV1 (D) cells in response to metformin (30μM), 
phenformin (30μM) with combination of insulin (10nM), DHT (10nM) and 
enzalutamide (10μM) was measured with qRT-PCR. Metformin did not alter 
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transcription of either FOXC2 or Vimentin in either cell line, while phenformin 
significantly decreased vimentin transcript levels. (n=3, *<0.05, **p<0.01 one-way 
ANOVA) 
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The effect of low dose biguanides on expression of IR was also investigated (Figure 
A1.4). In Chapter 3, insulin treatment in LNCaP cells had further increased 
expression of INSR-A. Here it is seen that combining low dose metformin (30μM) 
with insulin is unable to suppress the insulin driven rise in either isoforms of IR in 
LNCaP cells (Figure A1.4A). However, IR was not increased with addition of low 
dose phenformin (30μM) in LNCaPs (Figure A1.4A). In 22RV1 cells insulin 
treatment does not change INSR-A expression (Supplementary Figure A1.1). Again, 
it is seen that combining low does metformin (30μM) with these treatments in 
22RV1 cells produces the same results, indicating that this low dose of metformin 
does not significantly alter IR transcription in these cells (Figure A1. 4B). Consistent 
with findings in Chapter 3, DHT also significantly increased IR protein expression in 
DUCAP cells, even in the presence of metformin (30μM), while phenformin (30μM) 
lead to significant downregulation of IR protein levels (Figure A1.4C). Thus, 
together these results indicate that very low dosage of metformin, at 30μM, is unable 
to confer any direct cellular effects on IR regulation and expression in PCa cells, but 
even at lose dose phenformin may be adequate to suppress transcription of INSR.        
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Figure A1.4 Low dose of metformin does not directly affect IR in PCa cells. (A) 
qRT-PCR of LNCaP cells after 48h treatment with metformin (30μM) and 
phenformin (30μM) in combination with insulin (10nM), DHT (10nM) and 
enzalutamide (10μM). While phenformin inhibited insulin driven rise in IR-A and 
IR-B, metformin did not prevent this. (n=3) (B) qRT-PCR of 22RV1 cells after the 
same treatments to LNCaP in panel A. Insulin depresses IR in 22RV1s (Chapter 3), 
and use of either biguanide did not reverse this effect. (n=3) (C) Whole cell lysate 
western blot of DUCAP cells treated for 48h with various drugs. IR is increased in 
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DUCAPs by DHT (Chapter 3), and the low dose of metformin used in these 
experiments did not alter this effect.  (n=3) 
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The effect of low dose of metformin on androgen axis was also investigated by 
measuring expression of AR and PSA in different PCa cell lines. AR and PSA levels 
were not altered by low dose metformin in 22RV1 cells, which is keeping with the 
results of Chapter 3 of this thesis, and with the fact that 22RV1 cells are weakly AR 
responsive (Figure A1.5A). Phenformin (30μM), however, lead to significant 
suppression of AR and PSA transcripts in 22RV1 cells (Figure A1.5A). ). It was also 
previously noticed in Chapter 3 that IGF1R levels were not greatly increased by 
DHT in 22RV1 cells. Again, the same result was observed when combining 
metformin with DHT in 22RV1 cells for IGF1R, indicating that the low dose of 
metformin used (30μM) do not alter AR regulation of IGF1R in 22RV1 cells (Figure 
A1.4B). Insulin downregulates IGF1R transcripts in 22RV1 cells (Supplementary 
Figure A1.1), which was also seen in combination with low dose metformin (Figure 
A1.4B), again indicating that the metformin treatment did not alter insulin regulation 
of IGF1R either. The more toxic drug, phenformin was able to significantly reduce 
IGF1R transcript levels in 22RV1s, both alone and in combination with insulin 
(Figure A1.4B). PSA expression in LNCaP cells showed DHT driven rise even in 
combination with low dose metformin. However, in chapter 3, the PSA rose to 120-
fold over vehicle when treated with DHT in LNCaP cells, but in combination with 
metformin the rise observed here was only of 30-fold. (Figure A1.5B). It is well 
established that IGF1R is increased in response to DHT in LNCaP cells, which was 
also observed in Chapter 3 of this thesis. Again, low dose metformin (30μM) is 
unable to prevent DHT induced rise in IGF1R transcripts in LNCaPs (Figure A1.4A), 
although magnitude of rise is vastly reduced (DHT alone in chapter 3 lead to 15 fold 
rise in IGF1R, compared to a 3 fold rise when DHT is combined with metformin). 
DHT also strongly suppressed AR protein levels in DUCAP cells in chapter 3, which 
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was again observed even in combination with low dose metformin (Figure A1.5C). 
These results then indicate that low dose metformin may reduce the strength of DHT 
induced transcription in some PCa cells like LNCaPs but not in others such as 
22RV1 and DUCAPs. Thus, low dose of metformin may weakly inhibit androgen 
signalling in some PCa cells. 
 
 
Figure A1.5 Low dose metformin does not affect androgen axis in PCa cells. (A) 
qRT-PCR of 22RV1 cells after 48h of treatment with metformin (30μM) and 
phenformin (30μM) in combination with insulin (10nM), DHT (10nM) and 
enzalutamide (10μM). AR, PSA and IGF1R expression levels are not altered with 
metformin alone or in combination with other drugs (n=3). (B) qRT-PCR of LNCaP 
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cells showing relative change in PSA and IGF1R transcript levels after 48h of the 
same treatments in panel A done for 22RV1 cells. PSA and IGF1R upregulation by 
DHT in LNCaP cells is reduced, but not reversed by low dose metformin (n=3). (C) 
Whole cell lysate western blot of DUCaP cells after 48h of treatment. AR suppressed 
by DHT is not reversed by metformin (30μM) (n=3, ****p<0.0005 one-way 
ANOVA).  
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As metformin is a cation in physiological conditions, expression of cation 
transporters by PCa cells would affect how metformin is absorbed by the cells. The 
expression of cation transporters involved in metformin uptake by PCa cells is 
currently also unknown. Probing existing RNA-Seq data for expression of the known 
transporters of metformin in LNCaP cells in the presence of androgens showed that 
PMAT is the most abundant and likely transporter used by LNCaP cells for 
metformin uptake (Figure A1.6A). Furthermore, PMAT transcript levels were 
significantly increased in LNCaP cells upon androgen deprivation (Figure A1.6B), 
indicating that the capacity of the cells for metformin action may be increased upon 
androgen deprivation.  
 
Figure A1.6 PMAT may be involved in metformin uptake by PCa cells. (A) 
Table showing cation transporters that have been discovered to be involved in 
metformin uptake by various cells of the body, listed in the order of decreasing 
affinity for metformin (lower Km equals higher affinity) (Liang, et al., 2015). The 
average number of transcripts uncovered by RNA-Seq in LNCaP cells in the 
presence of androgens is also listed. The most abundant transporter transcript in 
LNCaP cells is PMAT. (B) Further analysis of the same RNA-Seq data in LNCaP 
cells revealed that PMAT levels increase significantly upon androgen deprivation 
  
Appendices 277 
treatment (ADT), while treatment with metformin (0.5mM) can lower levels of this 
transporter. (n=3, * p-value 0.05) 
 
A1.3 Discussion 
Normally, the serum plasma levels of metformin does not exceed 20μM, however it 
can reach over 300 μM in patients presenting with lactic acidosis. (Frid, et al., 2010). 
The direct effects of biguanides, metformin and phenformin on PCa cells at the 
pharmacologically dose relevant to plasma concentrations are currently unknown. It 
was observed that the low dose of 30μM is non-toxic to LNCaP cells for both 
metformin and phenformin, but AMPK activation was not strong at this 
concentration for either drug. It is important to note that this was measured in 
androgen-deplete conditions which increases phosphorylated AMPK levels. The data 
presented in figure A1.2 suggests there is no additional AMPK activation by 
metformin or phenformin. Moreover, low dose metformin had no effect on insulin 
regulation of EMT molecules such as FOXC2 or vimentin, or IR. Mild inhibition of 
AR signalling was however observed in LNCaP cells, manifested in muted PSA and 
IGF1R response when treated with DHT and metformin, compared to DHT alone. 
Phenformin had stronger direct effects at this low dosage on PCa cells, with 
consistent and significant suppression of vimentin expression as well as suppression 
of AR, PSA and IGF1R expression. Thus the results show that the plasma dose of 
metformin does not have immediate direct effects on PCa cells, with its main effect 
being weak disruption of AR signalling in some PCa cells. However, the more toxic 
drug phenformin may directly suppress the mesenchymal phenotype and also directly 
downregulates AR and IGF1R, which may lead to suppression of androgen, insulin, 
IGF1 and IGF2 signalling in PCa cells. As these ligands have each been shown to 
drive pathways that could result in PCa progression, phenformin use may benefit 
 278 Appendices 
PCa patients. However, phenformin at the same dose as metformin leads to lactic 
acidosis, which can be lethal in patients. Thus the dosage may have to be lowered for 
phenformin use clinically in patients, which may negate the direct beneficial effect of 
this drug in PCa tumours.  
The direct effects of metformin on proliferation, migration, invasion as well as EMT 
and IGF1R expression has been studied recently, although the dosage of metformin 
has been significantly higher among all the published literature so far.  
This study saw metformin at 5mM and above lead to significant reduction in LNCaP 
cells. While several studies confirm this observation, showing that metformin at 
5mM (Kato, et al., 2015), 10mM (Lee, et al., 2014) and 20mM (Wang et al., 2014) is 
able to reduce LNCaP proliferation, other studies have also shown that half that dose, 
at 2mM (Wang, et al., 2015) and 2.5mM (Chen et al., 2016) are also enough to 
significantly reduce LNCaP proliferation. Further studies have shown that 2mM-
20mM metformin concentrations are enough to reduced proliferation in a range of 
PCa cell lines including PC3, LNCaP-AI, VCAP, DU145 and 22RV1 cells (Chen, et 
al., 2016; Kato, et al., 2015; Lee, et al., 2014; Wang, et al., 2015; Wang, et al., 2014; 
Zhang et al., 2014). Animal studies have also shown that daily metformin 
intraperitoneal (i.p) injections of 50mg/kg can reduce LNCaP xenografts in mice by 
35% (Ben Sahra et al., 2008), while a higher dose of daily i.p. injections of 
250mg/kg reduced PC3 xenografts in nude mice on a high fat diet (HFD) (Kato, et 
al., 2015), and daily i.p. 125mg/kg was sufficient to reduce PC3 xenografts in nude 
mice without HFD (Chen, et al., 2016). Some controversy also exists regarding the 
dosage of metformin in mouse work. Humans are given metformin orally at 
50mg/kg/day, producing a plasma metformin concentration of 10-20μM. Mice given 
the same oral dose of 50mg/kg/day has been also shown to have a plasma 
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concentration of metformin at 20μM (Wilcock & Bailey, 1994), and another study 
reported that an oral dose of 250mg/kg/day in mice resulted in a plasma 
concentration of 10μM (Memmott et al., 2010). Xenograft studies in other cancers 
also use metformin and phenformin at a range of doses of 20mg/kg to 400mg/kg, 
with varying results (Appleyard et al., 2012; Gao et al., 2015; Lipner et al., 2016; 
Luo et al., 2012; Zhang, Guo, et al., 2013) and serum and tumour levels of 
biguanides are not reported. At the lower dose of 20mg/kg there was no effect on 
tumour growth, but tumour necrosis was increased(Gao, et al., 2015). No tumour 
growth for PDX was also observed at 400mg/kg in another study, but necrosis was 
not measured (Lipner, et al., 2016). Most animal studies so far provide metformin by 
i.p. injection. How this alters plasma, liver, or tumour concentrations of metformin 
compared to oral dosage is unknown.    
A weakened response to DHT represented in muted expression of PSA and IGF1R in 
LNCaP cells was observed with 30μM metformin, indicating that metformin may 
suppress androgen action in some PCa cells. Recent studies have also established that 
higher doses of metformin can directly inhibit androgen action in PCa cells, albeit at 
concentrations that may not be clinically reached. Metformin (2mM) significantly 
reduced 1nM DHT stimulated LNCaP, PPC-1 and C42B cell lines (Lee, et al., 2014). 
Metformin (1mM) also reduced DHT stimulated PSA expression in LNCaP and 
C42B cells (Lee, et al., 2014). Metformin (5mM) reduced PSA and AR expression in 
both LNCaP and 22RV1 cell lines, but did not affect nuclear AR localization in 
22RV1 cells even at 20mM (Wang, et al., 2015).  Metformin (3mM) is also able to 
reduced R1881 stimulated IGF1R expression in LNCaP cells, and 10mM metformin 
is able to inhibit IGF1 stimulated LNCaP growth and migration in the presence of 
R1881 (Malaguarnera, et al., 2014). Basal IGF1R expression and phosphorylation 
 280 Appendices 
can also be reduced by 5mM metformin in LNCaP, PC3 and LNCaP-AI cell lines 
(Kato, et al., 2015). Some mechanisms have been proposed for suppression of 
androgen action in PCa cells by metformin. 5mM metformin has been shown to act 
as a AR-corepressor by upregulating SMILE (Lee, et al., 2014) and 10mM-30mM 
metformin prevents activation of PI3K and MAPK pathways by AR (Malaguarnera, 
et al., 2014).  
It was observed that 1mM metformin obliterated invasion in LNCaP cells, however, 
30μM metformin was unable to reduce levels of mesenchymal markers FOXC2 and 
Vimentin. A recent study has shown that metformin can inhibit invasion and 
migration in LNCaP cells at concentrations lower than 1mM (0.625mM) (Chen, et 
al., 2016), but most studies use concentrations of 5mM upwards when showing 
reduction in gain of invasion and migration in LNCaP, PC3, VCAP and 22RV1 cells 
by metformin (Kato, et al., 2015; Tong et al., 2016; Zhang, et al., 2014). 
Significantly higher concentrations of metformin have also been shown to directly 
inhibit EMT, where 5mM metformin can inhibit TGF-β induced EMT in VCAP cells 
(Zhang, et al., 2014), while 10mM metformin induced an epithelial phenotype in 
PC3 and 22RV1 cells by increasing E-cadherin expression and reducing N-cadherin, 
vimentin and twist expression (Tong, et al., 2016). 300mg/mL daily oral dosage of 
metformin also reduced Twist, vimentin and N-cad expression in 22RV1 xenografts, 
while increasing E-cadherin expression (Tong, et al., 2016). It has been established 
that ADT can induce EMT in PCa cells and in patients (Bishop, et al., 2015; Li, et 
al., 2014; Nouri, et al., 2014). A small clinical study of 10 patients in each arm 
showed that tumours from patients who had metformin along with castration before 
radical prostatectomy had significantly reduced EMT signature (high E-cad, low 
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vimentin, N-cad and Twist) compared to those who had castration alone prior to 
surgery (Tong, et al., 2016). 
Metformin levels may be up to five-fold higher in organ tissues than plasma levels, 
and thus it could be postulated that levels in PCa tumours could safely reach up to 
150μM in patients (Wilcock & Bailey, 1994) (Figure A1.6).  The expression of 
cation transporters will also affect metformin absorption by the tumour. It was seen 
that among the known metformin transporters, PMAT is likely involved in 
metformin uptake by PCa cells and its levels increase upon androgen deprivation in 
LNCaP cells. This may suggest that metformin administration along with castration 
will increase the bioavailability of the drug at the tumour as its transporter levels are 
increased with castration. This would hypothetically increase the likelihood of direct 
effects of drug at the tumour. 
The ‘indirect’ anti-PCa effects of metformin could result due to its direct actions on 
hepatocytes to reduce hyperglycaemia (Figure A1.1). Concentrations of metformin in 
the liver (0.3mM) may reach to levels double of that found at PCa tumour (0.15mM) 
(Figure A1.7). The effects of metformin on the liver may be more significant than 
that in PCa tumours, such that the ‘indirect’ anti-PCa mechanisms, namely the 
lowering of systemic insulin levels, may be more clinically relevant than the ‘direct’ 
mechanisms on the tumour itself. Further studies should incorporate a greater range 
of low concentrations of metformin, namely between 0.1mM and 0.5mM. However, 
the length of treatment might also be important as metformin is hypothesized to 
accumulate in the mitochondrial matrix (Bridges, Jones, Pollak, & Hirst, 2014). The 
cellular microenvironment can also impact the effect of metformin on mitochondrial 
complex 1 inhibition and thus affect treatment resistance(Gui et al., 2016). Thus, 
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further studies in vitro studies should consider chronic treatment with low dose 
metformin.  
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Figure A1.7 Concentrations of metformin would determine the direct and 
indirect effects of the drug for PCa therapy. Metformin can have anti-PCa effect 
via two non-mutually exclusive pathways. “Indirect mechanisms” occur when the 
drug does not reach the tumour in sufficient quantities to produce biologically 
significant effects. Mice given an oral dose equivalent to that in humans 
(50mg/kg/day) produced a liver metformin concentration of 200-300μM, hepatic 
portal plasma concentration of 0.04-0.06mM, inferior venacava plasma concentration 
of 0.01-0.03mM and gastrointestinal (GI) lumen concentration of 1-2mM (Wilcock 
& Bailey, 1994). This is consistent with the plasma concentration of metformin in 
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normal and diabetic patients which ranges from 10-20μM (Frid, et al., 2010; Tucker 
et al., 1981). At the liver metformin can lower hyperglycaemia, which would reduce 
hyperinsulinaemia, which may suppress insulin signalling at the PCa tumour, 
suppressing insulin induced mechanisms of PCa progression, such as gain in 
migration and invasion. “Direct mechanisms” occur when metformin accumulates in 
the tumour in sufficient quantities to produce anti-cancer effects. Metformin 
concentration in PCa tumours has not been measured, but may be anywhere between 
the same as plasma concentration (0.01mM) to five times higher than that of plasma 
concentration (0.15mM). The five-fold increase has been postulated based on the fact 
that metformin in the liver accumulates to five-fold the concentration of metformin 
in the plasma of the incoming blood in the portal vein (Wilcock & Bailey, 1994). 
Alternatively metformin concentration may be the same as that found in plasma of 
general circulation, as in white fat the concentration of metformin is the same as 
circulation, while in brain it is half that of circulation, indicating that metformin does 
not accumulate to levels higher than plasma in white fat, and faces difficulty entering 
the brain (Wilcock & Bailey, 1994). In skeletal muscle and heart the concentration of 
metformin is double that of plasma concentration, indicating accumulation of 
metformin in peripheral tissue (Wilcock & Bailey, 1994).  
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Supplementary Figures  
 
Supplementary Figure 3.1 (A) Chinese Hamster Ovary cells overexpressing IR-A 
(CHO.IR) were cultured in 10% FBS containing media and then serum starved 
overnight prior to stimulation with insulin for 30 minutes. Cells were fixed and 
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stained at basal, and then at 5, 10, 15 and 30 minutes post treatment with insulin. IR 
antibody (ab983, 1:50) is able to detect signal triggered internalization of IR (green) 
in response to insulin in CHO.IR cells, indicating specificity of the antibody to IR. 
(B) IR antibody (ab983, 1:50) detects cytoplasmic IR (green), while IGF1R antibody 
detects plasma membrane IGF1R (red) in DUCAP cells cultured under androgen 
deprived conditions for 48hr prior to treatments with DHT (10nM), insulin (10nM) 
and IGF1 (10nM).  IGF1R levels are increased with DHT treatment (n=3).  
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Supplementary Figure 3.2 Androgen deprivation reduces PSA expression.  
DUCAP (A), LNCaP (B) and 22RV1 (C) cells were cultured under androgen 
deprived conditions for 48hr and treated with DHT (10nM), with and without AR 
inhibitors ARN509 (ARN) (10μM), bicalutamide (BIC) (10μM) and enzalutamide 
(ENZ) (10μM) for 24hr. (A) In DUCaP cells, PSA mRNa is dramatically decreased 
with androgen deprivation and AR inhibitors, while AR mRNA increases. (B) In 
LNCaP cells PSA is repressed similarly to DUCaP cells with AR suppression. AR is 
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slightly but not significantly increased. (C) In 22RV1 cells PSA and AR are 
unchanged, consistent with 22RV1 muted androgen response. (all graphs n=3, mean± 
SEM, SFM used as control for ANOVA * = p<0.05, ** = p<0.005, *** = p<0.0005, 
**** = p<0.00005)  
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Supplementary Figure 3.3 Androgen treated LNCaP cells are morphologically 
different. LNCaP shAR and shNT cells were cultured in 5% FBS containing media 
for 5 days with addition of puromycine (250ng/mL) every other day and with or 
without daily top up of doxycycline (250ng/mL). At 5 days, cells were further treated 
with insulin (10nM) or DHT (10nM). Bright field images show a clear 
morphological difference between DHT treated cells and those with AR knockdown 
in the absence of DHT (marked with yellow stars). Yellow stars all mark the cells in 
which nuclear IR protein levels went up. DHT treatment in doxycycline induced 
shAR cells are unable to take on the morphology of DHT treated cells with no AR 
knockdown. (n=3, scale bar shows 100μm) 
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Supplementary Figure 3.4 Morphological difference between insulin and 
androgen treated cells. C42B, VCAP and 22RV1 cells were cultured in androgen 
deprived conditions for 48h and treated with insulin (10nM) and DHT (10nM) for 
20hr. Bright field images show morphological changes in insulin treated cells that are 
different to those of DHT treated cells. Significant changes in subcellular localization 
of cytoplasmic AR (ARc) and IR (IRc) and nuclear AR (ARn) and IR (IRn) are 
marked with upward arrows for significant up-regulation and downward arrows for 
significant down regulation of protein levels for the given treatment in the respective 
cell line. (n=3, scale bars show 100μm) 
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Supplementary Figure 4.1. Optimization of insulin receptor (INSR) inhibitor 
concentrations. (A) BMS754807-04 prevented phosphorylation of insulin receptor 
at 0.05µM. (B) CP751871 reduced insulin receptor phosphorylation (pINSR) at 
5µg/mL. (C) Schematic showing inhibitory effects of the two molecules. 
BMS754807-04 blocks both homodimers of IR and hybrid IR:IGF1R receptors, 
while CP741871 antibody only blocks action of hybrid receptors. 
 
 
 
 
 
 292 Supplementary Figures 
 
 
Supplementary Figure 4.2 Optimization of anti-mitogen agents in migration 
assays (A) Panel of line graphs showing response of LNCaP cells to various anti-
mitogen agents in wound healing scratch assay (Incucyte). Nocodazole (Noc), 
mitomycin c (MMC). Graph on the left shows effects of Noc and MMC in media 
supplemented with 10% FBS, 10% CSS in the middle and EGF (50ng/mL) on the far 
right. (B) Panel of line graphs showing response of 22RV1 cells to various anti-
mitogen agents in wound healing scratch assay (Incucyte). Nocodazole (Noc), 
mitomycin c (MMC). Graph on the left shows effects of Noc and MMC in media 
supplemented with 10% FBS, 10% CSS in the middle and EGF (50ng/mL) on the far 
right. 
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Supplementary Figure 4.3. Insulin induced migration in PCa cells. In androgen 
deprived conditions, wound confluency calculated from real time cell imaging 
showed insulin (10nM) accelerates wound closure in LNCaP, 22RV1 and DU145. 
Image shows DU145 wound closure following 24hrs insulin treatment. The addition 
of 10mM pan insulin/IGF1R inhibitor BMS 745807-04, reduced the effects of 
insulin. The monoclonal antibody to IGF1R CP 751871 (5mg/ml) reduced insulin-
induced migration and LNCaP and DU145 cells, but had insignificant impact on 
insulin-induced migration in 22RV1 cells, (Mean ± SEM) 
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Supplementary Figure 4.4 Generation of shINSR LNCaP cells. LNCaP cells 
transduced with two separate doxycycline (dox)-inducible shRNA sequences against 
the insulin receptor (INSR) (shINSR2 and shINSR3 cells) and control cells with non-
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targeting shRNA (shNT cells) were produced with red fluorescent protein as a 
reporter for doxycycline action. Cells were cultured under normal conditions and 
treated with 250ng/mL daily top up of doxycycline and 250ng/mL of puromycin 
every other day to maintain selection pressure for shRNA retention. (A) Bright field 
and fluorescent images show expression of RFP in cells treated with doxycycline and 
resulted in decreased INSR RNA (B) and IR protein (C) after 3, 5 and 7 day dox 
induction compared to non-targeting control (NT). (D) Boyden chamber migration 
assay using androgen deprived shINSR2 LNCaP cells also replicate the shINSR3 
LNCaP results that insulin (10nM) driven migration is prevented upon a 5-day 
doxycycline (250ng/mL/day) induced knockdown of INSR. (all graphs n=3, 
*p<0.05, **p<0.01, ***p<0.001, One-way ANOVA, ± SEM) 
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Supplementary Figure 5.1. Optimization of primers for qRT-PCR validation of 
microarray data.  Primers for genes related to EMT and NEtD processes that were 
obtained from literature and those designed de novo were tested for amplification in 
lung cancer cell line NCI-H460 and PCa cell line PC3 which are known to be 
positive for both EMT and NEtD genes. LNCaP and PC3 cells were cultured under 
normal conditions prior to RNA collection. NCI-H460 RNA was kindly donated to 
Ms Rather at APCRCQ. Many of the tested primers showed amplification only in the 
lung cancer NCI-H460 cell (A), while others showed amplification only in the PCa 
PC3 cell line (B). A third group of genes were amplified in both the NCI H460 and 
the PC3 cell lines (C). 
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Supplementary figure 5.2 Insulin increases nuclear levels of EMT transcription 
factors FOXC2 and ZEB1. (A) 22RV1 cells cultured under androgen deprived 
conditions for 48hr were treated with insulin (10nM), DHT (10nM) and 
enzalutamide (10μM) for 20hr. Subcellular fractionation of lysates indicates insulin 
increases Zeb1 and FOXC2 protein levels in the nucleus. (B) Quantification of bands 
of the western blots also show increased FOXC2 levels in the nucleus compared to 
cytoplasmic fraction with insulin treatment. (n=3) 
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Supplementary Figure 5.3: Total and phosphorylated PI3K levels were 
investigated in LNCaP and DU145 cells with cells in CSS or CSS with insulin (INS), 
and the addition of the PI3K inhibitor, LY294002 (LY) or ERK1/2 inhibitor UO0126 
(UO). LY294002 reduced total and phosphorylated PI3K in LNCaP and DU145 
cells. UO0126 increased PI3K levels as well as its phosphorylation, suggesting a 
compensatory pathway.   
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Supplementary Figure A1.1 Insulin regulation of IR and androgen responsive 
molecules in PCa cells. (A) Androgen deprived DUCaP cells treated with insulin 
(10nM), enzalutamide (ENZ, 10μM) and DHT (10nM) for 48 hrs. qRT-PCR shows 
insulin does not affect INSR-A levels in the presence or absence of androgens or AR 
inhibitor enzalutamide, but IGF1R and PSA levels are increased by DHT. (B) 
Immunoblotting of DUCaP cells treated the same as panel (A) show DHT treatment 
significantly reduces AR expression, which correlates with increase in IR protein 
 300 Supplementary Figures 
levels. (C) qRT-PCR of 22RV1 cells, also treated the same as the DUCaPs in this 
figure, show insulin does not affect INSR-A levels, but significantly decrease IGF1R 
levels in the absence of androgens and with AR inhibitor enzalutamide. PSA is 
increased by DHT. (D) AR and IR protein levels are not changed with insulin 
treatments in 22RV1 cells treated the same as in (C).  
